Judd Wendell Moul
James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology. He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009. He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer. He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World. He is very committed to training residents and mentoring students and trainees.
Office Hours
Clinic days: 2nd and 4th Mondays, all Tuesdays , Thursday mornings generally from 8am to 5pm
OR Days: 1st, 3rd, 5th Mondays and all Wednesdays
OR Days: 1st, 3rd, 5th Mondays and all Wednesdays
Current Appointments & Affiliations
- James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine, Surgery, Urology, Surgery 2009
- Professor of Surgery, Surgery, Urology, Surgery 2005
- Professor in Anesthesiology, Anesthesiology, Clinical Science Departments 2012
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2004
Contact Information
- 1573 White Zone, Duke South, Durham, NC 27710
- Box 3707 Med Ctr, Durham, NC 27710
-
judd.moul@duke.edu
(919) 684-5057
- Background
-
Education, Training, & Certifications
- Fellowship, Urologic Oncology, Duke University 1988 - 1989
- Residency, Urology, Walter Reed Army Medical Center 1983 - 1987
- Residency, Surgery, Walter Reed Army Medical Center 1982 - 1983
- M.D., Thomas Jefferson University 1982
- B.S., Pennsylvania State University 1979
-
Previous Appointments & Affiliations
- Chief of the Division of Urology in the Department of Surgery, Surgery, Urology, Surgery 2004 - 2010
- Instructor, Temporary of Urology in the Department of Surgery, Surgery, Urology, Surgery 2004
- Recognition
-
Awards & Honors
- Expertise
-
Global Scholarship
- Research
-
Selected Grants
- A Prospective Trial - Evaluation of ExoDx Prostate in Men with Prostate Cancer in an Active Surveillance Regimen awarded by Exosome Diagnostics, Inc. 2022 - 2026
- Phase III Randomized Efficacy and Safety Study awarded by Medivation, Inc. 2016 - 2023
- A Prospective Observational Cohort Study of Patients with Castration Resistant Prostate Cancer awarded by Astellas Pharma Global Development, Inc 2015 - 2021
- Exercise Training, Erectile Dysfunction, and Prostate Cancer awarded by National Institutes of Health 2009 - 2013
- IPA - Jens Dannull awarded by Veterans Administration Medical Center 2007 - 2008
- Prostate Cancer Recovery Enhancement (PROCARE) for African American Men awarded by National Institutes of Health 2007 - 2008
- IPA Agreement - Jens Dannull awarded by Veterans Administration Medical Center 2006 - 2007
- Expression Analysis of Prostate Cancer's Clinical Behavior awarded by National Institutes of Health 2001 - 2006
-
External Relationships
- Astellas Pharma Inc.
- Best Doctors-Teledoc Health
- Exosome Diagnostics Inc
- IQVIA-Astellas
- Interpublic Inc
- Maritz Travel Corp- Bayer
- MedForce Inc
- Medical Leverage -Dendreon
- Pfizer Inc.
- Precision Scientia
- Sanofi-Genzyme/HSC Acquisitions LLC
- The CM Group
- Theralogix LLC
- Up to Date Inc
- VMLY & R Sudler
- Publications & Artistic Works
-
Selected Publications
-
Books
-
Merseburger, A. S., M. A. Kuczyk, and J. W. Moul. Urology at a glance, 2014. https://doi.org/10.1007/978-3-642-54859-8.Full Text
-
-
Academic Articles
-
Kotamarti, Srinath, Andrew J. Armstrong, Thomas J. Polascik, and Judd W. Moul. “Molecular Mechanisms of Castrate-Resistant Prostate Cancer.” Urol Clin North Am 49, no. 4 (November 2022): 615–26. https://doi.org/10.1016/j.ucl.2022.07.005.Full Text Link to Item
-
Mjaess, Georges, Aya Karam, Thierry Roumeguère, Romain Diamand, Fouad Aoun, Kevin McVary, Judd W. Moul, Cosimo De Nunzio, and Simone Albisinni. “Urinary microbiota and prostatic diseases: the key for the lock? A systematic review.” Prostate Cancer Prostatic Dis, October 8, 2022. https://doi.org/10.1038/s41391-022-00602-w.Full Text Link to Item
-
Michael, Zoe D., Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, et al. “Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen.” World J Mens Health, August 16, 2022. https://doi.org/10.5534/wjmh.220068.Full Text Link to Item
-
Moul, Judd W., and Grannum R. Sant. “How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.” Can J Urol 29, no. 4 (August 2022): 11224–30.Link to Item
-
Moul, Judd W. “Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer.” Eur Urol Focus 8, no. 3 (May 2022): 641–42. https://doi.org/10.1016/j.euf.2022.05.001.Full Text Link to Item
-
Gesztes, William, Cara Schafer, Denise Young, Jesse Fox, Jiji Jiang, Yongmei Chen, Huai-Ching Kuo, et al. “Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.” Sci Rep 12, no. 1 (March 30, 2022): 5404. https://doi.org/10.1038/s41598-022-08826-5.Full Text Link to Item
-
Morris, Kostantinos E., Dominic C. Grimberg, Rajan T. Gupta, Avani A. Pendse, and Judd W. Moul. “Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs.” Oncology (Williston Park) 36, no. 3 (March 8, 2022): 178–83. https://doi.org/10.46883/25920952.Full Text Open Access Copy Link to Item
-
Berger, Miles, Jeffrey N. Browndyke, Mary Cooter Wright, Chloe Nobuhara, Melody Reese, Leah Acker, W Michael Bullock, et al. “Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers.” Ann Clin Transl Neurol 9, no. 2 (February 2022): 155–70. https://doi.org/10.1002/acn3.51499.Full Text Open Access Copy Link to Item
-
Moul, Judd W. “The long-running disparity in early detection and treatment of prostate cancer in African American men.” Can J Urol 29, no. 1 (February 2022): 11003–4.Link to Item
-
Oyeyemi, Deborah M., Mary Cooter, Stacey Chung, Heather E. Whitson, Jeffrey N. Browndyke, Michael J. Devinney, Patrick J. Smith, et al. “Relationship Between Depression/Anxiety and Cognitive Function Before and 6 Weeks After Major Non-Cardiac Surgery in Older Adults.” J Geriatr Psychiatry Neurol 35, no. 1 (January 2022): 145–54. https://doi.org/10.1177/0891988720978791.Full Text Link to Item
-
Browndyke, Jeffrey N., Mary C. Wright, Rosa Yang, Ayesha Syed, John Park, Ashley Hall, Katherine Martucci, et al. “Perioperative neurocognitive and functional neuroimaging trajectories in older APOE4 carriers compared with non-carriers: secondary analysis of a prospective cohort study.” Br J Anaesth 127, no. 6 (December 2021): 917–28. https://doi.org/10.1016/j.bja.2021.08.012.Full Text Open Access Copy Link to Item
-
Moul, J. W. “Editorial Commentary.” Urology Practice 8, no. 6 (November 1, 2021): 674. https://doi.org/10.1097/UPJ.0000000000000261.01.Full Text
-
Morris, Kostantinos E., Dominic Grimberg, Rohith Arcot, and Judd W. Moul. “Aggressive prostate cancer masquerading as acute prostatitis.” Can J Urol 28, no. 4 (August 2021): 10799–801.Link to Item
-
Moul, Judd W. “The type of ADT may matter for testosterone recovery.” Can J Urol 28, no. 4 (August 2021): 10743.Open Access Copy Link to Item
-
Moul, Judd W. “Commentary.” Can J Urol 28, no. 3 (June 2021): 10668.Link to Item
-
Freedland, Stephen J., Jenifer Allen, Aubrey Jarman, Taofik Oyekunle, Andrew J. Armstrong, Judd W. Moul, Howard M. Sandler, et al. “Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).” Clin Cancer Res 27, no. 6 (March 15, 2021): 1823. https://doi.org/10.1158/1078-0432.CCR-21-0372.Full Text Link to Item
-
Terrando, Niccolò, John J. Park, Michael Devinney, Cliburn Chan, Mary Cooter, Pallavi Avasarala, Joseph P. Mathew, et al. “Immunomodulatory lipid mediator profiling of cerebrospinal fluid following surgery in older adults.” Sci Rep 11, no. 1 (February 4, 2021): 3047. https://doi.org/10.1038/s41598-021-82606-5.Full Text Open Access Copy Link to Item
-
Crawford, E David, Jason M. Hafron, Scott T. Tagawa, Przemyslaw W. Twardowski, Richard G. Harris, Judd W. Moul, Thomas E. Keane, et al. “Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.” J Urol 205, no. 2 (February 2021): 554–60. https://doi.org/10.1097/JU.0000000000001392.Full Text Link to Item
-
Moul, J. W. “Re: Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine.” Canadian Journal of Urology 28, no. 3 (January 1, 2021): 10668–10668.
-
Moul, J. W. “The type of ADT may matter for testosterone recovery.” Canadian Journal of Urology 28, no. 4 (January 1, 2021): 1–1.
-
VanDusen, Keith W., Yi-Ju Li, Victor Cai, Ashley Hall, Sarah Hiles, J Will Thompson, M Arthur Moseley, et al. “Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction.” J Alzheimers Dis 80, no. 3 (2021): 1281–97. https://doi.org/10.3233/JAD-201544.Full Text Open Access Copy Link to Item
-
Moul, Judd W. “Are COVID-19 Delays a Basis for Concern? Can We Use This for Future Good?” Oncology (Williston Park) 34, no. 9 (September 15, 2020): 344–45. https://doi.org/10.46883/ONC.2020.3409.0344.1.Full Text Link to Item
-
Nobuhara, Chloe K., W Michael Bullock, Thomas Bunning, Brian Colin, Mary Cooter, Michael J. Devinney, Michael N. Ferrandino, et al. “A protocol to reduce self-reported pain scores and adverse events following lumbar punctures in older adults.” J Neurol 267, no. 7 (July 2020): 2002–6. https://doi.org/10.1007/s00415-020-09797-1.Full Text Link to Item
-
Freedland, Stephen J., Jenifer Allen, Aubrey Jarman, Taofik Oyekunle, Andrew J. Armstrong, Judd W. Moul, Howard M. Sandler, et al. “A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).” Clin Cancer Res 26, no. 12 (June 15, 2020): 3035–43. https://doi.org/10.1158/1078-0432.CCR-19-3873.Full Text Link to Item
-
Aksenov, Leonid I., Ted Gansler, Helmneh M. Sineshaw, Stacey Fedewa, K Robin Yabroff, Ahmedin Jemal, and Judd Moul. “Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States.” J Geriatr Oncol 11, no. 5 (June 2020): 885–92. https://doi.org/10.1016/j.jgo.2019.11.003.Full Text Link to Item
-
Moul, Judd W., Andrew Chang, and Brant A. Inman. “Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute's Initial Experience.” Oncology (Williston Park) 34, no. 5 (May 13, 2020): 156–62.Open Access Copy Link to Item
-
Nash, K., S. Strope, R. Eisenberg, and J. Moul. “Is MRI fusion Bx the new gold standard for diagnosing PCA?” Urology Times 48, no. 4 (April 1, 2020).
-
Crawford, E David, Przemyslaw W. Twardowski, Raoul S. Concepcion, Jason M. Hafron, Richard G. Harris, Judd W. Moul, Lucio N. Gordan, et al. “The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.” J Urol 203, no. 4 (April 2020): 743–50. https://doi.org/10.1097/JU.0000000000000577.Full Text Link to Item
-
Moul, Judd W. “Secondary screening tests for prostate cancer: is more information better? Which test is best?” Can J Urol 27, no. 1 (February 2020): 10086.Link to Item
-
Harper, Shelby N., Laura P. Hale, Michael N. Ferrandino, and Judd W. Moul. “Acute Presentation of Previously Unrecognized Congenital Ureteropelvic Junction Obstruction 5 Weeks After Radical Retropubic Prostatectomy.” Urology 135 (January 2020): 20–23. https://doi.org/10.1016/j.urology.2019.08.009.Full Text Link to Item
-
VanDusen, Keith W., Sarada Eleswarpu, Eugene W. Moretti, Michael J. Devinney, Donna M. Crabtree, Daniel T. Laskowitz, Marty G. Woldorff, et al. “The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction.” J Alzheimers Dis 75, no. 4 (2020): 1319–28. https://doi.org/10.3233/JAD-191185.Full Text Open Access Copy Link to Item
-
Berger, Miles, David M. Murdoch, Janet S. Staats, Cliburn Chan, Jake P. Thomas, Grant E. Garrigues, Jeffrey N. Browndyke, et al. “Flow Cytometry Characterization of Cerebrospinal Fluid Monocytes in Patients With Postoperative Cognitive Dysfunction: A Pilot Study.” Anesth Analg 129, no. 5 (November 2019): e150–54. https://doi.org/10.1213/ANE.0000000000004179.Full Text Open Access Copy Link to Item
-
Kowalewski, Karl F., Christian Tapking, Svetlana Hetjens, Felix Nickel, Philipp Mandel, Philipp Nuhn, Manuel Ritter, Judd W. Moul, Joachim W. Thüroff, and Maximilian C. Kriegmair. “Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis.” Eur Urol Focus 5, no. 6 (November 2019): 980–91. https://doi.org/10.1016/j.euf.2018.05.009.Full Text Link to Item
-
Aminsharifi, Alireza, Ross Simon, Thomas J. Polascik, Cary N. Robertson, Debra L. Sudan, Bradley H. Collins, and Judd W. Moul. “Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.” J Urol 202, no. 3 (September 2019): 469–74. https://doi.org/10.1097/JU.0000000000000207.Full Text Link to Item
-
Moul, Judd W. “Editorial Comment.” J Urol 202, no. 2 (August 2019): 254. https://doi.org/10.1097/01.JU.0000559946.32495.63.Full Text Link to Item
-
Moul, Judd W. “How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.” Can J Urol 26, no. 3 (June 2019): 9782–86.Open Access Copy Link to Item
-
Berger, Miles, Deborah Oyeyemi, Mobolaji O. Olurinde, Heather E. Whitson, Kent J. Weinhold, Marty G. Woldorff, Lewis A. Lipsitz, et al. “The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction.” J Am Geriatr Soc 67, no. 4 (April 2019): 794–98. https://doi.org/10.1111/jgs.15770.Full Text Open Access Copy Link to Item
-
Alkazemi, Muhammad H., Steven Brousell, Joseph Fantony, Matvey Tsivian, and Judd W. Moul. “A Case of Fatal Clostridial Necrotizing Fasciitis After Radical Prostatectomy.” Urology 122 (December 2018): 28–31. https://doi.org/10.1016/j.urology.2018.06.043.Full Text Link to Item
-
Crawford, E David, Paul F. Schellhammer, David G. McLeod, Judd W. Moul, Celestia S. Higano, Neal Shore, Louis Denis, Peter Iversen, Mario A. Eisenberger, and Fernand Labrie. “Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.” J Urol 200, no. 5 (November 2018): 956–66. https://doi.org/10.1016/j.juro.2018.04.083.Full Text Link to Item
-
Moul, Judd W. “Yes or no to local therapy for oligometastatic prostate cancer?” Nat Rev Urol 15, no. 7 (July 2018): 399–400. https://doi.org/10.1038/s41585-018-0028-7.Full Text Link to Item
-
Wong, Yu-Ning, Judith Manola, Gary R. Hudes, Bruce J. Roth, Judd W. Moul, Andrea M. Barsevick, Richard M. Scher, et al. “Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.” Clin Genitourin Cancer 16, no. 2 (April 2018): e315–22. https://doi.org/10.1016/j.clgc.2017.10.001.Full Text Link to Item
-
Gansler, Ted, Stacey Fedewa, Robert Qi, Chun Chieh Lin, Ahmedin Jemal, and Judd W. Moul. “Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?” J Urol 199, no. 3 (March 2018): 706–12. https://doi.org/10.1016/j.juro.2017.10.014.Full Text Link to Item
-
Giri, Veda N., Karen E. Knudsen, William K. Kelly, Wassim Abida, Gerald L. Andriole, Chris H. Bangma, Justin E. Bekelman, et al. “Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.” J Clin Oncol 36, no. 4 (February 1, 2018): 414–24. https://doi.org/10.1200/JCO.2017.74.1173.Full Text Link to Item
-
Saltzstein, Daniel, Neal D. Shore, Judd W. Moul, Franklin Chu, Raoul Concepcion, Stephan de la Motte, John A. McLane, Stuart Atkinson, Alex Yang, and E David Crawford. “Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.” Ther Adv Urol 10, no. 2 (February 2018): 43–50. https://doi.org/10.1177/1756287217738150.Full Text Link to Item
-
Crawford, E David, B. Tombal, T. Keane, F. Boccardo, K. Miller, N. Shore, J. W. Moul, J. -. E. Damber, L. Collette, and B. -. E. Persson. “FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.” Scand J Urol 52, no. 5–6 (2018): 349–57. https://doi.org/10.1080/21681805.2018.1522372.Full Text Link to Item
-
Moul, Judd W. “The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE (R) Military Database EDITORIAL COMMENT.” Journal of Urology 198, no. 6 (December 1, 2017): 1301–1301.Link to Item
-
Moul, Judd W. “Editorial Comment.” J Urol 198, no. 6 (December 2017): 1300. https://doi.org/10.1016/j.juro.2017.07.090.Full Text Link to Item
-
Moul, Judd W. “Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy.” Oncology (Williston Park) 31, no. 11 (November 15, 2017): 830–35.Link to Item
-
Moul, Judd W. “Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy.” Oncology New York 31, no. 11 (November 1, 2017): 830-+.Link to Item
-
Qi, Robert, and Judd Moul. “African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect?” Am J Mens Health 11, no. 6 (November 2017): 1765–71. https://doi.org/10.1177/1557988317721107.Full Text Link to Item
-
Qi, Robert, Wen-Chi Foo, Michael N. Ferrandino, Leah G. Davis, Sitharthan Sekar, Thomas A. Longo, Ghalib Jibara, Tracy Han, Ilhan Gokhan, and Judd W. Moul. “Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.” Can J Urol 24, no. 5 (October 2017): 8982–89.Link to Item
-
Tay, K. J., R. T. Gupta, J. Holtz, R. K. Silverman, E. Tsivian, A. Schulman, J. W. Moul, and T. J. Polascik. “Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?” Prostate Cancer Prostatic Dis 20, no. 3 (September 2017): 323–27. https://doi.org/10.1038/pcan.2017.20.Full Text Link to Item
-
Schulman, Ariel A., Christina Sze, Efrat Tsivian, Rajan T. Gupta, Judd W. Moul, and Thomas J. Polascik. “The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.” Curr Urol Rep 18, no. 7 (July 2017): 52. https://doi.org/10.1007/s11934-017-0699-2.Full Text Link to Item
-
Madden-Fuentes, Ramiro Jose, Bridget F. Koontz, Michael R. Harrison, Daniel J. George, Brittany Davidson, Brian F. Gilmore, Judd W. Moul, Christopher Mantyh, and Andrew C. Peterson. “How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?” Oncology (Williston Park) 31, no. 4 (April 15, 2017): 286–94.Link to Item
-
Moul, Judd W. “Comparison of DRE and PSA in the Detection of Prostate Cancer.” J Urol 197, no. 2S (February 2017): S208–9. https://doi.org/10.1016/j.juro.2016.11.031.Full Text Link to Item
-
Shore, Neal D., Franklin Chu, Judd Moul, Daniel Saltzstein, Raoul Concepcion, John A. McLane, Stuart Atkinson, Alex Yang, and E David Crawford. “Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.” Bju Int 119, no. 2 (February 2017): 239–44. https://doi.org/10.1111/bju.13482.Full Text Link to Item
-
Giattino, Charles M., Jacob E. Gardner, Faris M. Sbahi, Kenneth C. Roberts, Mary Cooter, Eugene Moretti, Jeffrey N. Browndyke, et al. “Intraoperative Frontal Alpha-Band Power Correlates with Preoperative Neurocognitive Function in Older Adults.” Front Syst Neurosci 11 (2017): 24. https://doi.org/10.3389/fnsys.2017.00024.Full Text Open Access Copy Link to Item
-
Heidenreich, Axel, Judd W. Moul, Shahrokh Shariat, and R Jeffrey Karnes. “Role of salvage lymph node dissection in prostate cancer.” Curr Opin Urol 26, no. 6 (November 2016): 581–89. https://doi.org/10.1097/MOU.0000000000000343.Full Text Link to Item
-
Qi, R., and J. W. Moul. “Rising PSA Level in an Anxious Postprostatectomy Patient.” Oncology (Williston Park, N.Y.) 30, no. 9 (September 15, 2016).
-
Qi, R., and J. W. Moul. “Rising PSA Level in an Anxious Postprostatectomy Patient.” Oncology (Williston Park, N.Y.) 30, no. 9 (September 15, 2016).
-
Qi, Robert, and Judd W. Moul. “Rising PSA Level in an Anxious Postprostatectomy Patient.” Oncology (Williston Park) 30, no. 9 (September 15, 2016): 834–60.Link to Item
-
Moul, J. W. “Castration-resistant prostate cancer: Why should urologists care?” Urologia Colombiana 25, no. 3 (September 1, 2016): 195–97. https://doi.org/10.1016/j.uroco.2016.07.001.Full Text
-
Moul, J. W. “Castration-resistant prostate cancer: Why should urologists care?” Urologia Colombiana 25, no. 3 (September 1, 2016): 198–200. https://doi.org/10.1016/j.uroco.2016.07.002.Full Text
-
Sutton, S Scott, E David Crawford, Judd W. Moul, James W. Hardin, and Eric Kruep. “Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.” World J Urol 34, no. 8 (August 2016): 1107–13. https://doi.org/10.1007/s00345-015-1754-6.Full Text Link to Item
-
Lynch, Henry T., Omofolasade Kosoko-Lasaki, Stephen W. Leslie, Marc Rendell, Trudy Shaw, Carrie Snyder, Anthony V. D’Amico, et al. “Screening for familial and hereditary prostate cancer.” Int J Cancer 138, no. 11 (June 1, 2016): 2579–91. https://doi.org/10.1002/ijc.29949.Full Text Link to Item
-
McGinley, Kathleen F., Kae Jack Tay, and Judd W. Moul. “Prostate cancer in men of African origin.” Nat Rev Urol 13, no. 2 (February 2016): 99–107. https://doi.org/10.1038/nrurol.2015.298.Full Text Link to Item
-
Tay, Kae Jack, Judd W. Moul, and Andrew J. Armstrong. “Management of Prostate Cancer in the Elderly.” Clin Geriatr Med 32, no. 1 (February 2016): 113–32. https://doi.org/10.1016/j.cger.2015.08.001.Full Text Link to Item
-
Tay, Kae Jack, Rajan T. Gupta, Ardeshir R. Rastinehad, Efrat Tsivian, Stephen J. Freedland, Judd W. Moul, and Thomas J. Polascik. “Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls.” Expert Rev Anticancer Ther 16, no. 3 (2016): 303–11. https://doi.org/10.1586/14737140.2016.1131155.Full Text Link to Item
-
Moul, Judd W. “Hot topic of cancer survivorship and the 'seven deadly sins'.” Bju Int 116, no. 3 (September 2015): 310–11. https://doi.org/10.1111/bju.13115.Full Text Link to Item
-
Davis, Kristen, Sarah Wood, Emily Dill, Yuri Fesko, Rhonda L. Bitting, Michael R. Harrison, Andrew J. Armstrong, Judd W. Moul, and Daniel J. George. “Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.” Clin J Oncol Nurs 19, no. 3 (June 2015): 297–303. https://doi.org/10.1188/15.CJON.297-303.Full Text Link to Item
-
Moul, Judd W. “High-risk prostate cancer and radical prostatectomy in the setting and context of multidisciplinary care.” Urol Oncol 33, no. 5 (May 2015): 206–7. https://doi.org/10.1016/j.urolonc.2015.03.004.Full Text Link to Item
-
Tay, Kae Jack, Melissa Mendez, Judd W. Moul, and Thomas J. Polascik. “Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?” Curr Opin Urol 25, no. 3 (May 2015): 185–90. https://doi.org/10.1097/MOU.0000000000000168.Full Text Link to Item
-
Azrad, M., R. T. Vollmer, J. Madden, T. J. Polascik, D. C. Snyder, M. T. Ruffin, J. W. Moul, D. Brenner, X. He, and W. Demark-Wahnefried. “Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial.” Biotech Histochem 90, no. 3 (April 2015): 184–89. https://doi.org/10.3109/10520295.2014.976840.Full Text Link to Item
-
Crawford, E David, and Judd W. Moul. “ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.” Oncology (Williston Park) 29, no. 1 (January 2015): 55–66.Link to Item
-
Crawford, E. D., and J. W. Moul. “ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.” Oncology (Williston Park, N.Y.) 29, no. 1 (2015): 55–66.
-
Crawford, E David, Judd W. Moul, Oliver Sartor, and Neal D. Shore. “Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.” Expert Opinion on Drug Metabolism & Toxicology 11, no. 9 (January 2015): 1465–74. https://doi.org/10.1517/17425255.2015.1073711.Full Text
-
Moul, Judd W. “Hormone naïve prostate cancer: predicting and maximizing response intervals.” Asian J Androl 17, no. 6 (2015): 929–35. https://doi.org/10.4103/1008-682X.152821.Full Text Open Access Copy Link to Item
-
Qi, Robert, and Judd Moul. “High-Risk Prostate Cancer: Role of Radical Prostatectomy and Radiation Therapy.” Oncol Res Treat 38, no. 12 (2015): 639–44. https://doi.org/10.1159/000441736.Full Text Link to Item
-
Moul, Judd W., Mark J. Sarno, Jonathan E. McDermed, Melissa T. Triebell, and Mark A. Reynolds. “NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.” Urology 84, no. 6 (December 2014): 1427–32. https://doi.org/10.1016/j.urology.2014.07.059.Full Text Link to Item
-
Habib, Ashraf S., Judd W. Moul, Thomas J. Polascik, Cary N. Robertson, Anthony M. Roche, William D. White, Stephen E. Hill, Israel Nosnick, Tong J. Gan, and Tong J. Duke Perioperative Outcome Study Group. “Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial.” Curr Med Res Opin 30, no. 5 (May 2014): 937–43. https://doi.org/10.1185/03007995.2013.877436.Full Text Link to Item
-
Moul, Judd W. “Utility of LHRH antagonists for advanced prostate cancer.” Can J Urol 21, no. 2 Supp 1 (April 2014): 22–27.Link to Item
-
Halabi, Susan, Chen-Yen Lin, W Kevin Kelly, Karim S. Fizazi, Judd W. Moul, Ellen B. Kaplan, Michael J. Morris, and Eric J. Small. “Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.” J Clin Oncol 32, no. 7 (March 1, 2014): 671–77. https://doi.org/10.1200/JCO.2013.52.3696.Full Text Link to Item
-
Canfield, Steven E., Adam S. Kibel, Michael J. Kemeter, Phillip G. Febbo, H Jeffrey Lawrence, and Judd W. Moul. “A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.” Rev Urol 16, no. 4 (2014): 172–80.Link to Item
-
Moul, J. W. “Active surveillance for African-American men with prostate cancer: of course! Pro.” Oncology (Williston Park, N.Y.) 28, no. 1 (January 1, 2014).
-
Fizazi, Karim, Celestia S. Higano, Joel B. Nelson, Martin Gleave, Kurt Miller, Thomas Morris, Faith E. Nathan, Stuart McIntosh, Kristine Pemberton, and Judd W. Moul. “Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.” J Clin Oncol 31, no. 14 (May 10, 2013): 1740–47. https://doi.org/10.1200/JCO.2012.46.4149.Full Text Link to Item
-
Azrad, Maria, Robin T. Vollmer, John Madden, Mark Dewhirst, Thomas J. Polascik, Denise C. Snyder, Mack T. Ruffin, Judd W. Moul, Dean E. Brenner, and Wendy Demark-Wahnefried. “Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.” J Med Food 16, no. 4 (April 2013): 357–60. https://doi.org/10.1089/jmf.2012.0159.Full Text Link to Item
-
Kimura, M., L. L. Bañez, T. J. Polascik, R. M. Bernal, L. Gerber, C. N. Robertson, C. F. Donatucci, and J. W. Moul. “Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction.” Andrology 1, no. 2 (March 2013): 256–61. https://doi.org/10.1111/j.2047-2927.2012.00036.x.Full Text Link to Item
-
Abern, M. R., M. R. Bassett, M. Tsivian, L. L. Bañez, T. J. Polascik, M. N. Ferrandino, C. N. Robertson, S. J. Freedland, and J. W. Moul. “Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center.” Prostate Cancer Prostatic Dis 16, no. 1 (March 2013): 85–90. https://doi.org/10.1038/pcan.2012.38.Full Text Link to Item
-
Fu, Qiang, Judd W. Moul, Lionel Bañez, Leon Sun, Vladimir Mouraviev, Donghua Xie, and Thomas J. Polascik. “Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance.” Med Oncol 30, no. 1 (March 2013): 326. https://doi.org/10.1007/s12032-012-0326-5.Full Text Link to Item
-
Banez, L. L., L. Gerber, J. W. Moul, M. S. Anscher, W. R. Lee, and B. F. Koontz. “Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?” J Clin Oncol 31, no. 6_suppl (February 20, 2013): 56. https://doi.org/10.1200/jco.2013.31.6_suppl.56.Full Text Link to Item
-
Fu, Q., J. W. Moul, L. Bañez, L. Sun, V. Mouraviev, D. Xie, and T. J. Polascik. “Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance.” Medical Oncology (Northwood, London, England) 30, no. 1 (2013): 326–326.
-
Moul, Judd W., Hans Lilja, O John Semmes, Raymond S. Lance, Robert L. Vessella, Martin Fleisher, Clarisse Mazzola, et al. “NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.” Urology 80, no. 6 (December 2012): 1319–25. https://doi.org/10.1016/j.urology.2012.06.080.Full Text Link to Item
-
Stewart, S. B., C. D. Scales, J. W. Moul, and S. D. Reed. “Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?” Prostate Cancer Prostatic Dis 15, no. 4 (December 2012): 380–85. https://doi.org/10.1038/pcan.2012.26.Full Text Link to Item
-
Fu, Qiang, Judd W. Moul, Lionel L. Bañez, Leon Sun, Vladimir Mouraviev, Dongha Xie, and Thomas J. Polascik. “Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.” Med Oncol 29, no. 5 (December 2012): 3339–44. https://doi.org/10.1007/s12032-012-0270-4.Full Text Link to Item
-
Nelson, Joel B., Karim Fizazi, Kurt Miller, Celestia Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton, and Martin Gleave. “Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.” Cancer 118, no. 22 (November 15, 2012): 5709–18. https://doi.org/10.1002/cncr.27674.Full Text Link to Item
-
Campbell, Lisa C., Francis J. Keefe, Daphne C. McKee, Sandra J. Waters, and Judd W. Moul. “Masculinity beliefs predict psychosocial functioning in African American prostate cancer survivors.” Am J Mens Health 6, no. 5 (September 2012): 400–408. https://doi.org/10.1177/1557988312450185.Full Text Link to Item
-
Djavan, Bob, James Eastham, Leonard Gomella, Bertrand Tombal, Samir Taneja, Seyed Saeid Dianat, Amir Kazzazi, et al. “Testosterone in prostate cancer: the Bethesda consensus.” Bju Int 110, no. 3 (August 2012): 344–52. https://doi.org/10.1111/j.1464-410X.2011.10719.x.Full Text Link to Item
-
Catalona, W. J., A. V. D’Amico, W. F. Fitzgibbons, O. Kosoko-Lasaki, S. W. Leslie, H. T. Lynch, J. W. Moul, M. S. Rendell, and P. C. Walsh. “What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.” Annals of Internal Medicine 157, no. 2 (July 17, 2012): 137–38.
-
Catalona, William J., Anthony V. D’Amico, William F. Fitzgibbons, Omofolasade Kosoko-Lasaki, Stephen W. Leslie, Henry T. Lynch, Judd W. Moul, Marc S. Rendell, and Patrick C. Walsh. “What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.” Ann Intern Med 157, no. 2 (July 17, 2012): 137–38. https://doi.org/10.7326/0003-4819-157-2-201207170-00463.Full Text Link to Item
-
Moul, J. W. “Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard.” Oncology (Williston Park, N.Y.) 26, no. 7 (July 1, 2012).
-
Moul, Judd W. “Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard.” Oncology (Williston Park) 26, no. 7 (July 2012): 610–15.Link to Item
-
Yu, Evan Y., Kurt Miller, Joel Nelson, Martin Gleave, Karim Fizazi, Judd W. Moul, Faith E. Nathan, and Celestia S. Higano. “Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.” J Urol 188, no. 1 (July 2012): 103–9. https://doi.org/10.1016/j.juro.2012.03.008.Full Text Link to Item
-
Kimura, Masaki, Zahid N. Rabbani, Andrew R. Zodda, Hui Yan, Isabel L. Jackson, Thomas J. Polascik, Craig F. Donatucci, Judd W. Moul, Zeljko Vujaskovic, and Bridget F. Koontz. “Role of oxidative stress in a rat model of radiation-induced erectile dysfunction.” J Sex Med 9, no. 6 (June 2012): 1535–49. https://doi.org/10.1111/j.1743-6109.2012.02716.x.Full Text Link to Item
-
Boorjian, Stephen A., James A. Eastham, Markus Graefen, Bertrand Guillonneau, R Jeffrey Karnes, Judd W. Moul, Edward M. Schaeffer, Christian Stief, and Kevin C. Zorn. “A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.” Eur Urol 61, no. 4 (April 2012): 664–75. https://doi.org/10.1016/j.eururo.2011.11.053.Full Text Link to Item
-
Kimura, Masaki, Lionel L. Bañez, Leah Gerber, Jim Qi, Matvey Tsivian, Stephen J. Freedland, Takefumi Satoh, Thomas J. Polascik, Shiro Baba, and Judd W. Moul. “Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.” J Sex Med 9, no. 4 (April 2012): 1174–81. https://doi.org/10.1111/j.1743-6109.2011.02547.x.Full Text Link to Item
-
Wattson, Daniel A., Ming-Hui Chen, Brian J. Moran, Daniel E. Dosoretz, Michelle H. Braccioforte, Sharon A. Salenius, and Anthony V. D’Amico. “The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.” Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): e773–79. https://doi.org/10.1016/j.ijrobp.2011.11.023.Full Text Link to Item
-
Stephenson, Andrew J., Michel Bolla, Alberto Briganti, Cesare Cozzarini, Judd W. Moul, Mack Roach, Hein van Poppel, and Anthony Zietman. “Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.” Eur Urol 61, no. 3 (March 2012): 443–51. https://doi.org/10.1016/j.eururo.2011.10.010.Full Text Link to Item
-
Schroeck, Florian R., Tracey L. Krupski, Suzanne B. Stewart, Lionel L. Bañez, Leah Gerber, David M. Albala, and Judd W. Moul. “Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy.” J Urol 187, no. 3 (March 2012): 894–98. https://doi.org/10.1016/j.juro.2011.10.135.Full Text Link to Item
-
Moul, J. W., K. S. Ferenz, and B. D. Mautner. “Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 246.Link to Item
-
Moul, J. W., K. S. Ferenz, and B. D. Mautner. “Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 246. https://doi.org/10.1200/jco.2012.30.5_suppl.246.Full Text Link to Item
-
Singh, A. A., L. L. Banez, L. Gerber, S. J. Freedland, C. N. Robertson, M. Ferrandino, T. Polascik, P. J. Walther, and J. W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 34.Link to Item
-
Singh, A. A., L. L. Banez, L. Gerber, S. J. Freedland, C. N. Robertson, M. Ferrandino, T. Polascik, P. J. Walther, and J. W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.” J Clin Oncol 30, no. 5_suppl (February 10, 2012): 34. https://doi.org/10.1200/jco.2012.30.5_suppl.34.Full Text Link to Item
-
George, Daniel, and Judd W. Moul. “Emerging treatment options for patients with castration-resistant prostate cancer.” Prostate 72, no. 3 (February 2012): 338–49. https://doi.org/10.1002/pros.21435.Full Text Link to Item
-
Tang, Ping, Wei Du, Keji Xie, Jingao Fu, Hui Chen, Wenjun Yang, and Judd W. Moul. “Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.” Prostate 72, no. 2 (February 1, 2012): 173–80. https://doi.org/10.1002/pros.21418.Full Text Link to Item
-
Armstrong, A. J., J. W. Moul, and D. J. George. “What to order from the prostate cancer treatment menu?” Oncology (Williston Park, N.Y.) 26, no. 1 (January 1, 2012).
-
Koontz, Bridget F., Matvey Tsivian, Vladimir Mouraviev, Leon Sun, Zeljko Vujaskovic, Judd Moul, and W Robert Lee. “Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers.” Int J Radiat Oncol Biol Phys 82, no. 1 (January 1, 2012): 200–203. https://doi.org/10.1016/j.ijrobp.2010.11.023.Full Text Link to Item
-
Loeb, Stacy, H Ballentine Carter, William J. Catalona, Judd W. Moul, and Fritz H. Schroder. “Baseline prostate-specific antigen testing at a young age.” Eur Urol 61, no. 1 (January 2012): 1–7. https://doi.org/10.1016/j.eururo.2011.07.067.Full Text Link to Item
-
Moul, Judd W., and Nancy Dawson. “Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.” Cancer Invest 30, no. 1 (January 2012): 1–12. https://doi.org/10.3109/07357907.2011.629381.Full Text Link to Item
-
Stewart, Suzanne Biehn, Lionel L. Bañez, Cary N. Robertson, Stephen J. Freedland, Thomas J. Polascik, Donghua Xie, Bridget F. Koontz, et al. “Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.” J Urol 187, no. 1 (January 2012): 103–8. https://doi.org/10.1016/j.juro.2011.09.040.Full Text Link to Item
-
Azrad, Maria, Kui Zhang, Robin T. Vollmer, John Madden, Thomas J. Polascik, Denise C. Snyder, Mack T. Ruffin, et al. “Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism.” Plos One 7, no. 12 (2012): e53104. https://doi.org/10.1371/journal.pone.0053104.Full Text Open Access Copy Link to Item
-
Fu, Qiang, Judd W. Moul, Lionel L. Bañez, Leon Sun, Vladimir Mouraviev, Donghua Xie, and Thomas J. Polascik. “Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy.” Urol Int 89, no. 3 (2012): 296–300. https://doi.org/10.1159/000341556.Full Text Link to Item
-
Tsivian, Matvey, Daniel M. Moreira, Leon Sun, Vladimir Mouraviev, Masaki Kimura, Judd W. Moul, and Thomas J. Polascik. “Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight.” Urol Oncol 30, no. 1 (2012): 21–25. https://doi.org/10.1016/j.urolonc.2009.11.001.Full Text Link to Item
-
Chu, D. I., C. De Nunzio, L. Gerber, J. -. A. Thomas, E. E. Calloway, S. Albisinni, C. Senocak, et al. “Predictive value of digital rectal examination for prostate cancer detection is modified by obesity.” Prostate Cancer Prostatic Dis 14, no. 4 (December 2011): 346–53. https://doi.org/10.1038/pcan.2011.31.Full Text Link to Item
-
Bhaskar, R., A. Gkoulalas-Divanis, D. Kifer, S. Laxman, L. Singh, X. Wu, C. Clifton, et al. “Preface.” Proceedings Ieee International Conference on Data Mining, Icdm, December 1, 2011. https://doi.org/10.1109/ICDMW.2011.196.Full Text
-
Crawford, E David, Judd W. Moul, Kyle O. Rove, Curtis A. Pettaway, Lois E. Lamerato, and Alexa Hughes. “Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.” Bju Int 108, no. 11 (December 2011): 1743–49. https://doi.org/10.1111/j.1464-410X.2011.10224.x.Full Text Link to Item
-
Dreicer, Robert, Dean F. Bajorin, David G. McLeod, Daniel P. Petrylak, and Judd W. Moul. “New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.” Urology 78, no. 5 Suppl (November 2011): S494–98. https://doi.org/10.1016/j.urology.2011.06.058.Full Text Link to Item
-
Dreicer, Robert, Martin Gleave, Adam S. Kibel, J Brantley Thrasher, and Judd W. Moul. “Targeting the androgen receptor--theory and practice.” Urology 78, no. 5 Suppl (November 2011): S482–84. https://doi.org/10.1016/j.urology.2011.05.052.Full Text Link to Item
-
Moul, Judd W., Adam S. Kibel, Mack Roach, and Robert Dreicer. “Indications and practice with androgen deprivation therapy.” Urology 78, no. 5 Suppl (November 2011): S478–81. https://doi.org/10.1016/j.urology.2011.04.025.Full Text Link to Item
-
Moul, Judd W., Christopher P. Evans, Leonard G. Gomella, Mack Roach, and Robert Dreicer. “Traditional approaches to androgen deprivation therapy.” Urology 78, no. 5 Suppl (November 2011): S485–93. https://doi.org/10.1016/j.urology.2011.05.051.Full Text Link to Item
-
Moul, Judd W., and Robert Dreicer. “Focusing on testosterone.” Urology 78, no. 5 Suppl (November 2011): S476–77. https://doi.org/10.1016/j.urology.2011.06.004.Full Text Link to Item
-
Albers, Peter, Ferran Algaba, Gabriella Cohn-Cedermark, Maria DeSantis, Sabine Kliesch, and Judd W. Moul. “Diagnosis, staging, and risk factors: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.” Urology 78, no. 4 Suppl (October 2011): S427–34. https://doi.org/10.1016/j.urology.2011.03.053.Full Text Link to Item
-
Kimura, Masaki, Lionel L. Bañez, Florian R. Schroeck, Leah Gerber, Jim Qi, Takefumi Satoh, Shiro Baba, et al. “Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.” J Sex Med 8, no. 10 (October 2011): 2935–43. https://doi.org/10.1111/j.1743-6109.2011.02387.x.Full Text Link to Item
-
Cotter, Shane E., Ming Hui Chen, Judd W. Moul, W Robert Lee, Bridget F. Koontz, Mitchell S. Anscher, Cary N. Robertson, Philip J. Walther, Thomas J. Polascik, and Anthony V. D’Amico. “Salvage radiation in men after prostate-specific antigen failure and the risk of death.” Cancer 117, no. 17 (September 1, 2011): 3925–32. https://doi.org/10.1002/cncr.25993.Full Text Link to Item
-
Crawford, E David, Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Fritz Schröder, Neal Shore, Judd W. Moul, Jens-Kristian Jensen, Tine Kold Olesen, and Bo-Eric Persson. “A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.” J Urol 186, no. 3 (September 2011): 889–97. https://doi.org/10.1016/j.juro.2011.04.083.Full Text Link to Item
-
Arvold, Nils D., Ming-Hui Chen, Judd W. Moul, Brian J. Moran, Daniel E. Dosoretz, Lionel L. Bañez, Michael J. Katin, Michelle H. Braccioforte, and Anthony V. D’Amico. “Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.” J Urol 186, no. 1 (July 2011): 91–96. https://doi.org/10.1016/j.juro.2011.03.003.Full Text Link to Item
-
Tang, Ping, Leon Sun, Matthew A. Uhlman, Cary N. Robertson, Thomas J. Polascik, and Judd W. Moul. “Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men.” Bju Int 108, no. 1 (July 2011): 44–48. https://doi.org/10.1111/j.1464-410X.2010.09812.x.Full Text Link to Item
-
Tripathy, D., J. W. Moul, B. G. Durie, and B. D. Mautner. “Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): e19617.Link to Item
-
George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 4664.Link to Item
-
Moul, J. W. “What matters young low-risk men present conundrum.” Oncology Report, no. MAY (May 1, 2011): 12.
-
Arvold, N. D., M. Chen, J. W. Moul, B. J. Moran, D. E. Dosoretz, L. L. Banez, M. J. Katin, M. H. Braccioforte, and A. V. D’Amico. “Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease.” J Clin Oncol 29, no. 7_suppl (March 2011): 198.Link to Item
-
Moul, J. W., O. J. Semmes, R. Vessella, J. E. McDermed, and H. Lilja. “Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA.” J Clin Oncol 29, no. 7_suppl (March 2011): 47.Link to Item
-
Moul, Judd W. “Putting Provenge in perspective.” Oncology (Williston Park, N.Y.) 25, no. 3 (March 2011): 255–58.
-
Nelson, J. B., K. Fizazi, K. Miller, C. S. Higano, J. W. Moul, T. Morris, S. McIntosh, K. Pemberton, and M. E. Gleave. “Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).” J Clin Oncol 29, no. 7_suppl (March 2011): 117.Link to Item
-
Reed, Shelby D., Charles D. Scales, Suzanne B. Stewart, Jielin Sun, Judd W. Moul, Kevin A. Schulman, and Jianfeng Xu. “Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.” J Urol 185, no. 3 (March 2011): 841–47. https://doi.org/10.1016/j.juro.2010.10.078.Full Text Link to Item
-
Shore, N. D., J. W. Moul, E. Crawford, E. van der Meulen, T. Olesen, and B. Persson. “Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer.” J Clin Oncol 29, no. 7_suppl (March 2011): 12.Link to Item
-
Arvold, N. D., M. Chen, J. W. Moul, B. J. Moran, D. E. Dosoretz, L. L. Banez, M. J. Katin, M. H. Braccioforte, and A. V. D’Amico. “Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease.” Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 198–198. https://doi.org/10.1200/jco.2011.29.7_suppl.198.Full Text
-
Fu, Qiang, Judd W. Moul, and Leon Sun. “Contemporary radical prostatectomy.” Prostate Cancer 2011 (2011): 645030. https://doi.org/10.1155/2011/645030.Full Text Open Access Copy Link to Item
-
D’Amico, Anthony V., Ming-Hui Chen, Leon Sun, W Robert Lee, Vladimir Mouraviev, Cary N. Robertson, Philip J. Walther, Thomas J. Polascik, David M. Albala, and Judd W. Moul. “Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.” Bju Int 106, no. 11 (December 2010): 1618–22. https://doi.org/10.1111/j.1464-410X.2010.09447.x.Full Text Link to Item
-
Caso, Jorge R., Matvey Tsivian, Vladimir Mouraviev, Thomas J. Polascik, and Judd W. Moul. “Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer.” Bju Int 106, no. 11 (December 2010): 1623–27. https://doi.org/10.1111/j.1464-410X.2010.09439.x.Full Text Link to Item
-
Moreira, Daniel M., Joseph C. Presti, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Leon L. Sun, Judd W. Moul, and Stephen J. Freedland. “Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.” Int J Urol 17, no. 11 (November 2010): 914–22. https://doi.org/10.1111/j.1442-2042.2010.02631.x.Full Text Link to Item
-
Tang, Ping, Leon Sun, Matthew A. Uhlman, Cary N. Robertson, Thomas J. Polascik, David M. Albala, Craig F. Donatucci, and Judd W. Moul. “Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.” Urology 76, no. 5 (November 2010): 1058–62. https://doi.org/10.1016/j.urology.2009.09.049.Full Text Link to Item
-
Tang, Ping, Leon Sun, Matthew A. Uhlman, Thomas J. Polascik, Stephen J. Freedland, and Judd W. Moul. “Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience.” Cancer 116, no. 20 (October 15, 2010): 4711–17. https://doi.org/10.1002/cncr.25447.Full Text Link to Item
-
Ali, Amina, Bungo Furusato, Paul O. P. Ts’o, Zhao-Ping Lum, Sally Elsamanoudi, Ahmed Mohamed, Shiv Srivastava, et al. “Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.” Pathol Int 60, no. 10 (October 2010): 667–72. https://doi.org/10.1111/j.1440-1827.2010.02584.x.Full Text Link to Item
-
Caire, Arthur A., Leon Sun, Thomas J. Polascik, David M. Albala, and Judd W. Moul. “Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans.” Bju Int 106, no. 8 (October 2010): 1157–60. https://doi.org/10.1111/j.1464-410X.2010.09340.x.Full Text Link to Item
-
Caire, A. A., L. Sun, B. D. Lack, K. Lum, P. Tang, D. A. Stackhouse, C. N. Robertson, et al. “Predicting non-organ-confined prostate cancer in men diagnosed after 2000.” Prostate Cancer Prostatic Dis 13, no. 3 (September 2010): 248–51. https://doi.org/10.1038/pcan.2010.15.Full Text Link to Item
-
Teeter, Anna E., Leon Sun, Judd W. Moul, and Stephen J. Freedland. “External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database.” Bju Int 106, no. 6 (September 2010): 796–800. https://doi.org/10.1111/j.1464-410X.2010.09214.x.Full Text Link to Item
-
Droz, Jean-Pierre, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, et al. “Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.” Bju Int 106, no. 4 (August 2010): 462–69. https://doi.org/10.1111/j.1464-410X.2010.09334.x.Full Text Open Access Copy Link to Item
-
Hammerich, Kai H., Florian R. Schroeck, Dava West, and Judd W. Moul. “Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist.” Oncology (Williston Park) 24, no. 8 (July 2010): 757–60.Link to Item
-
Schröder, Fritz H., Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Neal D. Shore, E David Crawford, Judd Moul, Tine Kold Olesen, and Bo-Eric Persson. “Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.” Bju Int 106, no. 2 (July 2010): 182–87. https://doi.org/10.1111/j.1464-410X.2009.08981.x.Full Text Link to Item
-
Schroeck, Florian R., Michael W. Kattan, Judd W. Moul, William J. Aronson, Joseph C. Presti, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Leon Sun, and Stephen J. Freedland. “Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.” Bju Int 105, no. 12 (June 2010): 1654–59. https://doi.org/10.1111/j.1464-410X.2009.09060.x.Full Text Link to Item
-
Caire, Arthur A., Leon Sun, Cary N. Robertson, Thomas J. Polascik, Kelly E. Maloney, Daniel J. George, Marva M. Price, et al. “Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.” Urology 75, no. 5 (May 2010): 1122–27. https://doi.org/10.1016/j.urology.2009.06.091.Full Text Link to Item
-
Caso, Jorge R., Vladimir Mouraviev, Matvey Tsivian, Thomas J. Polascik, and Judd W. Moul. “Prostate cancer: an evolving paradigm.” J Endourol 24, no. 5 (May 2010): 805–9. https://doi.org/10.1089/end.2009.0539.Full Text Open Access Copy Link to Item
-
Tombal, Bertrand, Kurt Miller, Laurent Boccon-Gibod, Fritz Schröder, Neal Shore, E David Crawford, Judd Moul, Jens-Kristian Jensen, Tine Kold Olesen, and Bo-Eric Persson. “Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.” Eur Urol 57, no. 5 (May 2010): 836–42. https://doi.org/10.1016/j.eururo.2009.11.029.Full Text Link to Item
-
Choueiri, Toni K., Ming-Hui Chen, Anthony V. D’Amico, Leon Sun, Paul L. Nguyen, Julia H. Hayes, Cary N. Robertson, et al. “Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.” Cancer 116, no. 8 (April 15, 2010): 1887–92. https://doi.org/10.1002/cncr.25013.Full Text Link to Item
-
Uhlman, Matthew A., Leon Sun, Danielle A. Stackhouse, Thomas J. Polascik, Valdmir Mouraviev, Cary N. Robertson, David M. Albala, and Judd W. Moul. “Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.” J Urol 183, no. 3 (March 2010): 997–1001. https://doi.org/10.1016/j.juro.2009.11.046.Full Text Link to Item
-
Moreira, D. M., J. C. Presti, W. J. Aronson, M. K. Terris, C. J. Kane, C. L. Amling, L. L. Sun, J. W. Moul, and S. J. Freedland. “The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.” Prostate Cancer Prostatic Dis 13, no. 1 (March 2010): 87–93. https://doi.org/10.1038/pcan.2009.48.Full Text Link to Item
-
Tang, Ping, Leon Sun, Matthew A. Uhlman, Cary N. Robertson, Thomas J. Polascik, David M. Albala, Craig F. Donatucci, and Judd W. Moul. “Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.” J Urol 183, no. 3 (March 2010): 946–50. https://doi.org/10.1016/j.juro.2009.11.021.Full Text Link to Item
-
Uhlman, Matthew A., Leon Sun, Danielle A. Stackhouse, Arthur A. Caire, Thomas J. Polascik, Cary N. Robertson, John Madden, Robin Vollmer, David M. Albala, and Judd W. Moul. “Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?” Urology 75, no. 2 (February 2010): 460–66. https://doi.org/10.1016/j.urology.2009.06.059.Full Text Link to Item
-
Kawachi, Mark H., Robert R. Bahnson, Michael Barry, J Erik Busby, Peter R. Carroll, H Ballentine Carter, William J. Catalona, et al. “NCCN clinical practice guidelines in oncology: prostate cancer early detection.” J Natl Compr Canc Netw 8, no. 2 (February 2010): 240–62. https://doi.org/10.6004/jnccn.2010.0016.Full Text Link to Item
-
Droz, Jean-Pierre, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, et al. “Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.” Crit Rev Oncol Hematol 73, no. 1 (January 2010): 68–91. https://doi.org/10.1016/j.critrevonc.2009.09.005.Full Text Link to Item
-
Sun, Leon, Arthur A. Caire, Cary N. Robertson, Daniel J. George, Thomas J. Polascik, Kelly E. Maloney, Philip J. Walther, et al. “Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.” J Urol 182, no. 5 (November 2009): 2242–48. https://doi.org/10.1016/j.juro.2009.07.034.Full Text Link to Item
-
Chino, Junzo, Florian R. Schroeck, Leon Sun, W Robert Lee, David M. Albala, Judd W. Moul, and Bridget F. Koontz. “Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy.” Bju Int 104, no. 10 (November 2009): 1496–1500. https://doi.org/10.1111/j.1464-410X.2009.08588.x.Full Text Link to Item
-
Tsivian, Matvey, Leon Sun, Vladimir Mouraviev, John F. Madden, Janice M. Mayes, Judd W. Moul, and Thomas J. Polascik. “Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy.” Urology 74, no. 5 (November 2009): 1090–93. https://doi.org/10.1016/j.urology.2009.03.043.Full Text Link to Item
-
Uhlman, M. A., J. W. Moul, C. N. Robertson, and L. Sun. “Prostate-specific antigen screening and prostate cancer mortality: Implications of a randomized European study.” Aging Health 5, no. 3 (September 18, 2009): 281–86. https://doi.org/10.2217/ahe.09.29.Full Text
-
Caire, Arthur A., Leon Sun, Oludotun Ode, Danielle A. Stackhouse, Kelly Maloney, Craig Donatucci, Vladimir Mouraviev, et al. “Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?” Urology 74, no. 3 (September 2009): 643–47. https://doi.org/10.1016/j.urology.2009.02.049.Full Text Link to Item
-
Uhlman, Matthew A., Judd W. Moul, Ping Tang, Danielle A. Stackhouse, and Leon Sun. “Risk stratification in the hormonal treatment of patients with prostate cancer.” Ther Adv Med Oncol 1, no. 2 (September 2009): 79–94. https://doi.org/10.1177/1758834009340164.Full Text Link to Item
-
Xu, David D., Sandy D. Sun, Flint Wang, Leon Sun, Danielle Stackhouse, Thomas Polascik, David M. Albala, Judd W. Moul, Arthur Caire, and Cary N. Robertson. “Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.” Urology 74, no. 3 (September 2009): 654–58. https://doi.org/10.1016/j.urology.2008.12.063.Full Text Link to Item
-
Bañez, Lionel L., Leon Sun, Bruce J. Trock, Misop Han, Alan W. Partin, William J. Aronson, Martha K. Terris, et al. “Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.” J Urol 182, no. 2 (August 2009): 491–96. https://doi.org/10.1016/j.juro.2009.04.007.Full Text Link to Item
-
D’Alonzo, Richard C., Tong J. Gan, Judd W. Moul, David M. Albala, Thomas J. Polascik, Cary N. Robertson, Leon Sun, Philipp Dahm, and Ashraf S. Habib. “A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.” J Clin Anesth 21, no. 5 (August 2009): 322–28. https://doi.org/10.1016/j.jclinane.2008.09.005.Full Text Link to Item
-
Ou, Yangming, Dinggang Shen, Jianchao Zeng, Leon Sun, Judd Moul, and Christos Davatzikos. “Sampling the spatial patterns of cancer: optimized biopsy procedures for estimating prostate cancer volume and Gleason Score.” Med Image Anal 13, no. 4 (August 2009): 609–20. https://doi.org/10.1016/j.media.2009.05.002.Full Text Link to Item
-
Bañez, Lionel L., Gary W. Blake, David G. McLeod, E David Crawford, and Judd W. Moul. “Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.” Bju Int 104, no. 3 (August 2009): 310–14. https://doi.org/10.1111/j.1464-410X.2009.08400.x.Full Text Link to Item
-
Stackhouse, Danielle A., Leon Sun, Florian R. Schroeck, Jayakrishnan Jayachandran, Arthur A. Caire, Cyril O. Acholo, Cary N. Robertson, et al. “Factors predicting prostatic biopsy Gleason sum under grading.” J Urol 182, no. 1 (July 2009): 118–22. https://doi.org/10.1016/j.juro.2009.02.127.Full Text Link to Item
-
Habib, Ashraf S., Thomas J. Polascik, Alon Z. Weizer, William D. White, Judd W. Moul, Magdi A. ElGasim, and Tong J. Gan. “Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy.” Anesth Analg 108, no. 6 (June 2009): 1950–53. https://doi.org/10.1213/ane.0b013e3181a21185.Full Text Link to Item
-
Polascik, Thomas J., Janice M. Mayes, Florian R. Schroeck, Leon Sun, John F. Madden, Judd W. Moul, and Vladimir Mouraviev. “Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.” Cancer 115, no. 10 (May 15, 2009): 2104–10. https://doi.org/10.1002/cncr.24258.Full Text Link to Item
-
Caire, Arthur A., Leon Sun, Thomas J. Polascik, Cary N. Robertson, Kelly E. Maloney, Craig F. Donatucci, Daivd M. Albala, and Judd W. Moul. “PREDICTING NON-ORGAN CONFINED PROSTATE CANCER AFTER THE YEAR 2000.” The Journal of Urology 181, no. 4 (April 2009): 609–609. https://doi.org/10.1016/s0022-5347(09)61710-9.Full Text
-
Chen, Valerie H., Vladimir Mouraviev, Janice M. Mayes, Leon Sun, John F. Madden, Judd W. Moul, and Thomas J. Polascik. “Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection.” Technol Cancer Res Treat 8, no. 2 (April 2009): 99–104. https://doi.org/10.1177/153303460900800202.Full Text Link to Item
-
Lack, Benjamin D., Leon Sun, Arthur A. Caire, Craig F. Donatucci, Cary N. Robertson, Vladimir Mouraviev, Thomas J. Polascik, et al. “WHO DOES NOT NEED FOLLOW UP TWO YEARS AFTER PROSTATECTOMY? AN ANALYSIS OF 1739 PATIENTS AT DUKE UNIVERSITY MEDICAL CENTER.” Journal of Urology 181, no. 4S (April 2009): 759–759. https://doi.org/10.1016/s0022-5347(09)62115-7.Full Text
-
Lack, Benjamin D., Leon Sun, Arthur A. Caire, Oludotun Ode, Danielle A. Stackhouse, Kelly E. Maloney, Craig F. Donatucci, et al. “DELAYED PSA RECURRENCE AFTER RADICAL PROSTATECTOMY: HOW TO IDENTIFY PATIENTS AT RISK AND THEIR CLINICAL OUTCOMES?” Journal of Urology 181, no. 4S (April 2009): 457–457. https://doi.org/10.1016/s0022-5347(09)61296-9.Full Text
-
Moul, Judd W., Leon Sun, Benjamin D. Lack, Cary N. Robertson, Thomas J. Polascik, Craig F. Donatucci, Kelly E. Maloney, Marva Price, David M. Albala, and Arthur A. Caire. “SAY NO TO THE US PREVENTATIVE TASK FORCE RECOMMENDATION TO NO LONGER OFFER PROSTATE CANCER SCREENING AFTER AGE 75?” Journal of Urology 181, no. 4S (April 2009): 797–797. https://doi.org/10.1016/s0022-5347(09)62222-9.Full Text
-
Stackhouse, Danielle A., Leon Sun, Philipp Dahm, Louis R. Kavoussi, David Paulson, Craig F. Donatucci, Kelly E. Maloney, et al. “PERINEAL RADICAL PROSTATECTOMY: WHAT ARE THE TEN YEAR OUTCOMES?” Journal of Urology 181, no. 4S (April 2009): 210–210. https://doi.org/10.1016/s0022-5347(09)60604-2.Full Text
-
Nguyen, Paul L., Ming-Hui Chen, William J. Catalona, Judd W. Moul, Leon Sun, and Anthony V. D’Amico. “Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.” Int J Radiat Oncol Biol Phys 73, no. 3 (March 1, 2009): 659–64. https://doi.org/10.1016/j.ijrobp.2008.05.009.Full Text Link to Item
-
Moul, Judd W., Vladimir Mouraviev, Leon Sun, Florian R. Schroeck, and Thomas J. Polascik. “Prostate cancer: the new landscape.” Curr Opin Urol 19, no. 2 (March 2009): 154–60. https://doi.org/10.1097/mou.0b013e328323f5d6.Full Text Link to Item
-
Schroeck, F. R., T. L. Krupski, L. Sun, D. M. Albala, M. M. Price, T. J. Polascik, C. N. Robertson, A. K. Tewari, and J. W. Moul. “Satisfaction and Regret After Open Retropubic or Robot-Assisted Laparoscopic Radical Prostatectomy.” Journal of Urology 181, no. 2 (February 1, 2009): 635–36.Link to Item
-
Moul, J. “Prostate Cancer and Prostatic Diseases. Report from Durham.” Prostate Cancer Prostatic Dis 12, no. 1 (2009): 1. https://doi.org/10.1038/pcan.2009.1.Full Text Link to Item
-
Freedland, S. J., L. L. Bañez, L. L. Sun, N. J. Fitzsimons, and J. W. Moul. “Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database.” Prostate Cancer Prostatic Dis 12, no. 3 (2009): 259–63. https://doi.org/10.1038/pcan.2009.11.Full Text Link to Item
-
Moul, Judd W. “Post-radical prostatectomy management options for positive surgical margins: argument for observation.” Urol Oncol 27, no. 1 (2009): 92–96. https://doi.org/10.1016/j.urolonc.2008.04.011.Full Text Link to Item
-
Demark-Wahnefried, Wendy, Thomas J. Polascik, Stephen L. George, Boyd R. Switzer, John F. Madden, Mack T. Ruffin, Denise C. Snyder, et al. “Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.” Cancer Epidemiol Biomarkers Prev 17, no. 12 (December 2008): 3577–87. https://doi.org/10.1158/1055-9965.EPI-08-0008.Full Text Link to Item
-
Schroeck, Florian R., Craig F. Donatucci, Emily C. Smathers, Leon Sun, David M. Albala, Thomas J. Polascik, Judd W. Moul, and Tracey L. Krupski. “Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite.” Cancer 113, no. 10 (November 15, 2008): 2687–94. https://doi.org/10.1002/cncr.23887.Full Text Link to Item
-
Fitzpatrick, John M., John Anderson, Cora N. Sternberg, Neil Fleshner, Karim Fizazi, Xavier Rébillard, Luigi Dogliotti, et al. “Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.” Crit Rev Oncol Hematol 68 Suppl 1 (October 2008): S9–22. https://doi.org/10.1016/j.critrevonc.2008.07.019.Full Text Link to Item
-
Isariyawongse, Brandon K., Leon Sun, Lionel L. Bañez, Cary Robertson, Thomas J. Polascik, Kelly Maloney, Craig Donatucci, et al. “Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.” Urology 72, no. 4 (October 2008): 882–86. https://doi.org/10.1016/j.urology.2008.02.021.Full Text Link to Item
-
Polascik, Thomas J., Janice M. Mayes, Leon Sun, John F. Madden, Judd W. Moul, and Vladimir Mouraviev. “Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.” Prostate 68, no. 13 (September 15, 2008): 1380–86. https://doi.org/10.1002/pros.20804.Full Text Link to Item
-
Scales, Charles D., Jodi Antonelli, Lesley H. Curtis, Kevin A. Schulman, and Judd W. Moul. “Prostate-specific antigen screening among young men in the United States.” Cancer 113, no. 6 (September 15, 2008): 1315–23. https://doi.org/10.1002/cncr.23667.Full Text Link to Item
-
Freedland, Stephen J., Leon Sun, Christopher J. Kane, Joseph C. Presti, Martha K. Terris, Christopher L. Amling, Judd W. Moul, and William J. Aronson. “Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.” Bju Int 102, no. 8 (September 2008): 969–74. https://doi.org/10.1111/j.1464-410X.2008.07934.x.Full Text Link to Item
-
Habib, Ashraf S., William D. White, Magdi A. El Gasim, Gamal Saleh, Thomas J. Polascik, Judd W. Moul, and Tong J. Gan. “Transdermal nicotine for analgesia after radical retropubic prostatectomy.” Anesth Analg 107, no. 3 (September 2008): 999–1004. https://doi.org/10.1213/ane.0b013e31816f2616.Full Text Link to Item
-
Rampersaud, Edward N., Leon Sun, Judd W. Moul, John Madden, and Stephen J. Freedland. “Percent tumor involvement and risk of biochemical progression after radical prostatectomy.” J Urol 180, no. 2 (August 2008): 571–76. https://doi.org/10.1016/j.juro.2008.04.017.Full Text Link to Item
-
Schroeck, Florian R., Leon Sun, Stephen J. Freedland, David M. Albala, Vladimir Mouraviev, Thomas J. Polascik, and Judd W. Moul. “Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.” Bju Int 102, no. 1 (July 2008): 28–32. https://doi.org/10.1111/j.1464-410X.2008.07607.x.Full Text Link to Item
-
Weinrich, Sally P., Rachelle E. Seger, Ganesh S. Rao, Evelyn C. Chan, Robert M. Hamm, Paul A. Godley, Judd W. Moul, et al. “A decision aid for teaching limitations of prostate cancer screening.” J Natl Black Nurses Assoc 19, no. 1 (July 2008): 1–11.Link to Item
-
Mouraviev, Vladimir, Gloria Broadwater, Leon Sun, Janice M. Mayes, Judd W. Moul, and Thomas J. Polascik. “Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?” Urology 71, no. 6 (June 2008): 1020–23. https://doi.org/10.1016/j.urology.2007.11.016.Full Text Link to Item
-
Koontz, Bridget F., Vladimir Mouraviev, Jeffrey L. Johnson, Janice Mayes, Stephanie H. Chen, Terence Z. Wong, Mitchell S. Anscher, Leon Sun, Judd Moul, and Thomas J. Polascik. “Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.” Int J Radiat Oncol Biol Phys 71, no. 2 (June 1, 2008): 358–61. https://doi.org/10.1016/j.ijrobp.2007.10.020.Full Text Link to Item
-
Koontz, Bridget F., and Judd Moul. “Re: Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.” Cancer 112, no. 11 (June 2008): 2518–19. https://doi.org/10.1002/cncr.23464.Full Text Link to Item
-
Moul, J. W., D. Wiederkehr, M. Connolly, V. Sendersky, and E. Onel. “The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 16002.Link to Item
-
Moul, Judd W., Hongyu Wu, Leon Sun, David G. McLeod, Christopher Amling, Timothy Donahue, Leo Kusuda, et al. “Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.” J Urol 179, no. 5 Suppl (May 2008): S53–59. https://doi.org/10.1016/j.juro.2008.03.138.Full Text Link to Item
-
Schroeck, Florian R., Chiquita A Palha de Sousa, Ross A. Kalman, Maitri S. Kalia, Sean A. Pierre, George E. Haleblian, Leon Sun, Judd W. Moul, and David M. Albala. “Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate.” Urology 71, no. 4 (April 2008): 597–601. https://doi.org/10.1016/j.urology.2007.12.023.Full Text Link to Item
-
Whittemore, Darren E., Eric J. Hick, Mark R. Carter, Judd W. Moul, Alejandro J. Miranda-Sousa, and Wade J. Sexton. “Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.” J Urol 179, no. 2 (February 2008): 516–22. https://doi.org/10.1016/j.juro.2007.09.085.Full Text Link to Item
-
Schroeck, F. R., L. Sun, S. J. Freedland, J. Jayachandran, C. N. Robertson, and J. W. Moul. “Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.” Prostate Cancer Prostatic Dis 11, no. 4 (2008): 371–76. https://doi.org/10.1038/pcan.2008.18.Full Text Link to Item
-
Fitzsimons, Nicholas J., Leon L. Sun, Philipp Dahm, Judd W. Moul, John Madden, Tong J. Gan, and Stephen J. Freedland. “A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database.” Urology 70, no. 6 (December 2007): 1146–51. https://doi.org/10.1016/j.urology.2007.07.065.Full Text Link to Item
-
Mouraviev, Vladimir, Leon Sun, John F. Madden, Janice M. Mayes, Judd W. Moul, and Thomas J. Polascik. “Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.” Urology 70, no. 6 (December 2007): 1141–45. https://doi.org/10.1016/j.urology.2007.07.066.Full Text Link to Item
-
Scales, Charles D., Judd W. Moul, Lesley H. Curtis, Eric P. Elkin, M. E. Hughes, Peter R. Carroll, and Peter R. CaPSURE Investigators. “Prostate cancer in the Baby Boomer generation: results from CaPSURE.” Urology 70, no. 6 (December 2007): 1162–67. https://doi.org/10.1016/j.urology.2007.08.011.Full Text Link to Item
-
Bañez, Lionel L., Robert J. Hamilton, Alan W. Partin, Robin T. Vollmer, Leon Sun, Carmen Rodriguez, Yiting Wang, et al. “Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.” Jama 298, no. 19 (November 21, 2007): 2275–80. https://doi.org/10.1001/jama.298.19.2275.Full Text Link to Item
-
Moul, Judd W., Lionel L. Bañez, and Stephen J. Freedland. “Rising PSA in nonmetastatic prostate cancer.” Oncology (Williston Park) 21, no. 12 (November 2007): 1436–45.Link to Item
-
Nosnik, Israel P., Tong J. Gan, and Judd W. Moul. “Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer?” Expert Rev Anticancer Ther 7, no. 9 (September 2007): 1309–17. https://doi.org/10.1586/14737140.7.9.1309.Full Text Link to Item
-
Mouraviev, Vladimir, Janice M. Mayes, Leon Sun, John F. Madden, Judd W. Moul, and Thomas J. Polascik. “Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.” Cancer 110, no. 4 (August 15, 2007): 906–10. https://doi.org/10.1002/cncr.22858.Full Text Link to Item
-
Burnett, Arthur L., Gunnar Aus, Edith D. Canby-Hagino, Michael S. Cookson, Anthony V. D’Amico, Roger R. Dmochowski, David T. Eton, et al. “Erectile function outcome reporting after clinically localized prostate cancer treatment.” J Urol 178, no. 2 (August 2007): 597–601. https://doi.org/10.1016/j.juro.2007.03.140.Full Text Link to Item
-
Kawachi, Mark H., Robert R. Bahnson, Michael Barry, Peter R. Carroll, H Ballentine Carter, William J. Catalona, Jonathan I. Epstein, et al. “Prostate cancer early detection. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw 5, no. 7 (August 2007): 714–36.Link to Item
-
__. “Prostate Cancer Early Detection.” Journal of the National Comprehensive Cancer Network 5, no. 7 (August 2007): 714–714. https://doi.org/10.6004/jnccn.2007.0064.Full Text
-
D’Amico, Anthony V., Ming-Hui Chen, William J. Catalona, Leon Sun, Kimberly A. Roehl, and Judd W. Moul. “Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.” Cancer 110, no. 1 (July 1, 2007): 56–61. https://doi.org/10.1002/cncr.22737.Full Text Link to Item
-
Freedland, Stephen J., and Judd W. Moul. “Prostate specific antigen recurrence after definitive therapy.” J Urol 177, no. 6 (June 2007): 1985–91. https://doi.org/10.1016/j.juro.2007.01.137.Full Text Link to Item
-
Thompson, Ian, James Brantley Thrasher, Gunnar Aus, Arthur L. Burnett, Edith D. Canby-Hagino, Michael S. Cookson, Anthony V. D’Amico, et al. “Guideline for the management of clinically localized prostate cancer: 2007 update.” J Urol 177, no. 6 (June 2007): 2106–31. https://doi.org/10.1016/j.juro.2007.03.003.Full Text Link to Item
-
Zhan, Yiqiang, Dinggang Shen, Jianchao Zeng, Leon Sun, Gabor Fichtinger, Judd Moul, and Christos Davatzikos. “Targeted prostate biopsy using statistical image analysis.” Ieee Trans Med Imaging 26, no. 6 (June 2007): 779–88. https://doi.org/10.1109/TMI.2006.891497.Full Text Link to Item
-
Moul, Judd W. “Timely diagnosis of testicular cancer.” Urol Clin North Am 34, no. 2 (May 2007): 109–17. https://doi.org/10.1016/j.ucl.2007.02.003.Full Text Link to Item
-
Robinson, Marnie R., and Judd W. Moul. “Novel techniques for the treatment of localized prostate cancer: evidence of efficacy?” Curr Urol Rep 8, no. 3 (May 2007): 203–10. https://doi.org/10.1007/s11934-007-0007-7.Full Text Link to Item
-
Sun, Leon, Judd W. Moul, James M. Hotaling, Edward Rampersaud, Phillipp Dahm, Cary Robertson, Nicholas Fitzsimons, David Albala, and Thomas J. Polascik. “Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.” Bju Int 99, no. 4 (April 2007): 753–57. https://doi.org/10.1111/j.1464-410X.2006.06682.x.Full Text Link to Item
-
Tseng, Timothy Y., Quinton V. Cancel, Susan F. Fesperman, Hubert R. Kuebler, Leon Sun, Cary N. Robertson, Thomas J. Polascik, et al. “The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy.” J Urol 177, no. 4 (April 2007): 1318–23. https://doi.org/10.1016/j.juro.2006.11.035.Full Text Link to Item
-
Armstrong, A. J., P. G. Febbo, D. J. George, and J. Moul. “Systemic strategies for prostate cancer.” Minerva Urol Nefrol 59, no. 1 (March 2007): 11–25.Link to Item
-
Fitzsimons, Nicholas J., Leon Sun, and Judd W. Moul. “Medical technologies for the diagnosis of prostate cancer.” Expert Rev Med Devices 4, no. 2 (March 2007): 227–39. https://doi.org/10.1586/17434440.4.2.227.Full Text Link to Item
-
Cookson, Michael S., Gunnar Aus, Arthur L. Burnett, Edith D. Canby-Hagino, Anthony V. D’Amico, Roger R. Dmochowski, David T. Eton, et al. “Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.” J Urol 177, no. 2 (February 2007): 540–45. https://doi.org/10.1016/j.juro.2006.10.097.Full Text Link to Item
-
Moul, Judd W., Leon Sun, James M. Hotaling, Nicholas J. Fitzsimons, Thomas J. Polascik, Cary N. Robertson, Philipp Dahm, et al. “Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.” J Urol 177, no. 2 (February 2007): 499–503. https://doi.org/10.1016/j.juro.2006.09.063.Full Text Link to Item
-
Mouraviev, Vladimir, Israel Nosnik, Leon Sun, Cary N. Robertson, Philip Walther, David Albala, Judd W. Moul, and Thomas J. Polascik. “Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.” Urology 69, no. 2 (February 2007): 311–14. https://doi.org/10.1016/j.urology.2006.10.025.Full Text Link to Item
-
Scales, Charles D., Lesley H. Curtis, Regina D. Norris, Kevin A. Schulman, Philipp Dahm, and Judd W. Moul. “Relationship between body mass index and prostate cancer screening in the United States.” J Urol 177, no. 2 (February 2007): 493–98. https://doi.org/10.1016/j.juro.2006.09.059.Full Text Link to Item
-
Sun, Mei, Vasantha Srikantan, Lanfeng Ma, Jia Li, Wei Zhang, Gyorgy Petrovics, Mazen Makarem, et al. “Characterization of frequently deleted 6q locus in prostate cancer.” Dna Cell Biol 25, no. 11 (November 2006): 597–607. https://doi.org/10.1089/dna.2006.25.597.Full Text Link to Item
-
Efstathiou, Jason A., Ming-Hui Chen, William J. Catalona, David G. McLeod, Peter R. Carroll, Judd W. Moul, Kimberly A. Roehl, and Anthony V. D’Amico. “Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.” Urology 68, no. 2 (August 2006): 342–47. https://doi.org/10.1016/j.urology.2006.02.030.Full Text Link to Item
-
Moul, Judd W., and John F. Ward. “Management of the patient with a rising PSA alone.” Hematol Oncol Clin North Am 20, no. 4 (August 2006): 897–908. https://doi.org/10.1016/j.hoc.2006.03.006.Full Text Link to Item
-
Scales, Charles D., Lesley H. Curtis, Regina D. Norris, Kevin A. Schulman, David M. Albala, and Judd W. Moul. “Prostate specific antigen testing in men older than 75 years in the United States.” J Urol 176, no. 2 (August 2006): 511–14. https://doi.org/10.1016/j.juro.2006.03.060.Full Text Link to Item
-
Merseburger, Axel S., Jörg Hennenlotter, Perikles Simon, Carolin C. Müller, Ursula Kühs, Ruth Knüchel-Clarke, Judd W. Moul, Arnulf Stenzl, and Markus A. Kuczyk. “Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.” Oncol Rep 16, no. 1 (July 2006): 79–83.Link to Item
-
Penson, David, Judd Moul, Sanjay Gandhi, and Don Newling. “Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.” Urology 68, no. 1 (July 2006): 80–84. https://doi.org/10.1016/j.urology.2006.01.028.Full Text Link to Item
-
Freedland, Stephen J., Tracey L. Krupski, and Judd W. Moul. “Update on outcomes research databases in prostate cancer 2006.” Curr Opin Urol 16, no. 3 (May 2006): 168–72. https://doi.org/10.1097/01.mou.0000193394.62221.e9.Full Text Link to Item
-
Anscher, M. S., R. Clough, C. N. Robertson, L. R. Prosnitz, P. Dahm, P. Walther, C. F. Donatucci, et al. “Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.” Prostate Cancer Prostatic Dis 9, no. 3 (2006): 254–60. https://doi.org/10.1038/sj.pcan.4500903.Full Text Link to Item
-
Moul, Judd W. “Treatment of PSA only recurrence of prostate cancer after prior local therapy.” Curr Pharm Des 12, no. 7 (2006): 785–98. https://doi.org/10.2174/138161206776056092.Full Text Link to Item
-
Tseng, T. Y., D. W. Sevilla, J. W. Moul, and K. E. Maloney. “Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report.” Prostate Cancer Prostatic Dis 9, no. 2 (2006): 195–97. https://doi.org/10.1038/sj.pcan.4500870.Full Text Link to Item
-
Xu, L. L., C. Sun, G. Petrovics, M. Makarem, B. Furusato, W. Zhang, I. A. Sesterhenn, et al. “Quantitative expression profile of PSGR in prostate cancer.” Prostate Cancer Prostatic Dis 9, no. 1 (2006): 56–61. https://doi.org/10.1038/sj.pcan.4500836.Full Text Link to Item
-
Brassell, Stephen A., Tzu-Cheg Kao, Leon Sun, and Judd W. Moul. “Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.” Urology 66, no. 6 (December 2005): 1229–33. https://doi.org/10.1016/j.urology.2005.06.106.Full Text Link to Item
-
Cooperberg, Matthew R., Judd W. Moul, and Peter R. Carroll. “The changing face of prostate cancer.” J Clin Oncol 23, no. 32 (November 10, 2005): 8146–51. https://doi.org/10.1200/JCO.2005.02.9751.Full Text Link to Item
-
Moul, Judd W. “Screening for prostate cancer in military populations.” Mil Med 170, no. 11 (November 2005): 905–14. https://doi.org/10.7205/milmed.170.11.905.Full Text Link to Item
-
Zhou, Ping, Ming-Hui Chen, David McLeod, Peter R. Carroll, Judd W. Moul, and Anthony V. D’Amico. “Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.” J Clin Oncol 23, no. 28 (October 1, 2005): 6992–98. https://doi.org/10.1200/JCO.2005.01.2906.Full Text Link to Item
-
Stewart, Alexandra J., Howard I. Scher, Ming-Hui Chen, David G. McLeod, Peter R. Carroll, Judd W. Moul, and Anthony V. D’Amico. “Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.” J Clin Oncol 23, no. 27 (September 20, 2005): 6556–60. https://doi.org/10.1200/JCO.2005.20.966.Full Text Link to Item
-
Dahm, P., and J. W. Moul. “Early results of RTOG protocol 99-06 for bladder cancer 'encouraging'. Comment.” Oncology Report, no. FALL (September 1, 2005): 62–63.
-
Dahm, P., and J. W. Moul. “Cytokine therapy not recommended for metastatic RCC of intermediate prognosis. Comment.” Oncology Report, no. FALL (September 1, 2005): 64.
-
Moul, J. W. “Better than expected natural history for men with nonmetastatic prostate cancer and rising PSA. Comment.” Oncology Report, no. FALL (September 1, 2005): 57–58.
-
Moul, J. W. “Chemotherapy, bisphosphonates, now recommended for prostate cancer. Comment.” Oncology Report, no. FALL (September 1, 2005): 53–54.
-
Dahm, Philipp, Benjamin K. Yang, Chas R. Salmen, Judd W. Moul, and Tong J. Gan. “Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients.” J Urol 174, no. 1 (July 2005): 131–34. https://doi.org/10.1097/01.ju.0000161593.29525.e2.Full Text Link to Item
-
Moul, Judd W., and Fred Saad. “Low-risk prostate cancer patient: active treatment.” Can J Urol 12 Suppl 2 (June 2005): 25–27.Link to Item
-
Ward, John F., and Judd W. Moul. “Treating the biochemical recurrence of prostate cancer after definitive primary therapy.” Clin Prostate Cancer 4, no. 1 (June 2005): 38–44. https://doi.org/10.3816/cgc.2005.n.010.Full Text Link to Item
-
Zhou, P., M. H. Chen, D. McLeod, P. R. Carroll, J. W. Moul, and A. V. D’Amico. “Predictors of prostate cancer-specific mortality following radical prostatectomy or radiation therapy.” J Clin Oncol 23, no. 16_suppl (June 2005): 4548.Link to Item
-
Petrovics, Gyorgy, Aijun Liu, Syed Shaheduzzaman, Bungo Furusato, Chen Sun, Yongmei Chen, Martin Nau, et al. “Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.” Oncogene 24, no. 23 (May 26, 2005): 3847–52. https://doi.org/10.1038/sj.onc.1208518.Full Text Link to Item
-
Bañez, Lionel L., Shiv Srivastava, and Judd W. Moul. “Proteomics in prostate cancer.” Curr Opin Urol 15, no. 3 (May 2005): 151–56. https://doi.org/10.1097/01.mou.0000165547.48922.12.Full Text Link to Item
-
D’Amico, Anthony V., Judd Moul, Peter R. Carroll, Leon Sun, Deborah Lubeck, and Ming-Hui Chen. “Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.” J Urol 173, no. 5 (May 2005): 1572–76. https://doi.org/10.1097/01.ju.0000157569.59229.72.Full Text Link to Item
-
Moul, J. W. “Editorial introduction.” Current Opinion in Urology 15, no. 3 (May 1, 2005). https://doi.org/10.1097/01.mou.0000165545.41298.9b.Full Text
-
Ward, John F., and Judd W. Moul. “Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.” Curr Opin Urol 15, no. 3 (May 2005): 187–95. https://doi.org/10.1097/01.mou.0000165553.17534.e3.Full Text Link to Item
-
Ward, John F., and Judd W. Moul. “Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer.” Curr Opin Urol 15, no. 3 (May 2005): 181–86. https://doi.org/10.1097/01.mou.0000165552.79416.11.Full Text Link to Item
-
Ward, John F., and Judd W. Moul. “Rising prostate-specific antigen after primary prostate cancer therapy.” Nat Clin Pract Urol 2, no. 4 (April 2005): 174–82. https://doi.org/10.1038/ncpuro0145.Full Text Link to Item
-
George, D. J., and J. W. Moul. “Docetaxel/capecitabine well tolerated but less effective than docetaxel/estramustine.” Oncology Report, no. SPRING (March 1, 2005): 54–55.
-
George, D. J., and J. W. Moul. “Combined GM-CSF/docetaxel beneficial against HR prostate cancer.” Oncology Report, no. SPRING (March 1, 2005): 51–52.
-
George, D. J., and J. W. Moul. “CA9 shown to predict response to IL-2 therapy for renal cell carcinoma.” Oncology Report, no. SPRING (March 1, 2005): 59–60.
-
Vieweg, J., and J. W. Moul. “APC8015 vaccine on fast track against prostate cancer.” Oncology Report, no. SPRING (March 1, 2005): 53–54.
-
“EDITORIAL COMMENT.” Journal of Urology 173, no. 3 (March 2005): 750–51. https://doi.org/10.1016/s0022-5347(01)69220-6.Full Text
-
Moul, Judd W., and Alexandre R. Zlotta. “Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.” Bju Int 95, no. 3 (February 2005): 285–90. https://doi.org/10.1111/j.1464-410X.2005.05284.x.Full Text Link to Item
-
Semmes, O John, Ziding Feng, Bao-Ling Adam, Lionel L. Banez, William L. Bigbee, David Campos, Lisa H. Cazares, et al. “Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.” Clin Chem 51, no. 1 (January 2005): 102–12. https://doi.org/10.1373/clinchem.2004.038950.Full Text Link to Item
-
Gu, Yongpeng, Kee-Hong Kim, Daejin Ko, Shiv Srivastava, Judd W. Moul, David G. McLeod, and Johng S. Rhim. “Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.” Anticancer Res 25, no. 1A (2005): 1–8.Link to Item
-
Saad, F., and J. Moul. “Bone complications in prostate cancer: Current and future role of bisphosphonates.” Current Oncology 12, no. 3 (January 1, 2005): 71–75.
-
Woll, Michael M., Matthew T. Hueman, Gayle B. Ryan, Constantin G. Ioannides, Charles G. Henderson, Isabelle A. Sesterhan, Shiv Shrivasta, David G. McLeod, Judd W. Moul, and George E. Peoples. “Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.” Int J Oncol 25, no. 6 (December 2004): 1769–80.Link to Item
-
D’Amico, Anthony V., Judd Moul, Peter R. Carroll, Leon Sun, Deborah Lubeck, and Ming-Hui Chen. “Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.” J Urol 172, no. 5 Pt 2 (November 2004): S42–46. https://doi.org/10.1097/01.ju.0000141845.99899.12.Full Text Link to Item
-
Gu, Yongpeng, Kee-Hong Kim, Daejin Ko, Keiichiro Nakamura, Yutaka Yasunaga, Judd W. Moul, Shiv Srivastava, Paul Arnstein, and Johng S. Rhim. “A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.” Int J Oncol 25, no. 4 (October 2004): 1057–64.Link to Item
-
Moul, J. W., and G. Chodak. “Combination hormonal therapy: a reassessment within advanced prostate cancer.” Prostate Cancer Prostatic Dis 7 Suppl 1 (September 2004): S2–7. https://doi.org/10.1038/sj.pcan.4500741.Full Text Link to Item
-
Gilligan, Timothy, Judith Manola, Oliver Sartor, Sally P. Weinrich, Judd W. Moul, and Philip W. Kantoff. “Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population.” Clin Prostate Cancer 3, no. 2 (September 2004): 98–103. https://doi.org/10.3816/cgc.2004.n.019.Full Text Link to Item
-
Kirby, R. S., and J. W. Moul. “Editorial.” Prostate Cancer and Prostatic Diseases 7, no. 2 (July 28, 2004): 85–86. https://doi.org/10.1038/sj.pcan.4500731.Full Text
-
Woll, Michael M., Christine M. Fisher, Gayle B. Ryan, Jennifer M. Gurney, Catherine E. Storrer, Constantin G. Ioannides, Craig D. Shriver, et al. “Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.” J Clin Immunol 24, no. 4 (July 2004): 449–61. https://doi.org/10.1023/B:JOCI.0000029117.10791.98.Full Text Link to Item
-
Shen, Dinggang, Zhiqiang Lao, Jianchao Zeng, Wei Zhang, Isabel A. Sesterhenn, Leon Sun, Judd W. Moul, Edward H. Herskovits, Gabor Fichtinger, and Christos Davatzikos. “Optimized prostate biopsy via a statistical atlas of cancer spatial distribution.” Med Image Anal 8, no. 2 (June 2004): 139–50. https://doi.org/10.1016/j.media.2003.11.002.Full Text Link to Item
-
Zeng, J., A. Sofer, W. Zhang, L. Sun, I. Sesterhenn, J. Moul, S. K. Mun, and M. Chouikha. “Development and evaluation of optimal prostate biopsy protocols for individual groups of patients.” International Congress Series 1268, no. C (June 1, 2004): 803–8. https://doi.org/10.1016/j.ics.2004.03.347.Full Text
-
Moul, J. W., and R. S. Kirby. “Editorial.” Prostate Cancer and Prostatic Diseases 7, no. 1 (April 19, 2004): 1. https://doi.org/10.1038/sj.pcan.4500711.Full Text
-
D’Amico, Anthony V., Judd W. Moul, Peter R. Carroll, Kerri Cote, Leon Sun, Deborah Lubeck, Andrew A. Renshaw, Marian Loffredo, and Ming-Hui Chen. “Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.” J Natl Cancer Inst 96, no. 7 (April 7, 2004): 509–15. https://doi.org/10.1093/jnci/djh086.Full Text Link to Item
-
Moul, Judd W., Hongyu Wu, Leon Sun, David G. McLeod, Christopher Amling, Timothy Donahue, Leo Kusuda, et al. “Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.” J Urol 171, no. 3 (March 2004): 1141–47. https://doi.org/10.1097/01.ju.0000113794.34810.d0.Full Text Link to Item
-
Wu, Hongyan, Leon Sun, Judd W. Moul, Hong Yu Wu, David G. McLeod, Christopher Amling, Raymond Lance, et al. “Watchful waiting and factors predictive of secondary treatment of localized prostate cancer.” J Urol 171, no. 3 (March 2004): 1111–16. https://doi.org/10.1097/01.ju.0000113300.74132.8b.Full Text Link to Item
-
Shavers, Vickie L., Martin Brown, Carrie N. Klabunde, Arnold L. Potosky, William Davis, Judd Moul, and Angela Fahey. “Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.” Med Care 42, no. 3 (March 2004): 239–50. https://doi.org/10.1097/01.mlr.0000117361.61444.71.Full Text Link to Item
-
Amling, Christopher L., Robert H. Riffenburgh, Leon Sun, Judd W. Moul, Raymond S. Lance, Leo Kusuda, Wade J. Sexton, et al. “Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.” J Clin Oncol 22, no. 3 (February 1, 2004): 439–45. https://doi.org/10.1200/JCO.2004.03.132.Full Text Link to Item
-
Scher, Howard I., Mario Eisenberger, Anthony V. D’Amico, Susan Halabi, Eric J. Small, Michael Morris, Michael W. Kattan, et al. “Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.” J Clin Oncol 22, no. 3 (February 1, 2004): 537–56. https://doi.org/10.1200/JCO.2004.07.099.Full Text Link to Item
-
Shavers, Vickie L., Martin L. Brown, Arnold L. Potosky, Carrie N. Klabunde, W. W. Davis, Judd W. Moul, and Angela Fahey. “Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.” J Gen Intern Med 19, no. 2 (February 2004): 146–55. https://doi.org/10.1111/j.1525-1497.2004.30209.x.Full Text Link to Item
-
Petrovics, Gyorgy, Wei Zhang, Mazen Makarem, Jesse P. Street, Roger Connelly, Leon Sun, Isabell A. Sesterhenn, Vasantha Srikantan, Judd W. Moul, and Shiv Srivastava. “Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients.” Oncogene 23, no. 2 (January 15, 2004): 605–11. https://doi.org/10.1038/sj.onc.1207069.Full Text Link to Item
-
Petroski, R. A., W. B. Warlick, J. Herring, T. F. Donahue, L. Sun, C. V. Smith, R. R. Connelly, D. G. McLeod, and J. W. Moul. “External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence.” Prostate Cancer Prostatic Dis 7, no. 2 (2004): 170–77. https://doi.org/10.1038/sj.pcan.4500718.Full Text Link to Item
-
Moul, Judd W. “The evolving definition of advanced prostate cancer.” Rev Urol 6 Suppl 8, no. Suppl 8 (2004): S10–17.Link to Item
-
Carter, Corey A., Timothy Donahue, Leon Sun, Hongyu Wu, David G. McLeod, Christopher Amling, Raymond Lance, et al. “Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.” J Clin Oncol 21, no. 21 (November 1, 2003): 4001–8. https://doi.org/10.1200/JCO.2003.04.092.Full Text Link to Item
-
Barqawi, Al Baha, Judd W. Moul, Ali Ziada, Liann Handel, and E David Crawford. “Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.” Urology 62, no. 5 (November 2003): 872–76. https://doi.org/10.1016/s0090-4295(03)00667-8.Full Text Link to Item
-
D’Amico, Anthony V., Judd W. Moul, Peter R. Carroll, Leon Sun, Deborah Lubeck, and Ming-Hui Chen. “Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.” J Natl Cancer Inst 95, no. 18 (September 17, 2003): 1376–83. https://doi.org/10.1093/jnci/djg043.Full Text Link to Item
-
Moul, J. W., J. Anderson, D. F. Penson, L. H. Klotz, M. S. Soloway, and C. C. Schulman. “Early prostate cancer: prevention, treatment modalities, and quality of life issues.” Eur Urol 44, no. 3 (September 2003): 283–93. https://doi.org/10.1016/s0302-2838(03)00296-3.Full Text Link to Item
-
Moul, Judd W. “Population screening for prostate cancer and emerging concepts for young men.” Clin Prostate Cancer 2, no. 2 (September 2003): 87–97. https://doi.org/10.3816/cgc.2003.n.015.Full Text Link to Item
-
Xu, Linda L., Yinghui Shi, Gyorgy Petrovics, Chen Sun, Mazen Makarem, Wei Zhang, Isabell A. Sesterhenn, et al. “PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.” Cancer Res 63, no. 15 (August 1, 2003): 4299–4304.Link to Item
-
Gao, Chun-Ling, Sudhir K. Rawal, Leon Sun, Amina Ali, Roger R. Connelly, Lionel L. Bañez, Isabell A. Sesterhenn, David G. McLeod, Judd W. Moul, and Shiv Srivastava. “Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.” Clin Cancer Res 9, no. 7 (July 2003): 2545–50.Link to Item
-
D’Amico, Anthony V., Judd Moul, Peter R. Carroll, Leon Sun, Deborah Lubeck, and Ming-Hui Chen. “Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.” J Clin Oncol 21, no. 11 (June 1, 2003): 2163–72. https://doi.org/10.1200/JCO.2003.01.075.Full Text Link to Item
-
Ko, Daejin, Yongpeng Gu, Yutaka Yasunaga, Keiichiro Nakamura, Shiv Srivastava, Judd W. Moul, Isabell A. Sesterhenn, et al. “A novel neoplastic primary tumor-derived human prostate epithelial cell line.” Int J Oncol 22, no. 6 (June 2003): 1311–17.Link to Item
-
Massengill, Jason C., Leon Sun, Judd W. Moul, Hongyu Wu, David G. McLeod, Christopher Amling, Raymond Lance, et al. “Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.” J Urol 169, no. 5 (May 2003): 1670–75. https://doi.org/10.1097/01.ju.0000062674.43964.d0.Full Text Link to Item
-
Rao, Chilukuri N., Takehiko Segawa, Jason R. Navari, Linda Xu, Shiv Srivastava, Judd W. Moul, and Benette Phillips. “Methylation of TFPI-2 gene is not the sole cause of its silencing.” Int J Oncol 22, no. 4 (April 2003): 843–48.Link to Item
-
Johnstone, Peter A. S., Robert H. Riffenburgh, Judd W. Moul, Leon Sun, Hongyu Wu, David G. McLeod, Christopher J. Kane, et al. “Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.” Int J Radiat Oncol Biol Phys 55, no. 4 (March 15, 2003): 964–69. https://doi.org/10.1016/s0360-3016(02)04283-9.Full Text Link to Item
-
Gancarczyk, Kevin J., Hongyu Wu, David G. McLeod, Christopher Kane, Leo Kusuda, Raymond Lance, Judy Herring, et al. “Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.” Urology 61, no. 3 (March 2003): 589–95. https://doi.org/10.1016/s0090-4295(02)02287-2.Full Text Link to Item
-
Kane, Christopher J., Christopher L. Amling, Peter A. S. Johnstone, Nali Pak, Raymond S. Lance, J Brantley Thrasher, John P. Foley, Robert H. Riffenburgh, and Judd W. Moul. “Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.” Urology 61, no. 3 (March 2003): 607–11. https://doi.org/10.1016/s0090-4295(02)02411-1.Full Text Link to Item
-
Djavan, Bob, Judd W. Moul, Alexandre Zlotta, Mesut Remzi, and Vincent Ravery. “PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.” Eur Urol 43, no. 1 (January 2003): 12–27. https://doi.org/10.1016/s0302-2838(02)00505-5.Full Text Link to Item
-
Elliot, S. J., B. H. Zorn, D. G. McLeod, J. W. Moul, L. Nyberg, L. J. Striker, and G. E. Striker. “Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover.” Prostate Cancer Prostatic Dis 6, no. 2 (2003): 138–42. https://doi.org/10.1038/sj.pcan.4500632.Full Text Link to Item
-
Griewe, G. L., R. C. Dean, W. Zhang, D. Young, I. A. Sesterhenn, N. Shanmugam, D. G. McLeod, J. W. Moul, and S. Srivastava. “p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.” Prostate Cancer Prostatic Dis 6, no. 4 (2003): 281–85. https://doi.org/10.1038/sj.pcan.4500665.Full Text Link to Item
-
Merseburger, Axel S., Markus A. Kuczyk, Jurgen Serth, Carsten Bokemeyer, Denise Y. Young, Leon Sun, Roger R. Connelly, et al. “Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.” Oncol Rep 10, no. 1 (2003): 223–28.Link to Item
-
Moul, Judd W. “Variables in predicting survival based on treating "PSA-only" relapse.” Urol Oncol 21, no. 4 (2003): 292–304. https://doi.org/10.1016/s1078-1439(03)00103-0.Full Text Link to Item
-
Moul, Judd W. “Biochemical recurrence of prostate cancer.” Curr Probl Cancer 27, no. 5 (2003): 243–72. https://doi.org/10.1016/s0147-0272(03)00032-1.Full Text Link to Item
-
Moul, Judd W., Leon Sun, Hongyu Wu, David G. McLeod, Christopher Amling, Raymond Lance, John Foley, et al. “Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database.” Urol Oncol 21, no. 6 (2003): 447–55. https://doi.org/10.1016/s1078-1439(03)00056-5.Full Text Link to Item
-
Paquette, Edmond L., Roger R. Connelly, Leon Sun, Laurence R. Paquette, and Judd W. Moul. “Predictors of extracapsular extension and positive margins in African American and white men.” Urol Oncol 21, no. 1 (2003): 33–38. https://doi.org/10.1016/s1078-1439(02)00203-x.Full Text Link to Item
-
Segawa, Takehiko, Martin E. Nau, Linda L. Xu, Rao N. Chilukuri, Mazen Makarem, Wei Zhang, Gyorgy Petrovics, et al. “Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells.” Oncogene 21, no. 57 (December 12, 2002): 8749–58. https://doi.org/10.1038/sj.onc.1205992.Full Text Link to Item
-
Srikantan, Vasantha, Michael Valladares, Johng S. Rhim, Judd W. Moul, and Shiv Srivastava. “HEPSIN inhibits cell growth/invasion in prostate cancer cells.” Cancer Res 62, no. 23 (December 1, 2002): 6812–16.Link to Item
-
Paquette, Edmond L., Leon Sun, Laurence R. Paquette, Roger Connelly, David G. Mcleod, and Judd W. Moul. “Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing.” Urology 60, no. 5 (November 2002): 756–59. https://doi.org/10.1016/s0090-4295(02)01960-x.Full Text Link to Item
-
Catalona, William J., Jo Ann V. Antenor, Kimberly A. Roehl, and Judd W. Moul. “Screening for prostate cancer in high risk populations.” J Urol 168, no. 5 (November 2002): 1980–83. https://doi.org/10.1097/01.ju.0000033320.15267.a6.Full Text Link to Item
-
Heidenreich, Axel, and Judd W. Moul. “Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated?” Semin Urol Oncol 20, no. 4 (November 2002): 234–38. https://doi.org/10.1053/suro.2002.36980.Full Text Link to Item
-
Johnstone, Peter A. S., Christopher J. Kane, Leon Sun, Hongyu Wu, Judd W. Moul, David G. McLeod, Douglas D. Martin, et al. “Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.” Radiology 225, no. 2 (November 2002): 420–26. https://doi.org/10.1148/radiol.2252011491.Full Text Link to Item
-
Nakamura, Keiichiro, Yutaka Yasunaga, Takehiko Segawa, Daejin Ko, Judd W. Moul, Shiv Srivastava, and Johng S. Rhim. “Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines.” Int J Oncol 21, no. 4 (October 2002): 825–30.Link to Item
-
Sun, Mei, Lanfeng Ma, Linda Xu, Jia Li, Wei Zhang, Gyorgy Petrovics, Mazen Makarem, et al. “A human novel gene DERPC on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors.” Mol Med 8, no. 10 (October 2002): 655–63.Link to Item
-
Partin, Alan W., Gerald E. Hanks, Eric A. Klein, Judd W. Moul, William G. Nelson, and Howard I. Scher. “Prostate-specific antigen as a marker of disease activity in prostate cancer.” Oncology (Williston Park) 16, no. 9 (September 2002): 1218–24.Link to Item
-
Henderson, Charles G., Greg L. Griewe, Timothy S. Siegel, Dennis S. Peppas, Thomas A. Esther, and Judd W. Moul. “Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis.” J Urol 168, no. 2 (August 2002): 638–39.Link to Item
-
Moul, Judd W., Hongyu Wu, Leon Sun, David G. McLeod, Christopher Amling, Raymond Lance, Leo Kusuda, et al. “Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.” Surgery 132, no. 2 (August 2002): 213–19. https://doi.org/10.1067/msy.2002.125315.Full Text Link to Item
-
Partin, Alan W., Gerald E. Hanks, Eric A. Klein, Judd W. Moul, William G. Nelson, and Howard I. Scher. “Prostate-specific antigen as a marker of disease activity in prostate cancer.” Oncology (Williston Park) 16, no. 8 (August 2002): 1024–42.Link to Item
-
Moul, Judd W. “Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares.” Cancer 95, no. 2 (July 15, 2002): 211–14. https://doi.org/10.1002/cncr.10658.Full Text Link to Item
-
Donahue, Timothy, and Judd Moul. “Diagnostic accuracy of prostate needle biopsy.” Curr Urol Rep 3, no. 3 (June 2002): 215–21. https://doi.org/10.1007/s11934-002-0067-7.Full Text Link to Item
-
Moul, Judd W., Axel S. Merseburger, and Shiv Srivastava. “Molecular markers in prostate cancer: the role in preoperative staging.” Clin Prostate Cancer 1, no. 1 (June 2002): 42–50. https://doi.org/10.3816/cgc.2002.n.006.Full Text Link to Item
-
Zou, Zhiqiang, Wei Zhang, Denise Young, Martin G. Gleave, Paul Rennie, Theresa Connell, Roger Connelly, Judd Moul, Shiv Srivastava, and Isabell Sesterhenn. “Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.” Clin Cancer Res 8, no. 5 (May 2002): 1172–77.Link to Item
-
Nakamura, Keiichiro, Yutaka Yasunaga, Daejin Ko, Linda L. Xu, Judd W. Moul, Donna M. Peehl, Shiv Srivastava, and Johng S. Rhim. “Cadmium-induced neoplastic transformation of human prostate epithelial cells.” Int J Oncol 20, no. 3 (March 2002): 543–47.Link to Item
-
Desai, A., H. Wu, L. Sun, I. A. Sesterhenn, F. K. Mostofi, D. McLeod, C. Amling, et al. “Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients.” Prostate Cancer Prostatic Dis 5, no. 3 (2002): 212–18. https://doi.org/10.1038/sj.pcan.4500600.Full Text Link to Item
-
Johnstone, P. A. S., R. Booth, R. H. Riffenburgh, C. L. Amling, C. J. Kane, and J. W. Moul. “Initiation of salvage therapy for prostate cancer.” Prostate Cancer Prostatic Dis 5, no. 2 (2002): 136–43. https://doi.org/10.1038/sj.pcan.4500566.Full Text Link to Item
-
Opell, M. B., J. Zeng, J. J. Bauer, R. R. Connelly, W. Zhang, I. A. Sesterhenn, S. K. Mun, J. W. Moul, and J. H. Lynch. “Investigating the distribution of prostate cancer using three-dimensional computer simulation.” Prostate Cancer Prostatic Dis 5, no. 3 (2002): 204–8. https://doi.org/10.1038/sj.pcan.4500577.Full Text Link to Item
-
Piper, N. Y., L. Kusada, R. Lance, J. Foley, J. Moul, and T. Seay. “Adenocarcinoma of the prostate: an expensive way to die.” Prostate Cancer Prostatic Dis 5, no. 2 (2002): 164–66. https://doi.org/10.1038/sj.pcan.4500565.Full Text Link to Item
-
Davis, Leland D., Wei Zhang, Axel Merseburger, Denise Young, Linda Xu, Johng S. Rhim, Judd W. Moul, Shiv Srivastava, and Isabell A. Sesterhenn. “p63 expression profile in normal and malignant prostate epithelial cells.” Anticancer Res 22, no. 6C (2002): 3819–25.Link to Item
-
Koff, S. G., R. R. Connelly, J. J. Bauer, D. G. McLeod, and J. W. Moul. “Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.” Prostate Cancer Prostatic Dis 5, no. 2 (2002): 152–58. https://doi.org/10.1038/sj.pcan.4500551.Full Text Link to Item
-
Moul, Judd W. “Outcome research: prostate cancer databases.” Urol Oncol 7, no. 1 (2002): 39–42. https://doi.org/10.1016/s1078-1439(01)00134-x.Full Text Link to Item
-
Vanasupa, Bill P., Edmond L. Paquette, Hongyu Wu, Leon Sun, David G. McLeod, and Judd W. Moul. “The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL.” Urol Oncol 7, no. 4 (2002): 167–72. https://doi.org/10.1016/s1078-1439(02)00187-4.Full Text Link to Item
-
Jani, A. B., F. Vaida, G. Hanks, S. Asbell, O. Sartor, J. W. Moul, M. Roach, et al. “Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.” Int J Cancer 96, no. 6 (December 20, 2001): 363–71. https://doi.org/10.1002/ijc.1035.Full Text Link to Item
-
Moul, J. W., and K. Civitelli. “Managing advanced prostate cancer with Viadur (leuprolide acetate implant).” Urol Nurs 21, no. 6 (December 2001): 385–94.Link to Item
-
Yasunaga, Y., K. Nakamura, D. Ko, S. Srivastava, J. W. Moul, I. A. Sesterhenn, D. G. McLeod, and J. S. Rhim. “A novel human cancer culture model for the study of prostate cancer.” Oncogene 20, no. 55 (November 29, 2001): 8036–41. https://doi.org/10.1038/sj.onc.1205002.Full Text Link to Item
-
Paquette, E. L., R. R. Connelly, I. A. Sesterhenn, W. Zhang, L. Sun, L. R. Paquette, R. Greenspan, D. G. McLeod, and J. W. Moul. “Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma.” Cancer 92, no. 10 (November 15, 2001): 2673–79. https://doi.org/10.1002/1097-0142(20011115)92:10<2673::aid-cncr1621>3.0.co;2-2.Full Text Link to Item
-
Amling, C. L., C. J. Kane, R. H. Riffenburgh, J. F. Ward, J. L. Roberts, R. S. Lance, P. A. Friedrichs, and J. W. Moul. “Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy.” Urology 58, no. 5 (November 2001): 723–28. https://doi.org/10.1016/s0090-4295(01)01373-5.Full Text Link to Item
-
Merseburger, A. S., R. R. Connelly, L. Sun, E. Richter, and J. W. Moul. “Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients.” Urology 58, no. 5 (November 2001): 729–34. https://doi.org/10.1016/s0090-4295(01)01370-x.Full Text Link to Item
-
Bissonette, E. A., B. R. Fulmer, G. R. Petroni, J. W. Moul, and D. Theodorescu. “Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.” J Urol 166, no. 4 (October 2001): 1328–31.Link to Item
-
Moul, J. W., R. R. Connelly, D. P. Lubeck, J. J. Bauer, L. Sun, S. C. Flanders, G. D. Grossfeld, and P. R. Carroll. “Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.” J Urol 166, no. 4 (October 2001): 1322–27.Link to Item
-
Hartzell, J. D., T. C. Kao, J. C. Holland, S. R. Holt, and J. W. Moul. “Age-specific reference ranges for prostate specific antigen in young men: Retrospective study from the national defense university.” Prostate Journal 3, no. 1 (September 27, 2001): 36–41. https://doi.org/10.1046/j.1525-1411.2001.003001036.x.Full Text
-
Sun, L., K. Gancarczyk, E. L. Paquette, D. G. McLeod, C. Kane, L. Kusuda, R. Lance, et al. “Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era.” Urologic Oncology 6, no. 5 (September 3, 2001): 203–9. https://doi.org/10.1016/S1078-1439(01)00145-4.Full Text
-
Moul, J. W., C. J. Kane, and S. B. Malkowicz. “The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.” Urol Clin North Am 28, no. 3 (August 2001): 459–72. https://doi.org/10.1016/s0094-0143(05)70155-5.Full Text Link to Item
-
Campbell, T., J. Blasko, E. D. Crawford, J. Forman, G. Hanks, D. Kuban, J. Montie, et al. “Clinical staging of prostate cancer: reproducibility and clarification of issues.” Int J Cancer 96, no. 3 (June 20, 2001): 198–209. https://doi.org/10.1002/ijc.1017.Full Text Link to Item
-
Xu, L. L., Y. P. Su, R. Labiche, T. Segawa, N. Shanmugam, D. G. McLeod, J. W. Moul, and S. Srivastava. “Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes.” Int J Cancer 92, no. 3 (May 1, 2001): 322–28. https://doi.org/10.1002/ijc.1196.Full Text Link to Item
-
“EDITORIAL COMMENT.” Journal of Urology 165, no. 5 (May 2001): 1525–1525. https://doi.org/10.1016/s0022-5347(01)69649-6.Full Text
-
Moul, J. W. “Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials.” Urology 57, no. 4 Suppl 1 (April 2001): 174–77. https://doi.org/10.1016/s0090-4295(00)00967-5.Full Text Link to Item
-
Siegel, T., J. W. Moul, M. Spevak, W. G. Alvord, and R. A. Costabile. “The development of erectile dysfunction in men treated for prostate cancer.” J Urol 165, no. 2 (February 2001): 430–35. https://doi.org/10.1097/00005392-200102000-00019.Full Text Link to Item
-
Kirby, R., J. Moul, and M. Brawer. “Editorial.” Prostate Cancer and Prostatic Diseases 4, no. 1 (January 1, 2001): 5. https://doi.org/10.1038/sj.pcan.4500512.Full Text
-
Lance, R. S., P. A. Freidrichs, C. Kane, C. R. Powell, E. Pulos, J. W. Moul, D. G. McLeod, R. L. Cornum, and R. L. Brantley Thrasher J. “A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group.” Bju Int 87, no. 1 (January 2001): 61–65. https://doi.org/10.1046/j.1464-410x.2001.00023.x.Full Text Link to Item
-
Zeng, J., J. Bauer, W. Zhang, I. Sesterhenn, R. Connelly, J. Lynch, J. Moul, and S. K. Mun. “Prostate biopsy protocols: 3D visualization-based evaluation and clinical correlation.” Comput Aided Surg 6, no. 1 (2001): 14–21. https://doi.org/10.1002/igs.1006.Full Text Link to Item
-
Tarman, G. J., C. J. Kane, J. W. Moul, J. B. Thrasher, J. P. Foley, D. Wilhite, R. H. Riffenburgh, and C. L. Amling. “Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system.” Urology 56, no. 6 (December 20, 2000): 1016–20. https://doi.org/10.1016/s0090-4295(00)00808-6.Full Text Link to Item
-
Smith, C. V., J. J. Bauer, R. R. Connelly, T. Seay, C. Kane, J. Foley, J. B. Thrasher, L. Kusuda, and J. W. Moul. “Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.” J Urol 164, no. 6 (December 2000): 1964–67. https://doi.org/10.1016/s0022-5347(05)66929-7.Full Text Link to Item
-
Xu, L. L., B. G. Stackhouse, K. Florence, W. Zhang, N. Shanmugam, I. A. Sesterhenn, Z. Zou, et al. “PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.” Cancer Res 60, no. 23 (December 1, 2000): 6568–72.Link to Item
-
Moul, J. W. “Targeted screening for prostate cancer in African-American men.” Prostate Cancer Prostatic Dis 3, no. 4 (December 2000): 248–55. https://doi.org/10.1038/sj.pcan.4500472.Full Text Link to Item
-
Preston, D. M., L. I. Levin, D. J. Jacobson, S. J. Jacobsen, M. Rubertone, E. Holmes, G. P. Murphy, and J. W. Moul. “Prostate-specific antigen levels in young white and black men 20 to 45 years old.” Urology 56, no. 5 (November 1, 2000): 812–16. https://doi.org/10.1016/s0090-4295(00)00764-0.Full Text Link to Item
-
Richter, E., R. R. Connelly, and J. W. Moul. “The role of pretreatment serum albumin to predict pathological stage and recurrence among radical prostatectomy cases.” Prostate Cancer Prostatic Dis 3, no. 3 (November 2000): 186–90. https://doi.org/10.1038/sj.pcan.4500418.Full Text Link to Item
-
Srikantan, V., Z. Zou, G. Petrovics, L. Xu, M. Augustus, L. Davis, J. R. Livezey, et al. “PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer.” Proc Natl Acad Sci U S A 97, no. 22 (October 24, 2000): 12216–21. https://doi.org/10.1073/pnas.97.22.12216.Full Text Link to Item
-
Gao, C., Z. Zou, L. Xu, J. Moul, P. Seth, and S. Srivastava. “p53-dependent induction of heat shock protein 27 (HSP27) expression.” Int J Cancer 88, no. 2 (October 15, 2000): 191–94.Link to Item
-
Heidenreich, B., A. Heidenreich, A. Sesterhenn, S. Srivastava, J. W. Moul, and I. A. Sesterhenn. “Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.” Eur Urol 38, no. 4 (October 2000): 475–82. https://doi.org/10.1159/000020327.Full Text Link to Item
-
Davis, G. C., N. E. Aronson, and J. W. Moul. “Inferior vena cava compression due to massive hydronephrosis from bladder outlet obstruction.” Tech Urol 6, no. 3 (September 2000): 226–27.Link to Item
-
Moul, J. W., T. A. Esther, and J. J. Bauer. “Implementation of a web-based prostate cancer decision site.” Semin Urol Oncol 18, no. 3 (August 2000): 241–44.Link to Item
-
Bauer, J. J., J. Zeng, W. Zhang, D. G. McLeod, I. A. Sesterhenn, R. R. Connelly, S. K. Mun, and J. W. Moul. “Lateral biopsies added to the traditional sextant prostate biopsy pattern increases the detection rate of prostate cancer.” Prostate Cancer Prostatic Dis 3, no. 1 (July 2000): 43–46. https://doi.org/10.1038/sj.pcan.4500397.Full Text Link to Item
-
Xu, L. L., N. Shanmugam, T. Segawa, I. A. Sesterhenn, D. G. McLeod, J. W. Moul, and S. Srivastava. “A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.” Genomics 66, no. 3 (June 15, 2000): 257–63. https://doi.org/10.1006/geno.2000.6214.Full Text Link to Item
-
Moul, J. W. “Prostate specific antigen only progression of prostate cancer.” J Urol 163, no. 6 (June 2000): 1632–42.Link to Item
-
Moul, J. W. “Screening for prostate cancer in African Americans.” Curr Urol Rep 1, no. 1 (May 2000): 57–64. https://doi.org/10.1007/s11934-000-0036-y.Full Text Link to Item
-
Zou, Z., C. Gao, A. K. Nagaich, T. Connell, S. Saito, J. W. Moul, P. Seth, E. Appella, and S. Srivastava. “p53 regulates the expression of the tumor suppressor gene maspin.” J Biol Chem 275, no. 9 (March 3, 2000): 6051–54. https://doi.org/10.1074/jbc.275.9.6051.Full Text Link to Item
-
Kao, T. C., D. F. Cruess, D. Garner, J. Foley, T. Seay, P. Friedrichs, J. B. Thrasher, R. D. Mooneyhan, D. G. McLeod, and J. W. Moul. “Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy.” J Urol 163, no. 3 (March 2000): 858–64.Link to Item
-
Xu, L. L., V. Srikantan, I. A. Sesterhenn, M. Augustus, R. Dean, J. W. Moul, K. C. Carter, and S. Srivastava. “Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.” J Urol 163, no. 3 (March 2000): 972–79.Link to Item
-
Heidenreich, A., S. Srivastava, J. W. Moul, and R. Hofmann. “Molecular genetic parameters in pathogenesis and prognosis of testicular germ cell tumors.” Eur Urol 37, no. 2 (February 2000): 121–35. https://doi.org/10.1159/000020128.Full Text Link to Item
-
Kirby, R., J. Moul, and M. Brawer. “Editorial.” Prostate Cancer and Prostatic Diseases 3, no. 4 (January 1, 2000): 217. https://doi.org/10.1038/sj.pcan.4500492.Full Text
-
Klotz, L., M. Gleave, and S. L. Goldenberg. “Neoadjuvant hormone therapy: the Canadian trials.” Mol Urol 4, no. 3 (2000): 233–37.Link to Item
-
Moul, J. W. “Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.” Mol Urol 4, no. 3 (2000): 267–71.Link to Item
-
Stone, N. N., R. G. Stock, and P. Unger. “Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.” Mol Urol 4, no. 3 (2000): 163–68.Link to Item
-
Sylvester, J., J. C. Blasko, P. D. Grimm, R. Meier, and W. Cavanagh. “Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis.” Mol Urol 4, no. 3 (2000): 155–59.Link to Item
-
Bauer, J. J., J. Zeng, W. Zhang, D. G. McLeod, I. A. Sesterhenn, R. R. Connelly, S. K. Mun, and J. W. Moul. “3-D computer visualization and interactive prostate biopsy simulation leads to an improved systematic technique for the detection of prostate cancer: clinical correlation.” Stud Health Technol Inform 70 (2000): 20–25.Link to Item
-
Cookson, M. S. “Update on transrectal ultrasound-guided needle biopsy of the prostate.” Mol Urol 4, no. 3 (2000): 93–97.Link to Item
-
Koutcher, J. A., K. Zakian, and H. Hricak. “Magnetic resonance spectroscopic studies of the prostate.” Mol Urol 4, no. 3 (2000): 143–52.Link to Item
-
Zeng, J., J. J. Bauer, X. Yao, W. Zhang, D. G. McLeod, I. A. Sesterhenn, R. R. Connelly, J. W. Moul, and S. K. Mun. “Investigating 3D tumor distribution for optimized diagnosis of prostate cancer.” Stud Health Technol Inform 70 (2000): 392–98.Link to Item
-
Zhang, W., I. A. Sesterhenn, R. R. Connelly, F. K. Mostofi, and J. W. Moul. “Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen.” J Urol 163, no. 1 (January 2000): 131–36.Link to Item
-
Stackhouse, G. B., I. A. Sesterhenn, J. J. Bauer, F. K. Mostofi, R. R. Connelly, S. K. Srivastava, and J. W. Moul. “p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.” J Urol 162, no. 6 (December 1999): 2040–45. https://doi.org/10.1016/s0022-5347(05)68095-0.Full Text Link to Item
-
Moul, J. W. “Update of clinical and basic science research on prostate cancer from the department of defense center for prostate disease research (DOD-CPDR).” Prostate Cancer Prostatic Dis 2, no. S3 (November 1999): S22. https://doi.org/10.1038/sj.pcan.4500347.Full Text Link to Item
-
Zorn, B., J. J. Bauer, and J. W. Moul. “Benign prostatic hyperplasia: New concepts for the millennium.” American Journal of Managed Care 5, no. 7 (August 9, 1999): 911–22.
-
Moul, J. W., R. R. Connelly, R. M. Mooneyhan, W. Zhang, I. A. Sesterhenn, F. K. Mostofi, and D. G. McLeod. “Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.” J Urol 162, no. 2 (August 1999): 394–97.Link to Item
-
Moul, J. W. “Rising PSA after local therapy failure: immediate vs deferred treatment.” Oncology (Williston Park) 13, no. 7 (July 1999): 985–93.Link to Item
-
Srikantan, V., I. A. Sesterhenn, L. Davis, G. R. Hankins, F. A. Avallone, J. R. Livezey, R. Connelly, et al. “Allelic loss on chromosome 6Q in primary prostate cancer.” Int J Cancer 84, no. 3 (June 21, 1999): 331–35. https://doi.org/10.1002/(sici)1097-0215(19990621)84:3<331::aid-ijc23>3.0.co;2-j.Full Text Link to Item
-
Moul, J. W., and D. R. Lipo. “Prostate cancer in the late 1990s: hormone refractory disease options.” Urol Nurs 19, no. 2 (June 1999): 125–31.Link to Item
-
Bauer, J. J., J. Zeng, J. Weir, W. Zhang, I. A. Sesterhenn, R. R. Connelly, S. K. Mun, and J. W. Moul. “Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer.” Urology 53, no. 5 (May 1999): 961–67. https://doi.org/10.1016/s0090-4295(99)00068-0.Full Text Link to Item
-
Gao, C. L., S. Maheshwari, R. C. Dean, L. Tatum, R. Mooneyhan, R. R. Connelly, D. G. McLeod, S. Srivastava, and J. W. Moul. “Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.” Urology 53, no. 4 (April 1999): 714–21. https://doi.org/10.1016/s0090-4295(98)00608-6.Full Text Link to Item
-
Gao, C. L., R. C. Dean, A. Pinto, R. Mooneyhan, R. R. Connelly, D. G. McLeod, S. Srivastava, and J. W. Moul. “Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.” J Urol 161, no. 4 (April 1999): 1070–76.Link to Item
-
Moul, J. W. “Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.” Eur Urol 35, no. 5–6 (1999): 399–407. https://doi.org/10.1159/000019916.Full Text Link to Item
-
Sakr, W. A., M. K. Brawer, J. W. Moul, R. Donohue, C. G. Schulman, and Dr Sakr. “Pathology and bio markers of prostate cancer.” Prostate Cancer Prostatic Dis 2, no. S1 (January 1999): 7–14. https://doi.org/10.1038/sj.pcan.4500277.Full Text Link to Item
-
Sakr, W. A., M. K. Brawer, J. W. Moul, R. Donohue, and C. G. Schulman. “Pathology and bio markers of prostate cancer.” Prostate Cancer and Prostatic Diseases 2, no. 3331 (1999): 7–14.
-
Zeng, J., J. Bauer, W. Zhang, I. Sesterhenn, J. Moul, and S. K. Mun. “Prostate biopsy schemes: 3-d visualization-based evaluation.” Studies in Health Technology and Informatics 62 (January 1, 1999): 390–91. https://doi.org/10.3233/978-1-60750-906-6-390.Full Text
-
Preston, D. M., J. J. Bauer, R. R. Connelly, T. Sawyer, J. Halligan, E. S. Leifer, D. G. McLeod, and J. W. Moul. “Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.” Urology 53, no. 1 (January 1999): 131–38. https://doi.org/10.1016/s0090-4295(98)00464-6.Full Text Link to Item
-
Moul, J. W. “Pelvic muscle rehabilitation in males following prostatectomy.” Urol Nurs 18, no. 4 (December 1998): 296–301.Link to Item
-
Weinrich, M. C., S. J. Jacobsen, S. P. Weinrich, J. W. Moul, J. E. Oesterling, D. Jacobson, and R. Wise. “Reference ranges for serum prostate-specific antigen in black and white men without cancer.” Urology 52, no. 6 (December 1998): 967–73. https://doi.org/10.1016/s0090-4295(98)00448-8.Full Text Link to Item
-
Moul, J. W. “Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection.” J Natl Med Assoc 90, no. 11 Suppl (November 1998): S710–12.Link to Item
-
Heidenreich, A., I. A. Sesterhenn, F. K. Mostofi, and J. W. Moul. “Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours.” Int J Androl 21, no. 5 (October 1998): 283–88. https://doi.org/10.1046/j.1365-2605.1998.00131.x.Full Text Link to Item
-
Bauer, J. J., R. R. Connelly, I. A. Seterhenn, S. Srivastava, D. G. McLeod, and J. W. Moul. “Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer.” Mil Med 163, no. 9 (September 1998): 615–19.Link to Item
-
Heidenreich, A., I. A. Sesterhenn, F. K. Mostofi, and J. W. Moul. “Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.” Cancer 83, no. 5 (September 1, 1998): 1002–11.Link to Item
-
Moul, J. W., R. M. Mooneyhan, T. -. C. Kao, D. G. McLeod, and D. F. Cruess. “Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy.” Prostate Cancer Prostatic Dis 1, no. 5 (September 1998): 242–49. https://doi.org/10.1038/sj.pcan.4500248.Full Text Link to Item
-
Dean, R. C., and J. W. Moul. “New tumor markers of testis cancer.” Urol Clin North Am 25, no. 3 (August 1998): 365–73. https://doi.org/10.1016/s0094-0143(05)70027-6.Full Text Link to Item
-
Moul, J. W. “Treatment options for prostate cancer: Part 2 - Early and late stage and hormone refractory disease.” American Journal of Managed Care 4, no. 8 (August 1, 1998): 1171–82.
-
Bettencourt, M. C., J. J. Bauer, I. A. Sesterhenn, R. R. Connelly, and J. W. Moul. “CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.” J Urol 160, no. 2 (August 1998): 459–65.Link to Item
-
Moul, J. W. “Best screening tests for prostate cancer.” West J Med 169, no. 2 (August 1998): 109–10.Link to Item
-
Bauer, J. J., S. Srivastava, R. R. Connelly, I. A. Sesterhenn, D. M. Preston, D. G. McLeod, and J. W. Moul. “Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy.” Urology 51, no. 6 (June 1998): 970–76. https://doi.org/10.1016/s0090-4295(98)00103-4.Full Text Link to Item
-
Heidenreich, A., J. P. Gaddipati, J. W. Moul, and S. Srivastava. “Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.” J Urol 159, no. 5 (May 1998): 1725–30. https://doi.org/10.1097/00005392-199805000-00101.Full Text Link to Item
-
Li, Z., A. Rakkar, Y. Katayose, M. Kim, N. Shanmugam, S. Srivastava, J. W. Moul, D. G. McLeod, K. H. Cowan, and P. Seth. “Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model.” Gene Ther 5, no. 5 (May 1998): 605–13. https://doi.org/10.1038/sj.gt.3300636.Full Text Link to Item
-
Moul, J. W. “Contemporary hormonal management of advanced prostate cancer.” Oncology (Williston Park) 12, no. 4 (April 1998): 499–505.Link to Item
-
Moul, J. W. “Prostate cancer in African American men.” Prostate Cancer Prostatic Dis 1, no. 3 (March 1998): 109–18. https://doi.org/10.1038/sj.pcan.4500222.Full Text Link to Item
-
Bauer, J. J., R. R. Connelly, I. A. Seterhenn, J. Deausen, S. Srivastava, D. G. McLeod, and J. W. Moul. “Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.” J Urol 159, no. 3 (March 1998): 929–33.Link to Item
-
Moul, J. W., R. R. Connelly, B. Perahia, and D. G. McLeod. “The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.” J Urol 159, no. 3 (March 1998): 935–40.Link to Item
-
Heidenreich, A., S. Neubauer, and J. W. Moul. “Is a risk-adapted therapy possible in clinical stage i non-seminomatous testicular germ cell tumors?” Aktuelle Urologie 29, no. 3 (January 1, 1998): 93–102. https://doi.org/10.1055/s-2008-1065271.Full Text
-
Heidenreich, A., S. Srivastava, J. W. Moul, and U. H. Engelmann. “Mutation analysis of the tumor suppressor genes p16INKA and Mxi-1 in localized prostate cancer.” Aktuelle Urologie 29, no. 1 (January 1, 1998): 24–30. https://doi.org/10.1055/s-2008-1065256.Full Text
-
Moul, J. W. “Treatment options for prostate cancer: Part 1 - Stage, grade, PSA, and changes in the 1990s.” American Journal of Managed Care 4, no. 7 (January 1, 1998): 1031–38.
-
Heidenreich, A., N. S. Schenkman, I. A. Sesterhenn, K. F. Mostofi, J. W. Moul, S. Srivastava, and U. H. Engelmann. “Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours.” Apmis 106, no. 1 (January 1998): 90–99. https://doi.org/10.1111/j.1699-0463.1998.tb01324.x.Full Text Link to Item
-
Moul, J. W., J. J. Bauer, S. Srivastava, E. Colon, C. K. Ho, I. A. Sesterhenn, and D. G. McLeod. “Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation.” Urology 51, no. 1 (January 1998): 158–60. https://doi.org/10.1016/s0090-4295(97)00487-1.Full Text Link to Item
-
Kenner, J. R., L. C. Sperling, J. Waselenko, N. Dawson, P. Sau, and J. W. Moul. “Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.” J Urol 158, no. 6 (December 1997): 2245–46. https://doi.org/10.1016/s0022-5347(01)68218-1.Full Text Link to Item
-
Heidenreich, A., J. W. Moul, S. Srivastava, and U. H. Engelmann. “Synchronous bilateral testicular tumour: nonseminomatous germ cell tumours and contralateral benign tumours.” Scand J Urol Nephrol 31, no. 4 (August 1997): 389–92. https://doi.org/10.3109/00365599709030626.Full Text Link to Item
-
Heidenreich, A., N. S. Schenkmann, I. A. Sesterhenn, F. K. Mostofi, W. F. McCarthy, B. Heidenreich, and J. W. Moul. “Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.” J Urol 158, no. 2 (August 1997): 620–25.Link to Item
-
Douglas, T. H., T. O. Morgan, D. G. McLeod, J. W. Moul, G. P. Murphy, R. Barren, I. A. Sesterhenn, and F. K. Mostofi. “Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.” Cancer 80, no. 1 (July 1, 1997): 107–14. https://doi.org/10.1002/(sici)1097-0142(19970701)80:1<107::aid-cncr14>3.0.co;2-1.Full Text Link to Item
-
Douglas, T. H., D. G. McLeod, F. K. Mostofi, R. Mooneyhan, R. Connelly, J. W. Moul, and I. A. Sesterhenn. “Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens.” Prostate 32, no. 1 (June 15, 1997): 59–64. https://doi.org/10.1002/(sici)1097-0045(19970615)32:1<59::aid-pros8>3.0.co;2-7.Full Text Link to Item
-
Augenbraun, M., M. F. Go, J. W. Moul, and J. S. Tan. “Office management of chronic infections.” Patient Care 31, no. 9 (May 15, 1997): 78–94.
-
Asgari, K., I. A. Sesterhenn, D. G. McLeod, K. Cowan, J. W. Moul, P. Seth, and S. Srivastava. “Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector.” Int J Cancer 71, no. 3 (May 2, 1997): 377–82. https://doi.org/10.1002/(sici)1097-0215(19970502)71:3<377::aid-ijc13>3.0.co;2-d.Full Text Link to Item
-
Heidenreich, A., I. A. Sesterhenn, and J. W. Moul. “Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease.” Cancer 79, no. 9 (May 1, 1997): 1641–45. https://doi.org/10.1002/(sici)1097-0142(19970501)79:9<1641::aid-cncr1>3.0.co;2-f.Full Text Link to Item
-
Heffernan, J. P., H. B. Heidenberg, P. B. Irby, and J. W. Moul. “Gossypiboma (retained surgical sponge) and recurrent bladder neck contracture after radical retropubic prostatectomy and bilateral pelvic lymph node dissection.” J Urol 157, no. 4 (April 1997): 1356–57.Link to Item
-
Bauer, J. J., R. R. Connelly, I. A. Sesterhenn, M. C. Bettencourt, D. G. McLeod, S. Srivastava, and J. W. Moul. “Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.” Cancer 79, no. 5 (March 1, 1997): 952–62.Link to Item
-
Gaddipati, J. P., D. G. McLeod, I. A. Sesterhenn, C. J. Hussussian, Y. A. Tong, P. Seth, N. C. Dracopoli, J. W. Moul, and S. Srivastava. “Mutations of the p16 gene product are rare in prostate cancer.” Prostate 30, no. 3 (February 15, 1997): 188–94. https://doi.org/10.1002/(sici)1097-0045(19970215)30:3<188::aid-pros7>3.0.co;2-i.Full Text Link to Item
-
Jacobson, M. W. “Prostate-specific antigen in black men.” N Engl J Med 336, no. 2 (January 9, 1997): 133. https://doi.org/10.1056/NEJM199701093360212.Full Text Link to Item
-
Heidenreich, A., J. W. Moul, D. G. McLeod, F. K. Mostofi, and U. H. Engelmann. “The role of retroperitoneal lymphadenectomy in mature teratoma of the testis.” J Urol 157, no. 1 (January 1997): 160–63.Link to Item
-
Preston, D. M., S. M. Zeidman, M. Spevak, J. W. Moul, and R. A. Costabile. “Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance.” Tech Urol 3, no. 1 (1997): 51–53.Link to Item
-
Friedrichs, P. A., J. W. Moul, B. Wojcik, C. Donatucci, S. Optenberg, K. Kreder, and I. M. Thompson. “A long-term study of the efficacy of treatment of localized prostate cancer.” Urol Oncol 3, no. 5–6 (1997): 171–76. https://doi.org/10.1016/s1078-1439(98)00021-0.Full Text Link to Item
-
Heidenreich, A., R. Vorreuther, S. Neubauer, J. Westphal, U. H. Engelmann, and J. W. Moul. “The influence of ejaculation on serum levels of prostate specific antigen.” J Urol 157, no. 1 (January 1997): 209–11.Link to Item
-
Glajchen, M., and J. W. Moul. “Teleconferencing as a method of educating men about managing advanced prostate cancer and pain.” Journal of Psychosocial Oncology 14, no. 2 (December 1, 1996): 73–87. https://doi.org/10.1300/J077V14N02_05.Full Text
-
Heidenberg, H. B., J. J. Bauer, D. G. McLeod, J. W. Moul, and S. Srivastava. “The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?” Urology 48, no. 6 (December 1996): 971–79. https://doi.org/10.1016/s0090-4295(96)00365-2.Full Text Link to Item
-
Bauer, J. J., D. G. Mcleod, and J. W. Moul. “Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994.” Mil Med 161, no. 11 (November 1996): 646–53.Link to Item
-
Bauer, J. J., I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, S. Srivastava, and J. W. Moul. “Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.” J Urol 156, no. 4 (October 1996): 1511–16.Link to Item
-
Bettencourt, M. C., J. J. Bauer, I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, and J. W. Moul. “Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.” J Urol 156, no. 3 (September 1996): 1064–68.Link to Item
-
Moul, J. W., and A. Heidenreich. “Prognostic factors in low-stage nonseminomatous testicular cancer.” Oncology (Williston Park) 10, no. 9 (September 1996): 1359–74.Link to Item
-
Morgan, T. O., S. J. Jacobsen, W. F. McCarthy, D. J. Jacobson, D. G. McLeod, and J. W. Moul. “Age-specific reference ranges for serum prostate-specific antigen in black men.” N Engl J Med 335, no. 5 (August 1, 1996): 304–10. https://doi.org/10.1056/NEJM199608013350502.Full Text Link to Item
-
Moul, J. W., M. C. Bettencourt, I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, S. Srivastava, and J. J. Bauer. “Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.” Surgery 120, no. 2 (August 1996): 159–66. https://doi.org/10.1016/s0039-6060(96)80283-2.Full Text Link to Item
-
Styler, M. J., P. Crilley, J. Biggs, J. Moul, E. Copelan, D. Topolsky, B. Avalos, et al. “Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.” Bone Marrow Transplant 18, no. 1 (July 1996): 171–76.Link to Item
-
Moul, J. W., T. H. Douglas, W. F. McCarthy, and D. G. McLeod. “Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.” J Urol 155, no. 5 (May 1996): 1667–73.Link to Item
-
Moul, J. W., S. J. Maygarden, J. L. Ware, J. L. Mohler, P. D. Maher, N. S. Schenkman, and C. K. Ho. “Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy.” J Urol 155, no. 3 (March 1996): 982–85.Link to Item
-
Heidenreich, A., R. Vorreuther, B. Krug, J. W. Moul, and U. H. Engelmann. “Renal milk of calcium: contraindication to extracorporeal shockwave lithotripsy.” Tech Urol 2, no. 2 (1996): 102–7.Link to Item
-
Morgan, T. O., D. G. McLeod, E. S. Leifer, J. W. Moul, and G. P. Murphy. “Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA.” Prostate Suppl 7 (1996): 58–63.Link to Item
-
Srivastava, S., D. Katayose, Y. A. Tong, C. R. Craig, D. G. McLeod, J. W. Moul, K. H. Cowan, and P. Seth. “Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation.” Urology 46, no. 6 (December 1995): 843–48. https://doi.org/10.1016/S0090-4295(99)80355-0.Full Text Link to Item
-
Bauer, J. J., I. A. Sesterhenn, K. F. Mostofi, D. G. McLeod, S. Srivastava, and J. W. Moul. “p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.” Clin Cancer Res 1, no. 11 (November 1995): 1295–1300.Link to Item
-
Moul, J. W., I. A. Sesterhenn, R. R. Connelly, T. Douglas, S. Srivastava, F. K. Mostofi, and D. G. McLeod. “Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.” Jama 274, no. 16 (October 25, 1995): 1277–81.Link to Item
-
Heidenberg, H. B., I. A. Sesterhenn, J. P. Gaddipati, C. M. Weghorst, G. S. Buzard, J. W. Moul, and S. Srivastava. “Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer.” J Urol 154, no. 2 Pt 1 (August 1995): 414–21. https://doi.org/10.1097/00005392-199508000-00024.Full Text Link to Item
-
Schenkman, N. S., I. A. Sesterhenn, L. Washington, Y. A. Tong, C. M. Weghorst, G. S. Buzard, S. Srivastava, and J. W. Moul. “Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors.” J Urol 154, no. 2 Pt 1 (August 1995): 617–21. https://doi.org/10.1097/00005392-199508000-00081.Full Text Link to Item
-
Moul, J. W., P. B. Snow, E. B. Fernandez, P. D. Maher, and I. A. Sesterhenn. “Neural network analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer.” J Urol 153, no. 5 (May 1995): 1674–77.Link to Item
-
Moul, J. W. “Proper staging techniques in testicular cancer patients.” Tech Urol 1, no. 3 (1995): 126–32.Link to Item
-
Zhau, H. E., L. S. Zhao, L. W. Chung, B. Q. Chen, P. Troncoso, C. Kao, M. Kojima, et al. “Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations.” Urol Oncol 1, no. 2 (1995): 51–63. https://doi.org/10.1016/1078-1439(95)00009-7.Full Text Link to Item
-
Maygarden, S. J., D. B. Novotny, J. W. Moul, V. L. Bae, and J. L. Ware. “Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma.” Mod Pathol 7, no. 9 (December 1994): 930–36.Link to Item
-
Fernandez, E. B., I. A. Sesterhenn, W. F. McCarthy, F. K. Mostofi, and J. W. Moul. “Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.” J Urol 152, no. 4 (October 1994): 1133–38. https://doi.org/10.1016/s0022-5347(17)32522-3.Full Text Link to Item
-
Fernandez, E. B., J. W. Moul, J. P. Foley, E. Colon, and D. G. McLeod. “Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors.” Urology 44, no. 4 (October 1994): 548–52. https://doi.org/10.1016/s0090-4295(94)80056-1.Full Text Link to Item
-
Heidenberg, H. B., J. W. Moul, F. K. Mostofi, and D. G. McLeod. “Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man.” J Urol 152, no. 3 (September 1994): 966–67. https://doi.org/10.1016/s0022-5347(17)32626-5.Full Text Link to Item
-
Fernandez, E. B., E. Colon, D. G. McLeod, and J. W. Moul. “Efficacy of radiographic chest imaging in patients with testicular cancer.” Urology 44, no. 2 (August 1994): 243–48. https://doi.org/10.1016/s0090-4295(94)80139-8.Full Text Link to Item
-
Fowler, J. E., P. Pandey, N. T. Braswell, and L. Seaver. “Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.” Surgery 116, no. 2 (August 1994): 302–5.Link to Item
-
Gaddipati, J. P., D. G. McLeod, H. B. Heidenberg, I. A. Sesterhenn, M. J. Finger, J. W. Moul, and S. Srivastava. “Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.” Cancer Res 54, no. 11 (June 1, 1994): 2861–64.Link to Item
-
Moul, J. W. “For incontinence after prostatectomy, tap a diversity of treatments.” Contemp Urol 6, no. 4 (April 1994): 78–88.Link to Item
-
Moul, J. W. “An important goal of prostatectomy: minimizing incontinence.” Contemp Urol 6, no. 3 (March 1994): 15–28.Link to Item
-
Moul, J. W., F. J. Schanne, I. M. Thompson, H. A. Frazier, S. A. Peretsman, J. N. Wettlaufer, T. A. Rozanski, R. S. Stack, K. J. Kreder, and K. J. Hoffman. “Testicular cancer in blacks. A multicenter experience.” Cancer 73, no. 2 (January 15, 1994): 388–93. https://doi.org/10.1002/1097-0142(19940115)73:2<388::aid-cncr2820730225>3.0.co;2-q.Full Text Link to Item
-
Lewis, D. J., J. W. Moul, S. C. Williams, I. A. Sesterhenn, and E. Colon. “Perirenal liposarcoma containing extramedullary hematopoiesis associated with renal cell carcinoma.” Urology 43, no. 1 (January 1994): 106–9. https://doi.org/10.1016/s0090-4295(94)80279-3.Full Text Link to Item
-
Moul, J. W., D. J. Lewis, A. A. Ross, D. G. Kahn, C. K. Ho, and D. G. McLeod. “Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen.” Urology 43, no. 1 (January 1994): 68–73. https://doi.org/10.1016/s0090-4295(94)80267-x.Full Text Link to Item
-
Moul, J. W. “Benign prostatic hyperplasia. New concepts in the 1990s.” Postgrad Med 94, no. 6 (November 1, 1993): 141–52.Link to Item
-
Moul, Judd W. “Benign prostatic hyperplasia.” Postgrad Med 94, no. 6 (November 1993): 141–52. https://doi.org/10.1080/00325481.1993.11945750.Full Text Link to Item
-
Schenkman, N. S., J. W. Moul, E. R. Nicely, M. I. Maggio, and C. K. Ho. “Synchronous bilateral testis tumor: mixed germ cell and theca cell tumors.” Urology 42, no. 5 (November 1993): 593–95. https://doi.org/10.1016/0090-4295(93)90286-j.Full Text Link to Item
-
Moul, J. W., G. G. Wind, and C. R. Wright. “Tortuous and aberrant external iliac artery precluding radical retropubic prostatectomy for prostate cancer.” Urology 42, no. 4 (October 1993): 450–52. https://doi.org/10.1016/0090-4295(93)90384-m.Full Text Link to Item
-
Moul, J. W. “Prostatitis. Sorting out the different causes.” Postgrad Med 94, no. 5 (October 1993): 191–94.Link to Item
-
Moul, Judd W. “Prostatitis.” Postgrad Med 94, no. 5 (October 1993): 191–94. https://doi.org/10.1080/00325481.1993.11945739.Full Text Link to Item
-
Moul, J. W., J. P. Foley, C. L. Hitchcock, W. F. McCarthy, I. A. Sesterhenn, R. L. Becker, and J. L. Griffin. “Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.” J Urol 150, no. 3 (September 1993): 879–83. https://doi.org/10.1016/s0022-5347(17)35638-0.Full Text Link to Item
-
Moul, J. W., J. T. Bishoff, S. M. Theune, and E. H. Chang. “Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas.” J Urol 149, no. 6 (June 1993): 1389–94. https://doi.org/10.1016/s0022-5347(17)36397-8.Full Text Link to Item
-
Moul, J. W. “1992 New York-Tidewater chapters History of Military Medicine Essay Award recipient. James Claude Kimbrough: the father of modern U.S. Army urology.” Mil Med 158, no. 4 (April 1993): 213–22.Link to Item
-
Moul, J. W., S. M. Theune, and E. H. Chang. “Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization.” Genes Chromosomes Cancer 5, no. 2 (September 1992): 109–18. https://doi.org/10.1002/gcc.2870050204.Full Text Link to Item
-
Moul, J. W., and J. R. Moellman. “Unnecessary mastectomy for gynecomastia in testicular cancer patient.” Mil Med 157, no. 8 (August 1992): 433–34.Link to Item
-
“[title field missing].” Jama: The Journal of the American Medical Association 267, no. 19 (May 20, 1992): 2605–6. https://doi.org/10.1001/jama.267.19.2605.Full Text
-
Bishop, J. R., J. W. Moul, S. A. Sihelnik, D. S. Peppas, T. S. Gormley, and D. G. McLeod. “Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections.” J Urol 147, no. 2 (February 1992): 386–88. https://doi.org/10.1016/s0022-5347(17)37244-0.Full Text Link to Item
-
Moul, J. W., M. I. Maggio, M. R. Hardy, and D. S. Hartman. “Retroaortic left renal vein in testicular cancer patient: potential staging and treatment pitfall.” J Urol 147, no. 2 (February 1992): 454–56. https://doi.org/10.1016/s0022-5347(17)37269-5.Full Text Link to Item
-
Moul, J. W. “Retroperitoneal fibrosis following radiotherapy for stage I testicular seminoma.” J Urol 147, no. 1 (January 1992): 124–26. https://doi.org/10.1016/s0022-5347(17)37155-0.Full Text Link to Item
-
Moul, J. W., C. K. Ho, and D. G. McLeod. “Primary malignant melanoma of the scrotum.” Int Urol Nephrol 24, no. 6 (1992): 641–43. https://doi.org/10.1007/BF02551300.Full Text Link to Item
-
Moul, J. W., P. A. Friedrichs, R. S. Lance, S. M. Theune, and E. H. Chang. “Infrequent RAS oncogene mutations in human prostate cancer.” Prostate 20, no. 4 (1992): 327–38. https://doi.org/10.1002/pros.2990200407.Full Text Link to Item
-
Nicely, E. R., R. A. Costabile, and J. W. Moul. “Rupture of the deep dorsal vein of the penis during sexual intercourse.” J Urol 147, no. 1 (January 1992): 150–52. https://doi.org/10.1016/s0022-5347(17)37168-9.Full Text Link to Item
-
Moul, J. W., J. P. Foley, G. G. Wind, S. Rubin, J. A. Coffey, and D. G. McLeod. “Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma.” J Urol 146, no. 4 (October 1991): 1104–7. https://doi.org/10.1016/s0022-5347(17)38013-8.Full Text Link to Item
-
Moul, J. W., and D. F. Paulson. “The role of radical surgery in the management of radiation recurrent and large volume prostate cancer.” Cancer 68, no. 6 (September 15, 1991): 1265–71. https://doi.org/10.1002/1097-0142(19910915)68:6<1265::aid-cncr2820680615>3.0.co;2-g.Full Text Link to Item
-
Moul, J. W., M. R. Hardy, and D. G. McLeod. “Adrenal cortical carcinoma with vena cava tumor thrombus requiring cardiopulmonary bypass for resection.” Urology 38, no. 2 (August 1991): 179–83. https://doi.org/10.1016/s0090-4295(05)80083-4.Full Text Link to Item
-
Moul, J. W., R. K. Dodge, J. E. Robertson, D. F. Paulson, and P. J. Walther. “The impact of the "cisplatin era" of treatment on survival in testicular cancer.” World Journal of Urology 9, no. 1 (March 1, 1991): 45–50. https://doi.org/10.1007/BF00184714.Full Text
-
Paulson, D. F., J. W. Moul, and P. J. Walther. “Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results.” J Urol 144, no. 5 (November 1990): 1180–84. https://doi.org/10.1016/s0022-5347(17)39686-6.Full Text Link to Item
-
Bishop, J. R., J. W. Moul, L. Maldonado, and D. G. McLeod. “Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.” Urology 36, no. 4 (October 1990): 373–77. https://doi.org/10.1016/0090-4295(90)80253-j.Full Text Link to Item
-
Paulson, D. F., J. W. Moul, J. E. Robertson, and P. J. Walther. “Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule.” J Urol 143, no. 6 (June 1990): 1178–82. https://doi.org/10.1016/s0022-5347(17)40219-9.Full Text Link to Item
-
Moul, J. W., D. F. Paulson, and P. J. Walther. “Refusal of cancer therapy in testicular cancer: Recognizing and preventing a significant problem.” World Journal of Urology 8, no. 1 (March 1, 1990): 58–62. https://doi.org/10.1007/BF01576280.Full Text
-
Moul, J. W., D. F. Paulson, R. K. Dodge, and P. J. Walther. “Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years.” J Urol 143, no. 3 (March 1990): 520–23. https://doi.org/10.1016/s0022-5347(17)40007-3.Full Text Link to Item
-
Moul, J. W. “The problem of postprostatectomy incontinence.” Problems in Urology 4, no. 1 (January 1, 1990): 108–23.
-
Moul, J. W., J. E. Robertson, S. L. George, D. F. Paulson, and P. J. Walther. “Complications of therapy for testicular cancer.” J Urol 142, no. 6 (December 1989): 1491–96. https://doi.org/10.1016/s0022-5347(17)39135-8.Full Text Link to Item
-
Moul, J. W., D. F. Paulson, G. Fuller, M. R. Gottfried, and W. L. Floyd. “Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains.” J Urol 142, no. 5 (November 1989): 1328–29. https://doi.org/10.1016/s0022-5347(17)39078-x.Full Text Link to Item
-
Moul, J. W., and D. G. McLeod. “Negative pressure devices in the explanted penile prosthesis population.” J Urol 142, no. 3 (September 1989): 729–31. https://doi.org/10.1016/s0022-5347(17)38869-9.Full Text Link to Item
-
Moul, J. W., B. J. Miles, S. J. Skoog, and D. G. McLeod. “Risk factors for perineal seeding of prostate cancer after needle biopsy.” J Urol 142, no. 1 (July 1989): 86–88. https://doi.org/10.1016/s0022-5347(17)38668-8.Full Text Link to Item
-
Moul, J. W., R. Davis, J. A. Vaccaro, S. A. Sihelnik, W. D. Belville, and D. G. McLeod. “Acute urinary retention associated with prostatic carcinoma.” J Urol 141, no. 6 (June 1989): 1375–77. https://doi.org/10.1016/s0022-5347(17)41312-7.Full Text Link to Item
-
Dejter, S. W., R. E. Cunningham, P. D. Noguchi, R. V. Jones, J. W. Moul, D. G. McLeod, and J. H. Lynch. “Prognostic significance of DNA ploidy in carcinoma of prostate.” Urology 33, no. 5 (May 1989): 361–66. https://doi.org/10.1016/0090-4295(89)90026-5.Full Text Link to Item
-
Peppas, D. S., J. W. Moul, and D. G. McLeod. “Candida albicans corpora abscess following penile prosthesis placement.” J Urol 140, no. 6 (December 1988): 1541–42. https://doi.org/10.1016/s0022-5347(17)42101-x.Full Text Link to Item
-
Moul, J. W., and A. B. Belman. “A review of surgical treatment of undescended testes with emphasis on anatomical position.” J Urol 140, no. 1 (July 1988): 125–28. https://doi.org/10.1016/s0022-5347(17)41504-7.Full Text Link to Item
-
Moul, J. W., and D. G. McLeod. “Experience with the AMS 600 malleable penile prosthesis.” J Urol 135, no. 5 (May 1986): 929–31. https://doi.org/10.1016/s0022-5347(17)45926-x.Full Text Link to Item
-
-
Book Sections
-
Moul, J. W. “Population Screening for Prostate Cancer and Early Detection.” In Prostate Cancer: Science and Clinical Practice: Second Edition, 3–12, 2016. https://doi.org/10.1016/B978-0-12-800077-9.00001-3.Full Text
-
Abern, M. R., M. Tsivian, and J. W. Moul. “Prostate cancer.” In Urology at a Glance, 201–5, 2014. https://doi.org/10.1007/978-3-642-54859-8_40.Full Text
-
Bañez, L. L., S. Srivastava, and J. W. Moul. “Rationale for molecular markers of prostate cancer.” In Prostate Cancer: Principles and Practice, 259–68, 2005.
-
Moul, J. W. “Population Screening for Prostate Cancer and Early Detection in High-risk African American Men.” In Prostate Cancer: Science and Clinical Practice, 3–10, 2003. https://doi.org/10.1016/B978-012286981-5/50003-3.Full Text
-
Douglas, T. H., and J. W. Moul. “Artificial neural networks in urologic oncology.” In Artificial Neural Networks in Cancer Diagnosis, Prognosis, and Patient Management, 93–102, 2001.
-
Griewe, G. L., R. Dean, W. Zhang, I. A. Sesterhenn, S. Srivastava, and J. W. Moul. “Laser-capture microdissection.,” 53:165–73, 2001. https://doi.org/10.1385/1-59259-144-2:165.Full Text Link to Item
-
Srivastava, S., and J. W. Moul. “Chapter 8 Molecular progression of prostate cancer,” 3:155–87, 1999. https://doi.org/10.1016/S1569-254X(99)80009-0.Full Text
-
Douglas, T. H., and J. W. Moul. “Applications of neural networks in urologic oncology.,” 16:35–39, 1998.Link to Item
-
Moul, J. W., S. Srivastava, and D. G. McLeod. “Molecular implications of the antiandrogen withdrawal syndrome.,” 13:157–63, 1995.Link to Item
-
McLeod, D. G., and J. W. Moul. “Controversies in the treatment of prostate cancer with maximal androgen deprivation.,” 4:345–59, 1995.Link to Item
-
Moul, J. W. “Early and accurate diagnosis of testicular cancer,” 8:58–66, 1994.
-
Moul, J. W. “Early complications and toxicities of testicular cancer therapy,” 8:141–53, 1994.
-
Moul, J. W. “Molecular biology of testicular cancer,” 8:1–11, 1994.
-
Moul, J. W. “Renal adenoma,” 4:203–6, 1990.
-
Moul, J. W. “Renal cell carcinoma,” 4:255–72, 1990.
-
Moul, J. W. “Renal oncocytoma,” 4:207–21, 1990.
-
-
Other Articles
-
Moul, Judd W. “Editorial Comment.” Urology, January 2017. https://doi.org/10.1016/j.urology.2016.09.047.Full Text Link to Item
-
Moul, Judd W. “Editorial Comment.” J Urol, September 2016. https://doi.org/10.1016/j.juro.2016.03.185.Full Text Link to Item
-
Ostermann, J., and L. Onural. “Editorial.” 3dtv Conference, August 22, 2016. https://doi.org/10.1109/3DTV.2016.7548880.Full Text
-
Moul, Judd W., and James H. Semans. “Editorial Comment.” Urology, July 2016. https://doi.org/10.1016/j.urology.2015.11.067.Full Text Link to Item
-
Moul, J. W. “Editorial Commentary.” Urology Practice, May 1, 2016. https://doi.org/10.1016/j.urpr.2015.06.019.Full Text
-
Scales, Charles D. “Editorial Comment.” J Urol, May 2016. https://doi.org/10.1016/j.juro.2015.11.085.Full Text Link to Item
-
Moul, Judd W. “Editorial comment.” Urology, January 2016. https://doi.org/10.1016/j.urology.2015.08.027.Full Text Link to Item
-
Polascik, Thomas J., Kae Jack Tay, and Judd W. Moul. “Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer.” Eur Urol, December 2015. https://doi.org/10.1016/j.eururo.2015.02.024.Full Text Link to Item
-
Moul, Judd W. “Editorial Comment.” Urology, October 2015. https://doi.org/10.1016/j.urology.2015.05.035.Full Text Link to Item
-
Peterson, Andrew C. “Editorial comment.” Urology, May 2015. https://doi.org/10.1016/j.urology.2014.12.048.Full Text Link to Item
-
Leong, Kam W. “Editorial.” Biomaterials, January 2015. https://doi.org/10.1016/j.biomaterials.2014.10.047.Full Text Link to Item
-
Moul, Judd W., and James H. Semans. “Editorial comment.” Urology, January 2015. https://doi.org/10.1016/j.urology.2014.07.073.Full Text Link to Item
-
Moul, Judd. “Reply: To PMID 25432832.” Urology, December 2014. https://doi.org/10.1016/j.urology.2014.07.063.Full Text Link to Item
-
Moul, Judd. “Editorial comment.” Urology, November 2014. https://doi.org/10.1016/j.urology.2014.05.075.Full Text Link to Item
-
Moul, Judd W. “The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.” Oncology (Williston Park), August 2014.Link to Item
-
Routh, Jonathan C. “Editorial comment.” Urology, July 2014. https://doi.org/10.1016/j.urology.2014.02.031.Full Text Link to Item
-
Moul, Judd W. “Active surveillance for African-American men with prostate cancer: of course! Pro.” Oncology (Williston Park), January 2014.Link to Item
-
Moul, J. W., and J. E. McDermed. “Reply.” Urology, December 1, 2012. https://doi.org/10.1016/j.urology.2012.06.082.Full Text
-
Moul, Judd. “Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing postprostatectomy hernia.” Bju Int, December 2012. https://doi.org/10.1111/j.1464-410X.2012.11335.x.Full Text Link to Item
-
Moul, Judd W. “When should we pull the trigger for post-radical prostatectomy radiotherapy?” Eur Urol, September 2012. https://doi.org/10.1016/j.eururo.2012.05.066.Full Text Link to Item
-
Moul, J. W. “Radiotherapy comparison favors IMRT for prostate cancer: Commentary.” Oncology Report, May 1, 2012.
-
Moul, J. W. “Men avoid therapy for sexual side effects of prostatectomy: Commentary.” Oncology Report, May 1, 2012.
-
Moul, J. W. “In the pipeline: Galeterone lowers PSA in CRPC study: Commentary.” Oncology Report, May 1, 2012.
-
Moul, Judd W. “Prostate cancer: making the switch from LHRH antagonist to LHRH agonist.” Nat Rev Urol, January 31, 2012. https://doi.org/10.1038/nrurol.2012.5.Full Text Link to Item
-
Armstrong, Andrew J., Judd W. Moul, and Daniel J. George. “What to order from the prostate cancer treatment menu?” Oncology (Williston Park), January 2012.Link to Item
-
Loeb, S., H. B. Carter, W. J. Catalona, J. Moul, and F. H. Schroder. “Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen-Based Risk Assessment in Younger Men. Eur Urol 2012;61:8-9.” European Urology, January 1, 2012. https://doi.org/10.1016/j.eururo.2011.09.023.Full Text
-
Dreicer, Robert, and Judd W. Moul. “New data, new paradigms for treating patients with prostate cancer. Conclusion.” Urology, November 2011. https://doi.org/10.1016/j.urology.2011.03.060.Full Text Link to Item
-
Moul, Judd W., and Robert Dreicer. “New data, new paradigms for treating patients with prostate cancer: introduction.” Urology, November 2011. https://doi.org/10.1016/j.urology.2011.03.061.Full Text Link to Item
-
Tang, P., L. Sun, M. A. Uhlman, C. N. Robertson, T. J. Polascik, and J. W. Moul. “Re: Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men.” Journal of Urology, November 1, 2011. https://doi.org/10.1016/j.juro.2011.07.063.Full Text
-
Walsh, Patrick C. “Re: Salvage radiation in men after prostate-specific antigen failure and the risk of death.” J Urol, November 2011. https://doi.org/10.1016/j.juro.2011.08.056.Full Text Link to Item
-
Fitzpatrick, John M., Joaquim Bellmunt, Robert Dreicer, Neil E. Fleshner, Christopher J. Logothetis, Judd W. Moul, Bertrand Tombal, and Alexandre Zlotta. “Maximizing outcomes in genitourinary cancers across the treatment continuum.” Bju Int, April 2011. https://doi.org/10.1111/j.1464-410X.2010.10035.x.Full Text Link to Item
-
Moul, Judd W. “Putting Provenge in perspective.” Oncology (Williston Park), March 2011.Link to Item
-
Dreicer, R., and J. W. Moul. “Conclusion.” Urology, January 1, 2011. https://doi.org/10.1016/j.urology.2011.03.060.Full Text
-
Moul, Judd W. “Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy.” Urology, November 2010. https://doi.org/10.1016/j.urology.2010.04.055.Full Text Link to Item
-
Moul, Judd W. “Editorial comment.” Urology, September 2010. https://doi.org/10.1016/j.urology.2010.04.006.Full Text Link to Item
-
Moul, J. W. “Low-risk men can delay prostatectomy until biopsy upgrade: Comment.” Oncology Report, July 1, 2010.
-
Moul, J. W. “Radiation plus ADT improves overall, disease-free survival: Comment.” Oncology Report, July 1, 2010.
-
Moul, J. W. “Reliance on PSA triggers may lead to overtreatment: Commentary.” Oncology Report, May 20, 2010.
-
Moul, J. W. “Reply.” Urology, May 1, 2010. https://doi.org/10.1016/j.urology.2009.12.006.Full Text
-
Moul, Judd W. “Radiotherapy: Secondary malignancies after prostate cancer treatment.” Nat Rev Clin Oncol, May 2010. https://doi.org/10.1038/nrclinonc.2010.59.Full Text Link to Item
-
Moul, Judd W., Ping Tang, and Leon Sun. “Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.” Eur Urol, March 2010. https://doi.org/10.1016/j.eururo.2009.03.024.Full Text Link to Item
-
Moul, J. W. “Report from Durham.” Prostate Cancer Prostatic Dis, March 2010. https://doi.org/10.1038/pcan.2009.65.Full Text Link to Item
-
Moul, Judd W. “Editorial comment.” Urology, February 2010. https://doi.org/10.1016/j.urology.2009.07.1249.Full Text Link to Item
-
Moul, J. W. “Reply.” Urology, January 1, 2010. https://doi.org/10.1016/j.urology.2009.07.1247.Full Text
-
Moul, J. W. “Hormone therapy for prostate cancer raises heart disease risk: Commentary.” Oncology Report, December 1, 2009.
-
Stewart, Suzanne Biehn, Charles D. Scales, and Judd W. Moul. “Health policy: Health-care implications of resident duty-hour restrictions.” Nat Rev Urol, December 2009. https://doi.org/10.1038/nrurol.2009.230.Full Text Link to Item
-
Moul, J. W. “Four clinical risk factors predict survival surrogate: Commentary.” Oncology Report, September 1, 2009.
-
Moul, J. W. “Adjuvant radiotherapy remains rare in prostate cancer care: Commentary.” Oncology Report, September 1, 2009.
-
Moul, Judd W. “Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.” Cancer, August 1, 2009. https://doi.org/10.1002/cncr.24393.Full Text Link to Item
-
Moul, Judd W. “Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example.” Eur Urol, June 2009. https://doi.org/10.1016/j.eururo.2009.03.062.Full Text Link to Item
-
Moul, J. W. “Report from Durham.” Prostate Cancer Prostatic Dis, 2009. https://doi.org/10.1038/pcan.2009.34.Full Text Link to Item
-
Moul, Judd W. “Twenty-five year evolution of medical hormonal therapy for prostate cancer.” Bju Int, January 2009. https://doi.org/10.1111/j.1464-410X.2008.08271.x.Full Text Link to Item
-
Moul, Judd W. “Innovations in urology from military medicine.” Urol Oncol, 2009. https://doi.org/10.1016/j.urolonc.2009.01.022.Full Text Link to Item
-
Moul, Judd W. “Are we overtreating prostate cancer?” J Urol, December 2008. https://doi.org/10.1016/j.juro.2008.09.067.Full Text Link to Item
-
Moul, J. W., and V. Mouraviev. “Should elderly men be screened for prostate cancer?” Aging Health, October 10, 2008. https://doi.org/10.2217/1745509X.4.5.443.Full Text
-
Moul, J. W. “Rebuttal to Dr. Stock.” Brachytherapy, October 1, 2008. https://doi.org/10.1016/j.brachy.2008.08.006.Full Text
-
Moul, J. W. “Primary androgen blockade is no better than watchful waiting: Commentary.” Oncology Report, September 1, 2008.
-
Moul, J. W. “Sunitinib combination reduces PSA levels in metastatic HRPC: Commentary.” Oncology Report, September 1, 2008.
-
Moul, J. W. “More leukemia diagnosed years after EBRT for prostate cancer: Commentary.” Oncology Report, September 1, 2008.
-
Moul, J. W. “Androgen deprivation ups diabetes risk, but not AMIs: Commentary.” Oncology Report, September 1, 2008.
-
Moul, J. W. “Carboplatin matches radiation in stage I seminoma: Commentary.” Oncology Report, September 1, 2008.
-
Moul, Judd W. “Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.” Eur Urol, July 2008. https://doi.org/10.1016/j.eururo.2008.03.062.Full Text Link to Item
-
Moul, J. W. “Report from Durham.” Prostate Cancer Prostatic Dis, 2008. https://doi.org/10.1038/pcan.2008.43.Full Text Link to Item
-
Moul, J. W. “Report from Durham.” Prostate Cancer Prostatic Dis, 2008. https://doi.org/10.1038/pcan.2008.8.Full Text Link to Item
-
Moul, Judd W. “Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients.” Brachytherapy, 2008. https://doi.org/10.1016/j.brachy.2008.08.003.Full Text Link to Item
-
Petrovics, G., A. Liu, S. Shaheduzzaman, B. Furusato, C. Sun, Y. Chen, M. Nau, et al. “Erratum: Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome (Oncogene (2005) 24 (3847-3852) DOI:10.1038/sj.onc.1208518).” Oncogene, October 11, 2007. https://doi.org/10.1038/sj.onc.1210745.Full Text
-
Freedland, S. J., and J. W. Moul. “Flaxseed slows prostate cancer growth in randomized study: Commentary.” Oncology Report, September 1, 2007.
-
Freedland, S. J., and J. W. Moul. “PSA decline of 30% may be surrogate marker for overall survival: Commentary.” Oncology Report, September 1, 2007.
-
Freedland, S. J., and J. W. Moul. “Sunitinib active in bevacizumab-resistant kidney cancer: Commentary.” Oncology Report, September 1, 2007.
-
Freedland, S. J., and J. W. Moul. “Postsurgical prognostic tools give inaccurate predictions: Commentary.” Oncology Report, September 1, 2007.
-
Freedland, S. J., and J. W. Moul. “More positive needle biopsies in African American men: Commentary.” Oncology Report, September 1, 2007.
-
George, D. J., and J. W. Moul. “Bevacizumab plus interferon-α improves survival: Commentary.” Oncology Report, September 1, 2007.
-
George, D. J., and J. W. Moul. “Satraplatin boosts progression-free survival in SPARC: Commentary.” Oncology Report, September 1, 2007.
-
Lee, W. R., and J. W. Moul. “Adjuvant radiotherapy linked to better cause-specific survival: Commentary.” Oncology Report, September 1, 2007.
-
Lee, W. R., and J. W. Moul. “Follow-up after EBRT falls short of guideline: Commentary.” Oncology Report, September 1, 2007.
-
Lee, W. R., and J. W. Moul. “Adjuvant radiotherapy averts biochemical progression.” Oncology Report, September 1, 2007.
-
Moul, J. W. “Choice of consultation specialist sways treatment decisions: Commentary.” Oncology Report, September 1, 2007.
-
Moul, J. W. “Stress management eases fear, aids postsurgical function: Commentary.” Oncology Report, September 1, 2007.
-
Moul, J. W. “Circulating tumor cells may be better surrogate than PSA: Commentary.” Oncology Report, September 1, 2007.
-
Moul, J. W. “Better QOL with adjuvant chemotherapy than radiation: Commentary.” Oncology Report, September 1, 2007.
-
Moul, J. W. “Report from Durham.” Prostate Cancer and Prostatic Diseases, September 1, 2007. https://doi.org/10.1038/sj.pcan.4500998.Full Text
-
Moul, J. W. “Intermittent androgen suppression is safe alternative: Commentary.” Oncology Report, September 1, 2007.
-
Moul, J. W. “Report from Durham.” Prostate Cancer and Prostatic Diseases, March 1, 2007. https://doi.org/10.1038/sj.pcan.4500945.Full Text
-
Freedland, S. J., J. W. Moul, and J. F. Ward. “PSA recurrence of prostate cancer: Update 2006.” Consultant, December 1, 2006.
-
Moul, J. W. “The Eisenberger/Sinibaldi article reviewed.” Oncology, December 1, 2006.
-
Lee, W Robert, and Judd W. Moul. “Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?” Nat Clin Pract Oncol, October 2006. https://doi.org/10.1038/ncponc0612.Full Text Link to Item
-
Freedland, S. J., D. J. George, and J. W. Moul. “Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment.” Oncology Report, September 1, 2006.
-
Freedland, S. J., and J. W. Moul. “Bicalutamide added to standard care reduces risk of bone metastasis: Comment.” Oncology Report, September 1, 2006.
-
Freedland, S. J., and J. W. Moul. “Intermittent maximum androgen blockade is a worthwhile option for metastatic disease: Comment.” Oncology Report, September 1, 2006.
-
Freedland, S. J., and J. W. Moul. “Absolute PSA value is powerful predictor of survival after androgen deprivation: Comment.” Oncology Report, September 1, 2006.
-
George, D. J., and J. W. Moul. “Sunitinib and temsirolimus: New standards of care for metastatic RCC? Comment.” Oncology Report, September 1, 2006.
-
George, D. J., and J. W. Moul. “Perioperative chemotherapy surprisingly underused for transitional cell carcinoma: Comment.” Oncology Report, September 1, 2006.
-
George, D. J., and J. W. Moul. “Salvage chemotherapy yields high cure rate in recurrent germ cell tumors: Comment.” Oncology Report, September 1, 2006.
-
Moul, J. W. “PSA doubling time key to reducing prostate cancer mortality: Comment.” Oncology Report, September 1, 2006.
-
Moul, J. W. “Lower risk of recurrence with chemo than with lymph node dissection in stage I NSGCT: Comment.” Oncology Report, September 1, 2006.
-
Moul, J. W. “Report from Durham.” Prostate Cancer and Prostatic Diseases, September 1, 2006. https://doi.org/10.1038/sj.pcan.4500908.Full Text
-
Moul, J. W., S. J. Freedland, and D. J. George. “Peripheral androgen blockage produces durable PSA responses in prostate cancer: Comment.” Oncology Report, September 1, 2006.
-
Moul, Judd W. “The role of cytotoxic chemotherapy in prostate cancer - A critical reevaluation 20 years later - The Eisenberger/Sinibaldi article reviewed.” Oncology New York. P R R INC, July 1, 2006.Link to Item
-
Moul, J. W. “Prostate cancer.” Current Opinion in Urology, May 1, 2006. https://doi.org/10.1097/01.mou.0000193406.67166.83.Full Text
-
Moul, J. W. “Editorial introduction.” Current Opinion in Urology, May 1, 2006. https://doi.org/10.1097/01.mou.0000193408.12909.56.Full Text
-
Moul, J. W. “Report from Durham.” Prostate Cancer and Prostatic Diseases, March 1, 2006. https://doi.org/10.1038/sj.pcan.4500863.Full Text
-
Moul, J. W. “Treating the troops a model for battling health-care disparities.” Oncology New York. P R R INC, March 1, 2006.Link to Item
-
Moul, J. W. “Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: Results from CaPSURE - Commentary.” Journal of Urology, January 1, 2006. https://doi.org/10.1016/S0022-5347(05)00267-3.Full Text
-
Dahm, P., and J. W. Moul. “Immunization with TG4010 appears biologically active in prostate cancer. Comment.” Oncology Report, September 1, 2005.
-
Moul, J. W. “Adjuvant RT reduces biochemical progression after radical prostatectomy. Comment.” Oncology Report, September 1, 2005.
-
Moul, J. W. “Report from Durham.” Prostate Cancer and Prostatic Diseases, September 1, 2005. https://doi.org/10.1038/sj.pcan.4500829.Full Text
-
Moul, J. W. “High probability of metastases or death in untreated prostate cancer. Comment.” Oncology Report, September 1, 2005.
-
Moul, J. W. “Favorable trends with DN-101 and docetaxel in androgen-independent prostate cancer. Comment.” Oncology Report, September 1, 2005.
-
Moul, J. W. “RT-PCR for PSA predicts time to disease progression in HR prostate cancer. Comment.” Oncology Report, September 1, 2005.
-
Moul, J. W., and P. Dahm. “TICE chemotherapy achieves good response in germ cell tumors. Comment.” Oncology Report, September 1, 2005.
-
Moul, J. W. “Untitled.” Current Opinion in Urology. LIPPINCOTT WILLIAMS & WILKINS, May 1, 2005.Link to Item
-
Moul, J. W. “Treating invasive bladder cancer with TUR/chemotherapy feasible for selected patients.” Oncology Report, March 1, 2005.
-
Moul, J. W. “Radiation dose escalation for early-stage prostate cancer found safe and effective.” Oncology Report, March 1, 2005.
-
Vieweg, J., and J. W. Moul. “Promising phase II results for lenalidomide in metastatic renal cell cancer.” Oncology Report, March 1, 2005.
-
Moul, J. W. “In reply [2].” Journal of Clinical Oncology, February 20, 2005. https://doi.org/10.1200/JCO.2005.05.460.Full Text
-
Moul, J. W. “Prostate cancer.” Current Opinion in Urology, January 1, 2005. https://doi.org/10.1097/01.mou.0000165546.48922.5b.Full Text
-
Moul, J. “Report from Durham.” Prostate Cancer Prostatic Dis, 2005. https://doi.org/10.1038/sj.pcan.4500795.Full Text Link to Item
-
Pitts, W Reid. “Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.” J Urol, December 2004. https://doi.org/10.1097/01.ju.0000145135.83351.cb.Full Text Link to Item
-
Moul, J. W. “The Cooperberg/Park/Carroll article reviewed.” Oncology, September 1, 2004.
-
Moul, J. W. “Editorial.” Prostate Cancer and Prostatic Diseases, September 1, 2004. https://doi.org/10.1038/sj.pcan.4500759.Full Text
-
Kirby, R., and J. W. Moul. “Is the PSA test useless?” Prostate Cancer Prostatic Dis, 2004. https://doi.org/10.1038/sj.pcan.4500777.Full Text Link to Item
-
Kirby, R. S., and J. W. Moul. “Editorial.” Prostate Cancer and Prostatic Diseases, December 1, 2003. https://doi.org/10.1038/sj.pcan.4500702.Full Text
-
Tiguert, Rabi, and Brant A. Inman. “Re: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.” J Urol, December 2003. https://doi.org/10.1097/01.ju.0000095148.84868.ba.Full Text Link to Item
-
Moul, J. W., and R. Kirby. “PCPD editorial.” Prostate Cancer and Prostatic Diseases, October 9, 2003. https://doi.org/10.1038/sj.pcan.4500682.Full Text
-
Kirby, R. S., and J. W. Moul. “PCPD editorial.” Prostate Cancer and Prostatic Diseases, July 15, 2003. https://doi.org/10.1038/sj.pcan.4500659.Full Text
-
Kirby, R., M. Brawer, and J. Moul. “Editorial.” Prostate Cancer and Prostatic Diseases, January 1, 2003. https://doi.org/10.1038/sj.pcan.4500651.Full Text
-
Moul, J. W., and D. J. Vaughn. “Leuprolide acetate: Viewpoints.” American Journal of Cancer, January 1, 2003. https://doi.org/10.2165/00024669-200302010-00005.Full Text
-
Moul, J. W. “Radical prostatectomy nomograms in black American men: Accuracy and applicability. Editorial comment.” Journal of Urology, 2003. https://doi.org/10.1016/S0022-5347(01)69340-6.Full Text
-
Kirby, R. S., J. W. Moul, and M. K. Brawer. “Editorial.” Prostate Cancer and Prostatic Diseases, December 1, 2002. https://doi.org/10.1038/sj.pcan.4500642.Full Text
-
Moul, Judd W. “Prostate biopsy quantitative histology as a staging and prognostic factor.” J Urol, February 2002. https://doi.org/10.1097/00005392-200202000-00017.Full Text Link to Item
-
Kirby, R., J. Moul, and M. Brawer. “Editorial.” Prostate Cancer and Prostatic Diseases, January 1, 2002. https://doi.org/10.1038/sj.pcan.4500627.Full Text
-
Kirby, R., J. Moul, and M. Brawer. “Editorial.” Prostate Cancer and Prostatic Diseases, January 1, 2002. https://doi.org/10.1038/sj.pcan.4500578.Full Text
-
Kirby, R., M. Brawer, and J. Moul. “Editorial.” Prostate Cancer and Prostatic Diseases, January 1, 2002. https://doi.org/10.1038/sj.pcan.4500590.Full Text
-
Moul, J. W. “The D'Amico article reviewed: The CPDR/CaPSURE recurrence equation.” Oncology, December 1, 2001.
-
Kirby, R., J. Moul, and M. Brawer. “Editorial.” Prostate Cancer and Prostatic Diseases, October 14, 2001. https://doi.org/10.1038/sj.pcan.4500537.Full Text
-
Anscher, M. S. “Re: The development of erectile dysfunction in men treated for prostate cancer.” J Urol, September 2001.Link to Item
-
Kirby, R., J. Moul, and M. Brawer. “Editorial.” Prostate Cancer and Prostatic Diseases, July 24, 2001. https://doi.org/10.1038/sj.pcan.4500526.Full Text
-
Feleppa, E. J., J. A. Ketterling, A. Kalisz, S. Urban, C. R. Porter, J. Gillespie, P. B. Schiff, et al. “Prostate imaging based on RF spectrum analysis and non-linear classifiers for guiding biopsies and targeting radiotherapy.” Proceedings of Spie the International Society for Optical Engineering, January 1, 2001. https://doi.org/10.1117/12.428213.Full Text
-
Kirby, R., M. Brawer, and J. Moul. “Editorial.” Prostate Cancer and Prostatic Diseases, January 1, 2001. https://doi.org/10.1038/sj.pcan.4500558.Full Text
-
Zeng, J., A. Sofer, J. J. Bauer, W. Zhang, I. A. Sesterhenn, J. W. Moul, and S. K. Mun. “Probability of cancer detection with optimized prostate biopsy protocols.” Proceedings of Spie the International Society for Optical Engineering, January 1, 2001. https://doi.org/10.1117/12.428108.Full Text
-
Xu, L. L., N. Shanmugam, T. Segawa, I. A. Sesterhenn, D. G. McLeod, J. W. Moul, and S. Srivastava. “Erratum: A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate (Genomics (2000) 66:3 (257-263)).” Genomics, December 15, 2000. https://doi.org/10.1006/geno.2000.6458.Full Text
-
Moul, J. W., T. Segawa, L. L. Xu, L. Sun, I. A. Sesterhenn, and S. Srivastava. “cDNA microarray gene chip for prostate cancer and translational study in a prospective tissue bank and clinical longitudinal database.” Prostate Cancer Prostatic Dis, December 2000. https://doi.org/10.1038/sj.pcan.4500455.Full Text Link to Item
-
Bauer, J. J., J. Zeng, W. Zhang, I. A. Sesterhenn, R. Dean, J. W. Moul, and S. K. Mun. “Simulated prostate biopsy: Prostate cancer distribution and clinical correlation.” Proceedings of Spie the International Society for Optical Engineering, January 1, 2000.
-
Kirby, R., J. Moul, and M. Brawer. “Prostate cancer and prostatic diseases: Editorial.” Prostate Cancer and Prostatic Diseases, January 1, 2000. https://doi.org/10.1038/sj.pcan.4500414.Full Text
-
Kirby, R., M. Brawer, and J. Moul. “Prostate and prostatic diseases: Editorial.” Prostate Cancer and Prostatic Diseases, January 1, 2000. https://doi.org/10.1038/sj.pcan.4500484.Full Text
-
Zeng, J., J. J. Bauer, X. Yao, W. Zhang, I. A. Sesterhenn, R. R. Connelly, J. W. Moul, and S. K. Mun. “Building an accurate 3D map of prostate cancer using computerized models of 280 whole-mounted radical prostatectomy specimens.” Proceedings of Spie the International Society for Optical Engineering, January 1, 2000.
-
Heidenreich, A., I. A. Sesterhenn, F. K. Mostofi, J. W. Moul, and C. Hennequin. “Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.” Progres En Urologie, April 1, 1999.
-
Bauer, J. J., J. Zeng, J. Weir, W. Zhang, I. A. Sesterhenn, R. R. Connelly, J. W. Moul, and S. K. Mun. “Optimization of prostate biopsy.” Proceedings of Spie the International Society for Optical Engineering, January 1, 1999. https://doi.org/10.1117/12.349441.Full Text
-
Yu, P., M. McClain, J. Xuan, Y. Wang, I. A. Sesterhenn, J. W. Moul, W. Zhang, and S. K. Mun. “Model supported virtual environment for prostate cancer pattern analysis.” Proceedings of Spie the International Society for Optical Engineering, January 1, 1999. https://doi.org/10.1117/12.349418.Full Text
-
Herr, H. W. “Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease.” Cancer, January 1, 1998. https://doi.org/10.1002/(sici)1097-0142(19980101)82:1<231::aid-cncr33>3.0.co;2-1.Full Text Link to Item
-
Bauer, J. J., F. K. Mostofi, D. G. McLeod, S. Srivastava, and J. W. Moul. “Apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients.” British Journal of Urology, December 1, 1997.
-
Hayes, W. S., I. A. Sesterhenn, J. Xuan, Y. Wang, R. L. Becker, J. H. Lynch, J. W. Moul, et al. “Interactive three dimensional modeling of localized prostate cancer: Computer simulation of needle biopsy technique.” British Journal of Urology, December 1, 1997.
-
Heidenreich, A., I. A. Sesterhenn, K. F. Mostofi, and W. Judd. “Prognostic risk factors in low stage nonseminumatous testicular germ cell tumors (NTGCT).” British Journal of Urology, December 1, 1997.
-
Mostofi, F. K., I. A. Sesterhenn, C. J. Davis, D. G. McLeod, T. Douglas, and J. W. Moul. “Frequency and location of benign prostatic glands in the surgical margin of 147 radical retropubic prostatectomies for carcinoma.” British Journal of Urology, December 1, 1997.
-
Moul, J. W. “The Powell Article Reviewed.” Oncology, December 1, 1997.
-
Moul, J. W. “Prostate cancer 1997--practicing what we preach.” J Urol, November 1997. https://doi.org/10.1016/s0022-5347(01)64146-6.Full Text Link to Item
-
Moul, J. W. “PSA thresholds for prostate cancer detection.” Jama, September 3, 1997. https://doi.org/10.1001/jama.278.9.699b.Full Text Link to Item
-
Moul, J. W. “Epidemiology and screening for prostate cancer.” Am J Manag Care, August 1997.Link to Item
-
Moul, J. W. “Radical prostatectomy and cryotherapy--some answers, more questions.” J Urol, January 1997. https://doi.org/10.1016/s0022-5347(01)65339-4.Full Text Link to Item
-
Douglas, T. H., W. F. McCarthy, D. G. McLeod, and J. W. Moul. “Patient selection for experimental adjuvant therapy after radical prostatectomy.” Urology, February 1996. https://doi.org/10.1016/S0090-4295(99)80436-1.Full Text Link to Item
-
Moul, J. W. “DNA ploidy in nonseminomatous germ cell testicular tumor.” Urology, July 1994. https://doi.org/10.1016/s0090-4295(94)80037-5.Full Text Link to Item
-
Moul, J. W., W. F. McCarthy, E. B. Fernandez, and I. A. Sesterhenn. “Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.” Cancer Res, January 15, 1994.Link to Item
-
Stewart, D. A., D. J. Stewart, and K. T. Mai. “Active chemotherapy for metastatic stromal cell tumor of the testis.” Urology, December 1993. https://doi.org/10.1016/0090-4295(93)90547-n.Full Text Link to Item
-
Bejany, D. E., P. E. Perito, M. Lustgarten, and R. K. Rhamy. “Gangrene of the penis after implantation of penile prosthesis: case reports, treatment recommendations and review of the literature.” J Urol, July 1993. https://doi.org/10.1016/s0022-5347(17)35433-2.Full Text Link to Item
-
Moul, J. W. “Retroperitoneal lymphadenectomy.” Can J Surg, February 1993.Link to Item
-
Cookson, M. S., and P. W. Nadig. “Long-term results with vacuum constriction device.” J Urol, February 1993. https://doi.org/10.1016/s0022-5347(17)36059-7.Full Text Link to Item
-
Moul, J. W. “Testicular tumour.” Br J Hosp Med, October 21, 1992.Link to Item
-
Moul, J. W. “Refusal in testicular cancer patients: implications for surveillance.” Br J Cancer, May 1992. https://doi.org/10.1038/bjc.1992.168.Full Text Open Access Copy Link to Item
-
Moul, J. W. “Inappropriate surgery for testicular cancer.” Br J Hosp Med, January 9, 1992.Link to Item
-
Moul, J. W. “Gynaecomastia and extragonadal symptoms leading to diagnosis delay of germ cell tumours in young men.” Postgrad Med J, December 1991. https://doi.org/10.1136/pgmj.67.794.1082-a.Full Text Link to Item
-
Moul, J. W., D. F. Paulson, and P. J. Walther. “Refusal of cancer treatment in testicular cancer patients.” J Natl Cancer Inst, October 18, 1989. https://doi.org/10.1093/jnci/81.20.1587.Full Text Link to Item
-
Schuster, V., D. Alston, and N. McWilliam. “Preface.” Oxford Art Journal, 1978. https://doi.org/10.2307/1360077.Full Text Link to Item
-
-
Conference Papers
-
Kotamarti, S., K. Morris, and J. W. Moul. “Re-thinking how we use prostate health index for African American men.” In European Urology, 81:S559–60, 2022.Link to Item
-
Michael, Z. D., S. Kotamarti, R. Arcot, K. Morris, A. Shah, J. Anderson, A. Armstrong, et al. “Longitudinal outcomes following implementation of baseline PSA risk stratification of men in their forties.” In European Urology, 81:S567–68, 2022.Link to Item
-
Ha, Christine, Vanessa Cheong, Mary Cooter, Jeffrey N. Browndyke, Eugene Moretti, W. M. Bullock, Brian J. Colin, et al. “Cognitive and Cerebrospinal fluid Alzheimer's Disease biomarker changes over time in older surgical patients and matched nonsurgical controls.” In Anesthesia and Analgesia, 130:502–502, 2020.Link to Item
-
Freedland, Stephen J., Jenifer Allen, Andrew J. Armstrong, Judd W. Moul, Howard M. Sandler, Dana Levin, Lauren E. Howard, and Pao-hwa Lin. “Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2 (CAPS2).” In Journal of Clinical Oncology, 36:382–382. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.382.Full Text
-
Stone, Steven, Matthew R. Cooperberg, Darl D. Flake, John W. Davis, Judd W. Moul, Jonathan David Tward, and Michael K. Brawer. “Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.” In Journal of Clinical Oncology, 35:e16566–e16566. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e16566.Full Text
-
Moul, Judd W., John A. McLane, Stuart Atkinson, and Raoul S. Concepcion. “Head-to-head pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprorelin acetate formulations in male patients.” In Journal of Clinical Oncology, 35:e589–e589. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.6_suppl.e589.Full Text
-
Armstrong, A. J., S. Halabi, P. Healy, W. R. Lee, B. F. Koontz, J. W. Moul, K. Mundy, et al. “A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.” In Prostate Cancer Prostatic Dis, 19:100–106, 2016. https://doi.org/10.1038/pcan.2015.59.Full Text Link to Item
-
Scardino, Peter T., Jack M. Cuzick, Steve Stone, Brent Evans, Matthew R. Jorgensen, James Andrew Eastham, Thomas E. Keane, et al. “Application of active surveillance threshold to series of samples submitted for commercial testing.” In Journal of Clinical Oncology, 34:84–84. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.84.Full Text
-
Saltzstein, Daniel R., Judd W. Moul, Stephan de la Motte, John A. McLane, David W. Osborne, Alex Yang, and Raoul S. Concepcion. “Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere.” In Journal of Clinical Oncology, 33:e16048–e16048. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e16048.Full Text
-
Reed, S. D., S. Biehn Stewart, C. D. Scales, and J. W. Moul. “Use of PSA Slope to Guide Adjuvant Radiotherapy in Post-Prostatectomy Prostate Cancer has Potential to be Cost Effective.” In Value in Health, 17:A86–A86. Elsevier BV, 2014. https://doi.org/10.1016/j.jval.2014.03.499.Full Text
-
Reynolds, M. A., J. W. Moul, and J. McDermed. “NADIA® Psa Slope Impacts Urologists’ Recommendations for Adjuvant Radiotherapy for Prostate Cancer Patients with High-Risk Pathology Following Radical Prostatectomy.” In Value in Health, 17:A101–A101. Elsevier BV, 2014. https://doi.org/10.1016/j.jval.2014.03.591.Full Text
-
Koontz, B. F., N. S. Kalman, L. L. Bañez, K. P. Livengood, M. S. Anscher, J. W. Moul, and W. R. Lee. “Image Guidance Affects Biochemical Outcome for Postprostatectomy Radiation Therapy.” In International Journal of Radiation Oncology*Biology*Physics, 87:S362–63. Elsevier BV, 2013. https://doi.org/10.1016/j.ijrobp.2013.06.953.Full Text
-
Halabi, S., C. Y. Lin, W. K. Kelly, K. Fizazi, J. W. Moul, E. Kaplan, M. J. Morris, and E. J. Small. “A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer.” In European Journal of Cancer, 49:S679–S679. ELSEVIER SCI LTD, 2013.Link to Item
-
Kalman, Noah S., Lionel L. Banez, Leah Gerber, Judd W. Moul, Mitchell Steven Anscher, W Robert Lee, and Bridget F. Koontz. “Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.56.Full Text Link to Item
-
Moul, Judd W., Hans Lilja, Raymond Lance, Robert Vessella, Jonathan E. McDermed, Mark J. Sarno, and Thomas H. Adams. “Value of NADiA ProsVue on the CAPRA-S nomogram for predicting postprostatectomy clinical recurrence.” In Journal of Clinical Oncology, 31:139–139. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.139.Full Text
-
Moul, J. W., M. J. Moore, and H. A. Burris. “Oncologist roundtable: Is the Zaltrap pricing reversal a 'watershed moment'?” In Oncology Report, 9, 2013.
-
Bassett, Mitchell, Michael Abern, Lionel Lloyds Banez, Michael Ferrandino, Cary N. Robertson, Brant Allen Inman, Thomas Polascik, Stephen J. Freedland, Philip John Walther, and Judd W. Moul. “African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Moul, Judd W., Hans Lilja, Oliver John Semmes, Robert Vessella, Jonathan E. McDermed, Mark J. Sarno, and Robert E. Klem. “Post-prostatectomy PSA slope (ProsVue) in Gleason score >= 7 disease.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Moul, Judd W., Krag S. Ferenz, and Beatrice Delhey Mautner. “Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012. https://doi.org/10.1200/jco.2012.30.5_suppl.246.Full Text Link to Item
-
Singh, Abhay A., Lionel Lloyds Banez, Leah Gerber, Stephen J. Freedland, Cary N. Robertson, Michael Ferrandino, Thomas Polascik, Philip John Walther, and Judd W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012. https://doi.org/10.1200/jco.2012.30.5_suppl.34.Full Text Link to Item
-
Koontz, B. F., L. Gerber, L. L. Bañez, I. T. Degirmenci, Z. Vujaskovic, M. S. Anscher, C. N. Robertson, T. J. Polascik, J. W. Moul, and W. R. Lee. “3D Conformal and Intensity Modulated Radiotherapy to the Prostate Bed have Similar Biochemical Outcomes.” In International Journal of Radiation Oncology*Biology*Physics, 81:S406–7. Elsevier BV, 2011. https://doi.org/10.1016/j.ijrobp.2011.06.659.Full Text
-
Koontz, B. F., W. R. Lee, Z. Vujaskovic, M. Carroll, B. P. Quaranta, M. S. Anscher, C. N. Robertson, T. J. Polascik, and J. W. Moul. “Neoadjuvant Radiotherapy plus Prostatectomy for High Risk Prostate Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 81:S397–S397. Elsevier BV, 2011. https://doi.org/10.1016/j.ijrobp.2011.06.640.Full Text
-
Wattson, D. A., M. Chen, J. W. Moul, B. J. Moran, D. E. Dosoretz, C. N. Robertson, T. J. Polascik, M. H. Braccioforte, S. A. Salenius, and A. V. D’Amico. “The Number of High-Risk Factors and the Risk of Prostate Cancer-Specific Mortality Following Radical Prostatectomy or Brachytherapy.” In International Journal of Radiation Oncology*Biology*Physics, 81:S434–S434. Elsevier BV, 2011. https://doi.org/10.1016/j.ijrobp.2011.06.716.Full Text
-
George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium.” In Journal of Clinical Oncology, 29:4664–4664. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.4664.Full Text
-
Tripathy, D., J. W. Moul, B. G. Durie, and B. D. Mautner. “Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer.” In Journal of Clinical Oncology, 29:e19617–e19617. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.e19617.Full Text
-
Calloway, Elizabeth E., David I. Chu, Leah Gerber, Jean-Alfred Thomas, Cary N. Robertson, Thomas J. Polascik, Judd W. Moul, and Lionel L. Bañez. “1204 HEIGHT AND THE RISK FOR AGGRESSIVE PROSTATE CANCER AT THE TIME OF BIOPSY–RESULTS FROM THE DUKE PROSTATE CENTER DATABASE.” In Journal of Urology, Vol. 185. Ovid Technologies (Wolters Kluwer Health), 2011. https://doi.org/10.1016/j.juro.2011.02.839.Full Text
-
Chu, David I., Cosimo De Nunzio, Leah Gerber, Jean-Alfred Thomas, Elizabeth Calloway, Simone Albisinni, Madeline G. McKeever, et al. “2029 SHOULD A DIGITAL RECTAL EXAMINATION BE OPTIONAL FOR EARLY DETECTION OF PROSTATE CANCER IN OBESE MEN?” In Journal of Urology, Vol. 185. Ovid Technologies (Wolters Kluwer Health), 2011. https://doi.org/10.1016/j.juro.2011.02.2258.Full Text
-
Gerber, Leah, Lionel L. Bãnez, Stephen J. Freedland, Donghua Xie, Jim J. Qi, Thomas J. Polascik, Cary N. Robertson, and Judd W. Moul. “335 DIABETES MELLITUS AND THE RISK OF HIGH-GRADE PROSTATE CANCER: RESULTS FROM THE DUKE PROSTATE CENTER.” In Journal of Urology, Vol. 185. Ovid Technologies (Wolters Kluwer Health), 2011. https://doi.org/10.1016/j.juro.2011.02.419.Full Text
-
Nelson, J. B., K. Fizazi, K. Miller, C. S. Higano, J. W. Moul, T. Morris, S. McIntosh, K. Pemberton, and M. E. Gleave. “Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).” In Journal of Clinical Oncology, Vol. 29. AMER SOC CLINICAL ONCOLOGY, 2011.Link to Item
-
Moul, J. W., O. J. Semmes, R. Vessella, J. E. McDermed, and H. Lilja. “Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA.” In Journal of Clinical Oncology, 29:47–47. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.7_suppl.47.Full Text
-
Shore, N. D., J. W. Moul, E. Crawford, E. van der Meulen, T. Olesen, and B. Persson. “Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer.” In Journal of Clinical Oncology, 29:12–12. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.7_suppl.12.Full Text
-
Cotter, S. E., M. Chen, J. W. Moul, W. R. Lee, B. F. Koontz, M. S. Anscher, and A. V. D’Amico. “Salvage Radiation in Men with PSA Failure following Radical Prostatectomy and the Risk of Death.” In International Journal of Radiation Oncology*Biology*Physics, 78:S149–S149. Elsevier BV, 2010. https://doi.org/10.1016/j.ijrobp.2010.07.370.Full Text
-
Crawford, E., S. S. Sutton, J. W. Moul, C. A. Pettaway, J. W. Hardin, S. A. Poston, and E. J. Kruep. “Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.” In Journal of Clinical Oncology, 28:4565–4565. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.4565.Full Text
-
Shore, N. D., J. W. Moul, E. Crawford, T. Olesen, and B. Persson. “Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.” In Journal of Clinical Oncology, 28:4673–4673. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.4673.Full Text
-
Bañez, Lionel L., Leon Sun, Bruce J. Trock, Misop Han, Alan W. Partin, William J. Aronson, Martha K. Terris, et al. “BODY MASS INDEX AND PROSTATE-SPECIFIC ANTIGEN AS A PREDICTOR OF ADVERSE PATHOLOGY AND BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY.” In The Journal of Urology, 181:574–574. Ovid Technologies (Wolters Kluwer Health), 2009. https://doi.org/10.1016/s0022-5347(09)61619-0.Full Text
-
Koontz, Bridget F., Brian P. Quaranta, Madelaine Carroll, Zeljko Vujaskovic, W Robert Lee, Cary N. Robertson, Thomas J. Polascik, Mitchell S. Anscher, and Judd W. Moul. “PHASE I TRIAL OF PROSTATECTOMY AFTER PLANNED PRE-OPERATIVE RADIOTHERAPY FOR HIGH RISK LOCALIZED PROSTATE CANCER: PRELIMINARY RESULTS.” In The Journal of Urology, 181:713–713. Ovid Technologies (Wolters Kluwer Health), 2009. https://doi.org/10.1016/s0022-5347(09)61992-3.Full Text
-
Schroeck, Florian R., Michael W. Kattan, Judd W. Moul, William J. Aronson, Joseph C. Presti, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Leon Sun, and Stephen J. Freedland. “RECALIBRATION AND EXTERNAL VALIDATION OF AN EXISTING NOMOGRAM TO PREDICT AGGRESSIVE RECURRENCES AFTER RADICAL PROSTATECTOMY (RP).” In Journal of Urology, 181:54–54. Ovid Technologies (Wolters Kluwer Health), 2009. https://doi.org/10.1016/s0022-5347(09)60163-4.Full Text
-
Thomas, Jean A., Jayakrishnan Jayachandran, Lionel L. Bañez, Leon Sun, John C. Madden, Robin T. Vollmer, Amy L. Lark, Leah Gerber, Judd W. Moul, and Stephen J. Freedland. “DOES PATHOLOGICAL GLEASON SCORE RE-REVIEW BY A MODERN PATHOLOGIST IMPROVE RISK STRATIFICATION RELATIVE TO HISTORICAL GLEASON SCORE?” In Journal of Urology, 181:57–57. Ovid Technologies (Wolters Kluwer Health), 2009. https://doi.org/10.1016/s0022-5347(09)60171-3.Full Text
-
Chino, J. P., F. R. Schroeck, L. Sun, W. Lee, D. M. Albala, J. W. Moul, and B. F. Koontz. “Does Robotic Prostatectomy Increase the Need for Adjuvant Radiation Therapy? The Impact of Choice of Surgery and Pretreatment Disease Characteristics on Adjuvant Indications.” In International Journal of Radiation Oncology*Biology*Physics, 72:S304–S304. Elsevier BV, 2008. https://doi.org/10.1016/j.ijrobp.2008.06.1065.Full Text
-
Koontz, B. F., J. Chino, F. R. Schroeck, L. Sun, W. R. Lee, and J. W. Moul. “What Factors Influence Referral for Postoperative Radiation Therapy for Prostate Cancer?” In International Journal of Radiation Oncology*Biology*Physics, 72:S137–S137. Elsevier BV, 2008. https://doi.org/10.1016/j.ijrobp.2008.06.451.Full Text
-
Moul, J. W., D. Wiederkehr, M. Connolly, V. Sendersky, and E. Onel. “The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer.” In Journal of Clinical Oncology, 26:16002–16002. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.16002.Full Text
-
Banez, Lionel L., Leon Sun, William J. Aronson, Martha K. Terris, Joseph C. Presti, Christopher L. Amling, Christopher J. Kane, Judd W. Moul, and Stephen J. Freedland. “IS PSA A POOR PREDICTOR OF ADVERSE PATHOLOGY AND BIOCHEMICAL FAILURE FOLLOWING RADICAL PROSTATECTOMY IN OBESE MEN?” In Journal of Urology, 179:722–722. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)62105-9.Full Text
-
Fitzsimons, Nicholas J., Leon Sun, Judd W. Moul, John F. Madden, and Stephen J. Freedland. “OBESE MEN HAVE LARGER AND HIGHER-GRADE TUMORS: AN ANALYSIS OF THE DUKE PROSTATE CENTER DATABASE.” In Journal of Urology, 179:151–151. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)60433-4.Full Text
-
Freedland, Stephen J., Judd W. Moul, Leon Sun, Thomas B. Neville, David A. Kaminski, Virginia B. Falvello, Martha K. Terris, et al. “DYNAMIC SCREENING DETECTS PROSTATE CANCER (PC) EARLIER AND WOULD LEAD TO IMRPROVED CANCER CONTROL: RESULTS FROM THE DUKE PROSTATE CENTER AND THE SEARCH DATABASE.” In Journal of Urology, 179:688–688. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)62010-8.Full Text
-
Freedland, Stephen J., Leon Sun, Thomas B. Neville, David A. Kaminski, Virginia B. Falvello, and Judd W. Moul. “DYNAMIC SCREENING FOR PROSTATE CANCER IMPROVES AUCs RELATIVE TO STATIC SCREENING USING A SINGLE PSA THRESHOLD – RESULTS FROM THE DUKE PROSTATE CENTER.” In Journal of Urology, 179:641–42. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)61877-7.Full Text
-
Freedland, Stephen J., Leon Sun, and Judd W. Moul. “SMALL PROSTATE SIZE PREDICTS BIOCHEMICAL PROGRESSION AFTER RADICAL PROSTATECTOMY.” In Journal of Urology, 179:195–195. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)60565-0.Full Text
-
Jayachandran, Jayakrishnan, Lionel L. Banez, William J. Aronson, Martha K. Terris, Joseph C. Presti, Christopher L. Amling, Christopher J. Kane, Leon Sun, Judd W. Moul, and Stephen J. Freedland. “OBESITY AS A PREDICTOR OF ADVERSE OUTCOME ACROSS BLACK AND WHITE RACE: RESULTS FROM THE SEARCH AND DUKE PROSTATE CENTER DATABASES.” In Journal of Urology, 179:647–647. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)61893-5.Full Text
-
Moul, Judd W., Leon Sun, Cary N. Robertson, Craig F. Donatucci, David M. Albala, Phillip J. Walther, Vladimir Mouraviev, Florian R. Schroeck, and Thomas J. Polascik. “OLDER MEN ASSOCIATED WITH ADVANCED DISEASE AND POOR OUTCOME: AN ANALYSIS OF 14601 PROSTATE CANCER MEN IN DUKE PROSTATE CENTER.” In Journal of Urology, 179:641–641. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)61875-3.Full Text
-
Schroeck, Florian R., Leon Sun, Donna E. Levy, Kadi-Ann N. Bryan, Stephen J. Freedland, Jayakrishnan Jayachandran, Marva Price, Rachael Williams, and Judd W. Moul. “RACE AND PROSTATE WEIGHT AS INDEPENDENT PREDICTORS FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY.” In Journal of Urology, 179:198–198. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)60574-1.Full Text
-
Sun, Leon, Kevin C. Zorn, David M. Albala, Sergey A. Shikanov, Gregory P. Zagaja, Arieh L. Shalhav, Cary N. Robertson, et al. “PRE-TREATMENT FACTORS PREDICTIVE OF POSITIVE SURGICAL MARGIN IN CONTEMPORARY RADICAL PROSTATECTOMIES.” In Journal of Urology, 179:250–250. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)60724-7.Full Text
-
Joniau, S., L. Balducci, M. Bolla, M. Emberton, J. Fitzpatrick, M. Kattan, S. Monfardini, et al. “SIOG (INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY) LOCALISED PROSTATE CANCER GUIDELINES PROPOSALS IN SENIOR ADULT MEN.” In European Urology Supplements, 7:300–300. Elsevier BV, 2008. https://doi.org/10.1016/s1569-9056(08)60913-6.Full Text
-
Mouraviev, Vladimir, Leon Sun, John F. Madden, Janice M. Mayes, Judd W. Moul, Daniel J. George, Philip G. Febbo, and Thomas J. Polascik. “Tumor laterality does not predict biochemical prostate cancer recurrence after radical prostatectomy.” In Journal of Endourology, 21:A216–A216. MARY ANN LIEBERT INC, 2007.Link to Item
-
Bañez, Lionel L., Robert J. Hamilton, Robin T. Vollmer, Judd W. Moul, Christopher L. Amling, Christopher J. Kane, William J. Aronson, Matha K. Terris, Joseph C. Presti, and Stephen J. Freedland. “1418: Can Hemodilution Explain the Lower PSA Concentrations Among Obese Men?” In Journal of Urology, 177:468–468. Ovid Technologies (Wolters Kluwer Health), 2007. https://doi.org/10.1016/s0022-5347(18)31619-7.Full Text
-
Isariyawongse, Brandon K., Leon Sun, Lionel L. Banez, John Madden, Vladimir Mouraviev, and Judd W. Maul. “1884: Up to 53.8% Discrepancy between Diagnostic and Pathological Gleason Scores in 2963 Prostate Cancer Patients: The Predictive Value of Age and Prostate Size.” In Journal of Urology, 177:626–626. Ovid Technologies (Wolters Kluwer Health), 2007. https://doi.org/10.1016/s0022-5347(18)32057-3.Full Text
-
Rampersaud, Edward N., Leon Sun, and Judd W. Moul. “1027: Tumor Percentage of Prostatectomy Specimens is an Independent Risk Factor for Biochemical Recurrence and Negative Clinicopathological Variables.” In Journal of Urology, 177:339–339. Ovid Technologies (Wolters Kluwer Health), 2007. https://doi.org/10.1016/s0022-5347(18)31255-2.Full Text
-
Sun, Leon, Edward N. Rampersaud, and Judd W. Moul. “455: Racial Disparities Remain in Prostate Cancer - An Analysis on 10530 Men Diagnosed During PSA Era.” In Journal of Urology, 177:152–53. Ovid Technologies (Wolters Kluwer Health), 2007. https://doi.org/10.1016/s0022-5347(18)30708-0.Full Text
-
Furusato, R., D. Osborn, I. Rosner, J. Cullen, C. Davis, J. W. Moul, S. Srivastava, D. McLeod, I. Sesterhenn, and A. Allen. “Clinico-pathologic aspects of follow-up on small tumor volume prostate cancer after the radical prostatectomy at Walter reed army medical center.” In Modern Pathology, 20:147A-147A. NATURE PUBLISHING GROUP, 2007.Link to Item
-
Furusato, R., D. Osborn, I. Rosner, J. Cullen, C. Davis, J. W. Moul, S. Srivastava, D. McLeod, I. Sesterhenn, and A. Allen. “Clinico-pathologic aspects of follow-up on small tumor volume prostate cancer after the radical prostatectomy at Walter reed army medical center.” In Modern Pathology, 20:147A-147A, 2007.Link to Item
-
Proia, Alan D., Leon L. Sun, Kathryn R. Perkinson, Thomas J. Polascik, Vladimir Mouraviev, Craig F. Donatucci, Cary N. Robertson, et al. “262: KI-67: A Potential Prognostic Biomarker for PSA Recurrence?” In Journal of Urology, 175:87–87. Ovid Technologies (Wolters Kluwer Health), 2006. https://doi.org/10.1016/s0022-5347(18)32529-1.Full Text
-
Furusato, B., L. L. Banez, P. Prasan, Y. Chen, A. Ali, J. W. Moul, D. G. McLeod, S. Srivastava, and I. A. Sesterhenn. “Evaluation of serum SELDI-TOF proteomic information and tumor volume in prostate cancer patients.” In Laboratory Investigation, 86:137A-137A. NATURE PUBLISHING GROUP, 2006.Link to Item
-
Furusato, B., L. L. Banez, P. Prasan, Y. Chen, A. Ali, J. W. Moul, D. G. McLeod, S. Srivastava, and I. A. Sesterhenn. “Evaluation of serum SELDI-TOF proteomic information and tumor volume in prostate cancer patients.” In Modern Pathology, 19:137A-137A. NATURE PUBLISHING GROUP, 2006.Link to Item
-
Zhou, P., M. H. Chen, D. McLeod, P. R. Carroll, J. W. Moul, and A. V. D’Amico. “Predictors of prostate cancer-specific mortality following radical prostatectomy or radiation therapy.” In Journal of Clinical Oncology, 23:389S-389S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Banez, Lionel L., Bungo Furusato, Premkala Prasanna, Yongmei Chen, Amina Ali, Judd W. Moul, David G. McLeod, Isabell A. Sesterhenn, and Shiv Srivastava. “235: Evaluation of Serum Seldi-Tof Proteomic Information and Tumor Volume in Prostate Cancer Patients.” In Journal of Urology, 173:64–65. Ovid Technologies (Wolters Kluwer Health), 2005. https://doi.org/10.1016/s0022-5347(18)34500-2.Full Text
-
Yang, Benjamin K., Chas R. Salmen, Tong J. Gan, Judd W. Moul, and Philipp Dahm. “195: Radical Perineal Prostatectomy for the Treatment of Localized Prostate Cancer in Obese and non-obese Patients: A Matched Control Study.” In Journal of Urology, 173:53–53. Ovid Technologies (Wolters Kluwer Health), 2005. https://doi.org/10.1016/s0022-5347(18)34460-4.Full Text
-
Banez, Lionel L., Premkala Prasanna, Leon Sun, Amina Ali, Bao-Ling Adam, David G. McLeod, Judd W. Moul, and Shiv Srivastava. “1666: Serum Proteomic Profiling Using Seldi-Tof for Prostate Cancer Diagnosis.” In Journal of Urology, 171:440–41. Ovid Technologies (Wolters Kluwer Health), 2004. https://doi.org/10.1016/s0022-5347(18)38874-8.Full Text
-
Banez, L. L., P. Prasanna, L. Sun, A. Ali, Z. Q. Zou, D. G. McLeod, J. W. Moul, and S. Srivastava. “Diagnostic potential of serum proteomic patterns in prostate cancer.” In Journal of Urology, 169:54–55. LIPPINCOTT WILLIAMS & WILKINS, 2003.Link to Item
-
Zeng, J., J. J. Bauer, A. Sofer, X. Yao, B. Opell, W. Zhang, I. A. Sesterhenn, J. W. Moul, J. Lynch, and S. K. Mun. “Distribution of prostate cancer for optimized biopsy protocols.” In Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 1935:287–96, 2000. https://doi.org/10.1007/978-3-540-40899-4_29.Full Text
-
Bauer, J. J., J. Zeng, K. A. Sesterhenn, J. W. Moul, and S. K. Mun. “Comparison of prostate biopsy protocols using 3D computer simulation.” In Proceedings Pacific Medical Technology Symposium: Transcending Time, Distance and Structural Barriers, Pacmedtek 1998, 1998-August:109–14, 1998. https://doi.org/10.1109/PACMED.1998.767940.Full Text
-
Wang, Y., H. Ding, J. Xuan, I. A. Sesterhenn, J. W. Moul, and S. K. Mun. “3D model supported virtual environment for prostate disease interpretation and biopsy design.” In Proceedings Pacific Medical Technology Symposium: Transcending Time, Distance and Structural Barriers, Pacmedtek 1998, 1998-August:1–6, 1998. https://doi.org/10.1109/PACMED.1998.769990.Full Text
-
Xuan, J., Y. Wang, I. A. Sesterhenn, J. W. Moul, and S. K. Mun. “3-D model supported prostate biopsy simulation and evaluation.” In Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 1496:358–67, 1998. https://doi.org/10.1007/bfb0056220.Full Text
-
-
- Teaching & Mentoring
-
Advising & Mentoring
- I serve as a mentor for the Duke Medical School 3rd year research year. I also serve as a mentor for the Duke CAPE program for undergraduates interested in a career in medicine. I also serve as a mentor for Duke urology residents including the Duke Urology Residents who are part of the Duke- US Army urology training agreement
Available to mentor:
- Fellow
- Professional
- Resident
- Undergraduate
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.